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ABSTRACT 
The increasing incidence of multi-drug resistant strains of Mycobacterium 
tuberculosis and the very few drugs available for treatment are promoting the 
development of a new line of drugs that try to solve these problems. Following 
this idea, we explored the antibacterial peptide AS-48, produced by E. faecalis, 
which is targeting the bacterial membrane, and it is active against several Gram-
positive bacteria. We demonstrated that AS-48 has a bactericidal action against M. 
tuberculosis including H37Rv and other clinical and reference strains, and also 
against some non-tuberculous clinical mycobacterial species. We highlight the 
synergistic effect of the combination of AS-48 with either lysozyme or ethambutol 
(commonly used in the treatment of tuberculosis), two compounds that increase 
antimicrobial action of AS-48. Under these conditions, AS-48 kills M. tuberculosis 
at a lower dose, and exhibits a MIC (Minimal Inhibitory Concentration) close to 
some of the first line anti-TB agents.  
In addition, we assayed cytotoxicity of AS-48 against THP-1, MHS and J774 
macrophage cell lines, and found that at concentrations close to the MIC of AS-48 
we could not detect any cytotoxic effect. The activity of AS-48 for inhibiting M. 
tuberculosis growth was also observed within the infected macrophages; in this 
model, synergy was also observed for combinations of AS-48 and ethambutol. 
We have explored the mechanism of action of bacteriocin AS-48 against 
M.tuberculosis showing that, AS-48 is affecting the membrane, which is one of the 
unexplored targets that would reduce the incidence of new resistant strains. In 
addition, some mechanism related with the appearance of persistent strains seems 
to be altered after treating M. tuberculosis with AS-48. We have assayed 
transcriptomics analysis in order to better understand the As-48 mode of action.  
Interestingly, we have demonstrated that, AS-48 is also targeting the mobility of 
the DNA, probably affecting other molecular process. Therefore, we can consider 
AS-48 as a multitarget drug reducing the probabilities to develop a resistant 
mutant strain. 
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In vivo toxicity studies, have been performed showing that the BALB/c strain is 
lesser sensitive to AS-48 than C57BL/6.  The subchronic toxicity assays shows that 
mice are keeping healthy in treatments of ten days with doses of 2-1 mg/Kg body 
weight of AS-48. 
However, in the efficacy assay, AS-48 does not exhibit the antitubercular activity 
observed in the in vitro assays, even along with ethambutol was not shown to 
reduce bacterial burden in M. tuberculosis infected mice. 
In summary, we consider that combination of ethambutol and the bacteriocin AS-
48 has an interesting potential in antituberculosis therapy, due to its activity 
against mycobacterial species and its low cytotoxicity against cell lines. 
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RESUMEN 
La creciente incidencia de cepas multirresistentes de Mycobacterium tuberculosis y 
los pocos medicamentos disponibles para su tratamiento están promoviendo el 
desarrollo de una nueva línea de medicamentos que tratan de resolver estos 
problemas. Siguiendo esta idea, exploramos el péptido antibacteriano AS-48, 
producido por E. faecalis, cuya diana es la membrana bacteriana y, además, es 
activo contra varias bacterias grampositivas. Demostramos que AS-48 tiene una 
acción bactericida contra M.tuberculosis, incluyendo H37Rv y otras cepas clínicas 
y de referencia, también contra algunas especies micobacterianas clínicas no 
tuberculosas. Destacamos el efecto sinérgico de la combinación de AS-48 con 
lisozima o etambutol (comúnmente utilizado en el tratamiento de la tuberculosis), 
dos compuestos que aumentan la acción antimicrobiana de AS-48. En estas 
condiciones, AS-48 mata a M. tuberculosis a una dosis más baja y muestra una CIM 
(Concentración Inhibitoria Mínima) cercana a algunos de los agentes anti-TB de 
primera línea. 
Además, ensayamos la citotoxicidad de AS-48 contra las líneas celulares de 
macrófagos THP-1, MHS y J774, y encontramos que a concentraciones cercanas a 
la CIM de AS-48 no pudimos detectar ningún efecto citotóxico. La actividad de 
AS-48 para inhibir el crecimiento de M. tuberculosis también se observó dentro de 
los macrófagos infectados; en este modelo, también se observó sinergia para las 
combinaciones de AS-48 y etambutol. 
Hemos explorado el mecanismo de acción de la bacteriocina AS-48 contra M. 
tuberculosis que muestra que AS-48 está afectando la membrana, que es una de las 
dianas menos exploradas, y que reduciría la incidencia de nuevas cepas 
resistentes. Además, algunos mecanismos relacionados con la aparición de cepas 
persistentes parecen estar alterados después de tratar M. tuberculosis con AS-48. 
Hemos realizado un análisis transcriptómico para comprender mejor el modo de 
acción AS-48. 
Curiosamente, hemos demostrado que AS-48 también tiene como diana la 
movilidad del ADN, probablemente afectando a otros procesos moleculares. Por 
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lo tanto, podemos considerar que AS-48 es un fármaco multidiana que reduce las 
probabilidades de desarrollar una cepa mutante resistente. 
Se han realizado estudios de toxicidad in vivo que muestran que la cepa BALB/c 
es menos sensible a AS-48 que C57B/6. Los ensayos de toxicidad subcrónica 
muestran que los ratones se mantienen saludables en tratamientos de diez días con 
dosis de 2-1 mg/Kg de peso corporal de AS-48. 
Sin embargo, en el ensayo de eficacia, el AS-48 no muestra la actividad 
antituberculosis observada en los ensayos in vitro, incluso junto con etambutol no 
demostró reducir la carga bacteriana en ratones infectados con M. tuberculosis. 
En resumen, consideramos que la combinación de etambutol y bacteriocina AS-48 
tiene un potencial interesante en el tratamiento antituberculoso, debido a su 
actividad contra las especies micobacterianas y su baja citotoxicidad contra las 
líneas celulares. 
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HISTORY OF TUBERCULOSIS DISEASE 
TUBERCULOSIS, A PANDEMIC STILL IN 21ST CENTURY 
Tuberculosis is the most lethal infectious disease in our days, according to 
the WHO 2018 report (1) causing 1.4 million deaths per year. It has caused through 
history a great amount of deaths, taking a huge importance not only in the field of 
medicine but also in the literature, art and music. It is thought that tuberculosis 
could be the oldest disease in the history of humanity, it is thought that an early 
progenitor of M. tuberculosis was present in East Africa as around 3 million years 
ago, infecting early hominids (2). In Egypt, mummies of humans affected by 
tuberculosis infection dated from the 3rd Intermediate Period (1064-656 BC) have 
been found (3, 4). In the false door of a mastaba tomb of the Old Kingdom date(4th 
or 5th Dynasty, 2900 B.C.) has been discovered the representation of two humane 
figures with a deformity in the back, in the upper thoracic region, which is 
indicative of the Pott’s disease (5), a form of tuberculosis outside the lungs and 
affecting the spine (Figure 1). 
Figure 1: False door of a mastaba tomb (Glyptotek NY Carlsberg, Copenhagen). Detail of the 
human figure showing deformity due to tuberculous upper thoracic spine. 
In ancient Greece, the disease of tuberculosis was cited in the Book I, Of the 
Epidemics wrote by Hippocrates (460-370 B.C.); tuberculosis was known as phtisis 
and described in this book as “comsumption was the most considerable of the 
INTRODUCTION 
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disease which then prevailed, and the only one which proved fatal to many 
persons” (6). 
Tuberculosis was also an important disease in the Middle Ages and in 
Modern Era, having a high incidence across the centuries. The epidemic of 
tuberculosis was called “The White Plague”, increased notably in the 17th century, 
and persisted for the following 200 years. The industrialization process triggered 
the migration of the population to the cities, where the high population density, 
poorly ventilated housing, malnutrition and the bad sanitary conditions make 
most of Europe and America the best environment for the spread of the disease 
(7). The huge amount of deaths that happened in the 18th century defined 
tuberculosis as “Captain of All These Men of Death” (7, 8). 
During the 20th century, the development of a vaccine (BCG) (9) and the 
finding of several antituberculosis drugs, resulted in a decrease in the incidence of 
this disease; also patients had not to be hospitalized and the success of the 
treatment was high. Because of these factors, tuberculosis seemed to be a disease 
under control; in fact, in the earliest 80’s tuberculosis was thought to be almost 
extinct. However, during this decade, the rising incidence of HIV infection and a 
general relaxation in measures for prevention, diagnosis and treatment of 
tuberculosis resulted in an upturn of this disease. In this way, the coinfection with 
HIV in tuberculosis patients was one of the key factors behind the increase of the 
incidence of tuberculosis, predominantly in those countries where both diseases 
are endemic (10). 
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THE CAUSATIVE AGENT OF TUBERCULOSIS 
It was at the end of 19th century (1882) when Robert Koch identified the 
etiologic agent of tuberculosis as a bacterium that was named Mycobacterium 
tuberculosis. He performed new innovative methods to cultivate bacteria, in this 
case using potato and agar to get a pure culture of M. tuberculosis. Robert Koch also 
demonstrated that the origin of this disease was the presence of the bacilli of 
M. tuberculosis in animals or humans (4, 6). This was part of the Henle-Koch 
postulates that settle the basis for the study of the rest of the infectious diseases. 
Moreover, Robert Koch presented the “tuberculin” as a therapeutic for curing 
tuberculosis, but the results were not what expected. Even though, nowadays, 
tuberculin is still in use as a test for tuberculosis diagnosis (Mantoux test). 
Image 2: Timeline summary of the history of tuberculosis. 
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THE GENUS MYCOBACTERIUM 
Species in genus Mycobacterium are mostly free-living bacteria and do not 
to infect humans or cause any disease commonly. Classically, they have been 
divided according to their growth rate, hence being distinguished between fast-
growing mycobacteria with a generation time between 2 and 5 hours, like 
M. smegmatis, and slow-growing mycobacteria like M. tuberculosis, that takes 
around 14-15 hours in completing a duplication round. In addition, slow-growing 
mycobacteria were classified based on the production of pigments and 
photoreactivity. Those species that produce carotenoid pigments when they are 
exposed to light, like M. kansasii and M. marinum, are named photochromogenic. 
The scotochromogenic mycobacteria produce orange or yellow colonies 
independently of the presence of light, like M. gordonae or M. paraffinicum. Finally, 
those mycobacteria that do not produce any pigments are known as non-
chromogenic, like M. tuberculosis and M. bovis. This classification of mycobacteria 
is known as the Runyon classification and dates from 1959 (11). 
In our days, however, mycobacterial species have been classified according 
to their genetic and evolutionary relationships, in particular those species 
belonging to the M. tuberculosis complex. This has been possible because 
Mycobacterium tuberculosis has a low mutation rate, and this has allowed to date 
the possible origin of modern ancestor of M. tuberculosis around 20,000-35,000 
years ago (2). According to the study presented by  Gutierrez MC, et al. (2), 
Mycobacterium canetti could correspond to a lineage from which the M. tuberculosis 
complex was evolved. More recently, Riojas MA, et al.(12) have observed that all 
the Mycobacterium species analysed are extremely close related indicating that they 
belong to the same specie (Mycobacterium tuberculosis) (Image 3), and they propose 
the use of a variants to define the current Mycobactium species (i.e. M. tuberculosis 
var bovis).   
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Image 3: Phylogenomic tree showing the relationship between the whole genomes of 
type strains of species of MTBC and the type strains of various other species of the genus 
Mycobacterium with Nocardia asteroides as an outgroup (12). 
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CHARACTERISTICS OF M. TUBERCULOSIS 
Mycobacterium tuberculosis is an aerobic bacteria, so it grows in well aerated 
tissues, with a high oxygen tension, as it is the case of the lungs, where they grow 
mainly in the upper lobes. In laboratory conditions, an atmosphere of a 5-10% of 
carbon dioxide is provided since this promotes growth (13). Also, M. tuberculosis 
is neutrophilic and mesophilic, the best conditions to keep M. tuberculosis in 
culture are at 37ºC and neutral pH.  Among the most common culture media used 
for M. tuberculosis, we find Middlebrook 7H9 (broth) and 7H10 and 7H11 (solid 
agar-containing media), and Coletsos and Lowenstein-Jensen (egg-based solid 
media). Middlebrook media must be supplemented with ADC (Albumin, 
Dextrose and Catalase) or OADC (Oleic, Albumin, Dextrose and Catalase) 
supplements. Giving that the hydrophobic mycobacterial envelope cause bacteria 
to clump when using liquid media, detergents or other dispersing agents are used 
to avoid clumps formation (14). 
 
GENERAL FEATURES OF MYCOBACTERIAL CELLS 
The mycobacteria are acid-fast, non-motile, non-spore forming and aerobic 
bacilli that belong to the phylum Actinobacteria. Then, phylogenetically, they 
belong to the group of Gram positive bacteria but present notable differences 
compared with the vast majority of other Gram positive bacteria, as detailed 
below.  Mycobacteria have a high content of guanine cytosine (65.6%) in its DNA 
(15), and a high content of lipids in their cell wall. In fact, the 6.6%, of the total of 
4111 genes described for M. tuberculosis (Mycobrowser database 
https://mycobrowser.epfl.ch/), are involved in lipid metabolism. Indeed, one of 
the most remarkable aspects of mycobacterial physiology is the composition and 
structure of their cell envelope. 
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MYCOBACTERIAL ENVELOPE: THE MEMBRANE, THE CELL WALL, AND THE 
CAPSULE 
As in other bacteria, the membrane (16) is where many essential metabolic 
processes take place, such us transport of nutrients and wastes, communication 
with other cells in the microbial community, the respiratory chain and other 
metabolic process. The membrane must to keep its structure for the survival even 
when they are in non-replicating forms.  
Mycobacterial cell wall (17-20) contains peptidoglycan, arabinogalactan, 
and an outermost layer of mycolic acids that confers a cover similar to wax. This 
is one of the aspects that makes mycobacterial envelope so impermeable and hence 
resistant to external agents. The structure and composition of the cell wall seems 
to be related with the slow growth rate of mycobacterial cells, given that the 
production of all complex components of the cell wall represents a high metabolic 
cost for the bacteria. 
The peptidoglycan covers all the surface of bacterial membrane but differs 
from peptidoglycan present in other Gram positive bacteria in that, first, the 
muramic acid moiety has an N-glycolyl substituent instead of an N-acetyl group, 
and second, the number of cross-links between two peptidoglycan chains is higher 
than in other Gram positive bacteria. 
 The arabinogalactan is composed by D-arabinofuranosyl and D-
galactofuranosyl sugars and keeps linked to the peptidoglycan through 
phosphodiester links.  
The mycolic acids are hydrophobic hydrocarbon -branched, -
hydroxylated fatty acids with around 90 carbon atoms with a high molecular 
weight. Mycolic acids are bond to the arabinose terminal residue of the 
arabinogalactan, in the external side of the cell wall, creating a hydrophobic layer 
that looks like the external membrane typically described in Gram negative 
bacteria, and that is frequently referred to as the mycomembrane. The length of 
mycolic acids is thought to be related with the virulence of the strain and the 
INTRODUCTION 
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survival of bacilli intracellularly (21). The mycomembrane also contains 
phospholipids, glycolipids, trehalose dimycolate, trehalose monomycolate, 
phosphatidylinositol-mannosides, and the lipoarabinomanan (LAM) that is a 
polysaccharide present in all kind of actinomycetales. The mycomembrane also 
contains porins, which create hydrophilic channels that allow the passive 
transport of hydrophilic molecules and other proteins. 
The high content of lipids in mycobacterial cell wall contributes not only to 
its low permeability but also the innate resistance of mycobacteria to dehydration 
and consequently to their great resistance to antibacterial substances, and to its 
virulence. In fact, during the Gram staining, mycobacterial cells stain slightly blue 
due to colorants that cannot penetrate into the cell. For microscopy, giving they 
are resistant to de-coloration by acids and alcohols, they can be stained with acid-
fast staining such as Ziehl-Neelsen or auramine-rhodamine fluorochrome stain 
(22). 
Finally, mycobacteria also have a capsule, composed by proteins, 
polysaccharides and other lipids that are considered as virulence factor such us, 
the cord factor, a glycolipid also present in the cell wall. Cord factor is a trehalose 
6,6’-dimycolate; this molecule is responsible for the characteristic chain formation 
of mycobacterial cells and their adhesion to the respiratory tract. This factor is also 
thought to be associated to the pathogenicity of M. tuberculosis and considered 
responsible of the inhibition of the acidification of the phagosome and granuloma 
formation (23). 
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Image 4: Schematic representation of the cell wall structure. 
 
PATHOGENICITY AND VIRULENCE OF M. TUBERCULOSIS 
Humans are the unique reservoir of M. tuberculosis, and it seems that we, 
humans and M. tuberculosis, evolved together through years. M. tuberculosis is an 
obligate intracellular pathogen that is adapted to live within the pulmonary 
macrophages. M. tuberculosis is able to colonize also other tissues, developing 
other extra-pulmonary diseases, which are less common than the pulmonary 
tuberculosis (24, 25). 
The success of the colonization in lungs implies the inhibition of numerous 
processes within the macrophages, which finally allows the intracellular 
proliferation of the bacilli. For example, M. tuberculosis blocks the fusion between 
the phagosome (the compartment where it resides, after having been 
phagocytosed) and the lysosomes; it also inhibits the antigen presentation, the 
beginning of the apoptotic cascade and the stimulation of the bactericide response 
mediated by MAP kinases, -interferon and calcium signals (26). 
INTRODUCTION 
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At the cellular level, the infection can be contained in a special structure 
called granuloma (Image 5).  
Image 5: Process of macrophage infection and granuloma formation. 
 It is composed by macrophages containing the bacilli, epithelioid cells, 
dendritic cells, neutrophils, fibroblast, and lymphocytes B and T. In some lesions, 
the granuloma can content an extracellular and fibrous matrix surrounding the 
cells that compose the granuloma. It is thought that the granuloma keeps the 
infection controlled, concentrating the immune response to this localized area, but 
it has been demonstrated that mycobacteria can escape from the granuloma and 
colonize other areas (25, 27). The 90% of the population infected with 
M. tuberculosis are able to control the infection within the granuloma and will not 
present any symptomatology of the disease; in this case, we say that tuberculosis 
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is in latent form. When the bacilli multiply uncontrolledly, the macrophage lyse 
and the bacilli that are released could be internalized by other macrophages or 
could escape from the granuloma. When this happens, an inflammation, 
calcification and colonization of the lymphatic nodules occurs creating the named 
Ghon complex. After the Ghon complex formation, the liquefaction process could 
happen in the bronchioles and the bacilli goes out through the respiratory tract, 
where it can be incorporated into small contagious particles that will be released 
in form of aerosol when the patient coughs of sneezes. If the liquefaction happens 
in a blood vessel, the infection could be spread throughout the organism. The 
granuloma could evolve into a necrotizing granuloma, which commonly begins 
by the centre of the granuloma forming a caseum core that eventually spread all 
around generating serious damage in the lung tissue. The bacilli are mainly found 
within the macrophage away of the immune system but it could be allocated in all 
kind of cells and type of lesion (27, 28). 
Given that during infection, M. tuberculosis can go through a diversity of 
intra and extracellular locations, one factor contributing to the complexity of 
tuberculosis disease is that different subpopulations of bacteria are present during 
the infection, and there are numerous barriers that difficult the penetration of the 
different drugs to reach their targets. 
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CONFRONTING M. TUBERCULOSIS INFECTIONS 
Similar to other microbial infections, the three major approaches to control 
tuberculosis disease are based on prevention, diagnostics and treatment. 
PREVENTION 
After the success obtained in the development of a smallpox vaccine by 
Edward Jenner, efforts concentrated in developing a vaccine for protecting against 
tuberculosis. Albert Calmette and Camile Guérin selected a Mycobacterium bovis 
strain, the etiological agent responsible of the tuberculosis infection in cattle, 
although it was discovered that also can cause the disease in humans. Calmette 
and Guérin subcultivated it for 230 times until they got an attenuated bacillus, 
named Bacille Calmette-Guérin (BCG). Since 1921, BCG has been the unique 
vaccine to prevent tuberculosis infection. 
On recent decades, lack of protection conferred by BCG vaccine has been 
pointed out as one of the reasons for the increased incidence of tuberculosis. This 
has promoted a world wide effort to develop novel vaccines against tuberculosis, 
with improved protection than BCG. The University of Zaragoza is developing 
MTBVAC (Image 6), an attenuated live vaccine candidate based on the disruption 
of a transcriptional regulator that controls several virulence factors (29-31). 
Currently this vaccine candidate is in clinical phase II in adults and newborns. 
Image 6: MTBVAC candidate, live attenuated vaccine. Developed in the University of 
Zaragoza and produced by Biofabri. 
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DIAGNOSTICS 
Classical methods to diagnose(32) whether a patient has tuberculosis, 
include chest X-ray (Image 7) since it allows to see the pulmonary lesions; 
however, this technique is not specific for tuberculosis and other infectious (or 
even, non-infectious) diseases may lead to a wrong diagnostic. Then, normally, it 
has to be confirmed with a microscopic examination of a sputum sample (after, for 
example, a Zielh-Neelsen stain (Image 7)), as well as a bacteriological culture test. 
However, cultivation of M. tuberculosis takes between 2 and 6 weeks to show a 
positive result on conventional tuberculosis culture media (although this time can 
be importantly reduced by using fluorescent detection of mycobacterial growth, 
using automated systems such as the MGIT-960 (Becton Dickinson)). The 
tuberculosis skin test (Mantoux test) has been also widely used, and consists on 
the injection of a small amount of tuberculin subcutaneously (33). If a skin reaction 
is observed at the site of injection (Image 7), it is assumed to reveal the presence of 
M. tuberculosis in the organism, but it cannot distinguish between latent and active 
forms. Moreover, Mantoux test cannot distinguish neither between vaccinated and 
infected patients, and previous immunization by environmental non-tuberculous 
mycobacteria also can lead to false positive results. 
 
Image 7: A) Thorax x-Ray showing lesions produced by tuberculosis (arrows). B) Zielh-
Neelsen stain, the bacilli of M. tuberculosis are in pink. C) Mantoux test. 
Given the uncertainty associated to most classical diagnostic methods, 
novel methods based on molecular analysis (34) have been developed in recent 
years, which frequently are complementary to one or several of the classical 
methods described above. The Interferon Gamma Release Assay (IGRAs) is an 
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immunological assay that measures the production of the cytokine interferon 
gamma in blood samples when stimulated with specific M. tuberculosis antigens. 
Other molecular methods, more specific and sensitive, are those based on nucleic 
acid amplification through the PCR technique, frequently combined with 
hybridization on strip, for easy detection of amplification products. Most of these 
methods have been automatized and are adapted for convenient and fast 
diagnosis of tuberculosis in clinical microbiology laboratories, such as the 
GeneXpert® (Cepheid) system (35). 
 
TREATMENT AND DRUG RESISTANCE 
The different treatments used to cure tuberculosis have been changing 
along history, from bathing in human urine, eating wolf liver, avoid eating, doing 
exercise or having rest in the mountains. Indeed, the sanatoriums in the 
mountains, far away from the cities, became very popular during 19th century and 
the first half of 20th century to treat tuberculosis. The medical prescription was to 
rest in sanatorium, and take fresh air and good nutrition; the fact is that some 
patients cured spontaneously from the disease (33, 36). 
In 1943, Selman Waksman discovered the antibiotic streptomycin from a 
Streptomyces griseus isolate; this was the first antimicrobial used in the treatment of 
tuberculosis, although resistance to streptomycin arose frequently (37). One year 
later, para-aminosalicylic acid (PAS), a derivative from aspirin, showed great 
results in tuberculosis treatment, and seemed to be less prone to select resistance 
than streptomycin. At that time, it was observed that, when applying a 
combination of both antimicrobials, patients had more probabilities to recover 
than when they were treated with only one of these drugs. This was the beginning 
of the combined therapy, a key factor in tuberculosis treatment. 
Isoniazid was the third antibiotic discovered to have antitubercular activity 
and included in the combined treatment. With these three drugs, tuberculosis 
became a disease completely curable, but the treatment still has to be administered 
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during a long period, 18-24 months. In the decade of the 60s PAS was substituted 
by ethambutol and timing was reduced to 18 months. After introducing rifampicin 
and pyrazinamide, treatment was reduced up to six months (38). Nowadays, the 
antitubercular therapy include always a combined treatment of isoniazid, 
rifampicin, pyrazinamide and ethambutol during two months, and is followed by 
four months taking only rifampicin and isoniazid. Since then, combined therapy 
was established as the only way to cure tuberculosis infection. It was clear that 
applying one single drug as monotherapy forced the selection of those bacilli that 
are drug resistant, which could proliferate again without curing the infection (39). 
Over the years, other antitubercular drugs have been discovered. 
Antitubercular drugs can be classified as first, second and third line drugs 
depending on the preference for treatment, which is based on efficacy of 
antitubercular activity as well as toxicity. First-line drugs are rifampicin, isoniazid, 
pyrazinamide, streptomycin and ethambutol. Belonging to the group of second 
line drugs are kanamycin, amikacin, capreomycin, ethionamide and 
fluoroquinolones. 
In 1990, in New York, it was isolated the so called “W strain” as being the 
first strain resistant to isoniazid, rifampicin, ethambutol and streptomycin. In three 
years, this strain had spread to eleven other hospitals and had affected 367 people. 
The patients infected with this strain had a death rate of 83%, due to the difficulty 
to use an appropriate treatment (40).  
Over the years, other M. tuberculosis strains resistant to main 
antituberculosis drugs have been isolated world-wide. Investigation of molecular 
basis of drug resistance have revealed that in M. tuberculosis, the major mechanism 
of drug resistance is mediated through the acquisition of chromosomal mutations 
in genes encoding either drug target proteins or drug activating enzymes. 
Extensive reports of mutations found in drug resistant isolates have allowed the 
development of molecular methods for detecting drug resistant isolates (41-45). 
Most methods are based on PCR, frequently in combination with chromatographic 
detection on strips with immobilized oligonucleotides containing the most 
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popular mutations that result in drug resistance; in such devices (like for example 
the Line Probe Assay (46)) hybridization of the PCR amplification product on the 
strip results in a pattern indicative of drug resistance. 
Globally, a strain in considered as MDR (multi-drug resistant) when it is 
resistant to rifampicin and isoniazid at least; XDR (extensively drug resistant) 
strains are those MDR strains that also show resistance to fluoroquinolone, and 
one of the injectable second-line drugs (amikacin, kanamycin or capreomycin). In 
light of the increase of the MDR and XDR prevalence, there is an urgent need for 
developing new antimicrobials against tuberculosis. 
Since the 1970s, only bedaquiline (47) and delamanid (48) have reached the 
market of novel drugs against tuberculosis, which seems insufficient for 
confronting the tuberculosis epidemic and their resistant variants. New strategies 
that pursue the reduction of the treatment, by using combined therapy (as it has 
been proved useful in the past for reducing tuberculosis treatment) need to be 
investigated. 
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INTRODUCTION 
 
APPROACHES FOR ANTIMICROBIAL DRUG DISCOVERY 
There are different experimental approaches for the discovery of new 
antimicrobial drugs, the two major ones are target-based and whole cell-based 
screenings. Both methods have advantages and disadvantages; the whole cell 
screening (also known as phenotypic screening) is used to identify new molecules 
that directly kill the bacterial cells, and this may lead to the discovery of drugs 
with novel modes of action but that may have important issues on cytotoxicity on 
mammalian cells. Most of the screens focused on the inhibition of the enzymatic 
activity of the target have resulted in the identification of compounds with a 
known mechanism of action, that sometimes may have a poor permeation through 
the bacterial cell wall (1). All the drugs commonly used in tuberculosis treatment 
were discovered by phenotypic approaches. Phenotypic assays (in comparison 
with target based approaches) reintroduce biological complexity into the 
screening model system and allow the study of disease-relevant pathways in a 
more physiological context (2). This approach may offer the possibility to find new 
drug targets or vulnerable pathways, as long as drugs with complex mechanisms 
of action or even with a multi-mode of action (3, 4). 
 
ANTIMICROBIAL PEPTIDES 
In the context of antimicrobial drug discovery, not only in M. tuberculosis 
but also in many other bacterial pathogens, antimicrobial peptides (AMPs) may 
have a great potential use in treatment, either used by themselves or in 
combination with other antimicrobial drugs. They seem to be a good alternative to 
the actual treatments that have become inefficient against MDR strains. 
AMPs can be produced by eukaryotic or prokaryotic cells; they are mostly 
cationic and have an amphiphilic nature. Those AMPs produced by bacterial cells 
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are called bacteriocins, and exhibit antimicrobial activity mostly against those 
species that are phylogenetically close related with the producer species.  
 
Bacteriocins 
Bacteriocins are ribosomally synthetized small peptides with bactericidal 
activity against a range of closely related species. They are capable of interacting 
with different pathways and targets in the bacterial cells; some bacteriocins may 
affect the same target as common antibiotics, and some others may inhibit new 
targets; moreover, bacteriocins can affect several targets simultaneously (5). 
Bacteriocins are being widely used in the field of food preservation; they 
are generally regarded as safe (GRAS), so that in the case of nisin (a product of 
Lactococcus lactis), this bacteriocin has been accepted by the FDA as a food additive 
in Title 21 of the Code of Federal Regulations (21 CFR 184). Nisin preparation from 
Lactococcus lactis Lancefield Group N for use as an antimicrobial agent to inhibit 
the outgrowth of Clostridium botulinum spores and toxin formation in pasteurized 
cheese spreads (21 CFR 184.1538) (6). It has been suggested antimicrobial activity 
of bacteriocin could be useful in other fields, such as the fight against clinically 
relevant microorganisms. The main restrictions for using bacteriocins for 
therapeutic applications are that, due to their peptidic nature, they are susceptible 
to proteolytic degradation in the gut and that proteolysis-resistant bacteriocins 
may alter or even arrest the growth of the natural microbiota. Despite of this, the 
fact is that many bacteriocins have been isolated from bacteria commonly found 
in human sources, suggesting that they are naturally present in our bodies. Some 
strategies such as nano-encapsulation would provide bacteriocins with a more 
suitable way to be delivered orally, avoiding the degradation by proteolytic 
enzymes (7). The broad spectrum antimicrobial activity and the potential to 
enhance the effect of other antimicrobials are the best advantages of the use of 
bacteriocins against infectious diseases. In addition, bacteriocins are equally active 
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against antibiotic susceptible or antibiotic resistant strains (8), so that bacteriocins 
may have an important role in antimicrobial drug discovery. 
It is accepted a recently classification of bacteriocins (9) where Class I (less 
than 10 kDa), encompasses all the peptides that undergo enzymatic modification 
during biosynthesis, which provides molecules with uncommon amino acids and 
structures, having an impact on their properties. Thus, there are lanthipeptides 
(Class Ia), head-to-tail cyclic peptides (Class Ib), sactibiotics that are sulphur-to-α 
-carbon-containing peptides (Class Ic) and linear azol (in)e-containing peptides 
(Class Id). Class II (less than 10 kDa) includes unmodified bacteriocins that do not 
require enzymes for their maturation; and finally, Class III that consists of heat-
labile bacteriocins without modifications, larger than 10 kDa and with 
bacteriolytic or non-lytic mechanism of action. The prototype of the ribosomally 
synthesized and post-translationally modified peptides (RiPPs) by head-to-tail 
cyclization to render a circular molecule is the bacteriocin AS-48 (Class Ib). All 
these cyclic peptides are synthesized as a linear precursor containing a leader 
sequence with a high molecular weight, and then are post-translationally 
modified.  
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Image 8: Bacteriocins of Lactic Acid Bacteria (LAB) classification proposed by Alvarez-
Sieiro, et al. (9). 
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AS-48, a bacteriocin with a great potential 
The bacteriocin AS-48 is a 70 amino acid, alpha-helical membrane-
interacting peptide (Image 9) produced by Enterococcus faecalis, which displays a 
broad antimicrobial spectrum against Gram-positive and Gram-negative bacteria. 
The mechanism of AS-48 antibacterial activity involves the accumulation of 
positively charged molecules at the membrane surface leading to a disruption of 
the membrane potential (10, 11). Its antimicrobial activity has already been proven 
in food products (12) and has been observed against numerous Gram-positive 
bacteria including Listeria monocytogenes and enterotoxic Staphylococcus aureus (13). 
Most of the studies on bacteriocins focus on their potential application as 
food preservatives and only a few of them are focused on their potential 
biomedical applications and, specifically, in antimicrobial or antituberculosis 
activity. Nisin and lacticin 3147 activity has been proved against Mycobacterium 
strains such as: M. kansasii, M. avium paratuberculosis and M. tuberculosis H37Ra; in 
particular, lacticin 3147 exhibit greater antimycobacterial activity than nisin (14). 
The antimycobacterial activity of several bacteriocins was found to be similar to 
rifampicin against M. tuberculosis (15). 
 
Image 9: AS-48 aminoacidic composition, structure and possible interaction with the 
plasmatic membrane (16). 
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BACTERIOCIN ENGINEERING 
One of the strategies that can be followed to improve properties such as 
antimicrobial activity of bacteriocins is to modify its chemical structure, and this 
can be easily accomplished by genetically modifying the structural gene encoding 
the bacteriocin. The improvement of the activity, solubility and stability of current 
bacteriocins at broad pH ranges has increased the probabilities for a further 
therapeutic application of bacteriocins. In the case of Microcin B17, a DNA gyrase 
inhibitor, it has been found that the derivative molecule Mcc[Gly46-Ile69] is much 
more stable than the original molecule, while retaining a similar gyrase inhibitory 
activity (17). Engineered modifications have also improved the production rate of, 
for example, the nisin mutants D19A, F18H, F18M, L16D, L16K and L16A (18). 
There are other examples in which structural modifications have not resulted in a 
significant improvement of the activity; this is the case of AS-48, the bacteriocin 
featured in this study: all several mutants resulting from engineering 
modifications had the same or lower antimicrobial activity than the wild type 
molecule (11). 
 
SYNERGY AND COMBINATION THERAPIES INCLUDING BACTERIOCINS 
Antimicrobial peptides, and in particular bacteriocins, have a great 
potential as alternatives for common antimicrobials because of their innate 
antimicrobial activity. In addition to consider their use as antimicrobials by 
themselves, they can be considered as helper compounds that could enhance the 
antimicrobial activity of other antimicrobial peptides or antibiotic-based therapies, 
as long as they have a synergistic interaction. A combined therapy has some 
advantages in comparison with those based on single drugs. First, a synergistic 
relationship reduces considerably the concentration of the components needed for 
the same antibacterial effect, and consequently, reduces also their potential side-
effects. Second, a synergistic combination of antimicrobial compounds reduces 
considerably the probability of arising and selecting resistant mutants. 
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The molecular interaction profile of a drug describes its interactions with 
other biomolecules, pathways or processes attributable to its pharmacodynamics, 
toxicological, pharmacokinetic and combination effects. A combination of drugs is 
synergistic, with no interaction, or antagonistic if its effect is greater than, equal to, 
or lower than the summed effects of the individual drugs, respectively. We refer 
also to synergy when the therapeutic activity of one drug is enhanced by another 
drug, via regulation of its absorption, distribution, metabolism and excretion 
(ADME) (19). According to Jia et al. (20) there are three situations in which synergy 
combinations act. First, an effect anti-counteractive in the drugs combined, reduce 
the side effects that one of the drugs could have or with a compensatory activity 
(21). In the second group, the drugs have complementary actions to reach one 
target or pathway site (22). The third group, involves facilitating actions: one drug 
enhance the activity of another drug, for example when combining gentamicin and 
vancomycin: the alterations in the cell wall caused by the action of vancomycin 
increases the accession of gentamicin to reach the ribosome (23). Despite this, a 
recent report concluded that antagonism is more common than synergy and 
occurs almost exclusively between drugs that target different cellular processes 
(24). Cokol et al. (25) also have reported a higher prevalence of antagonism 
combinations in antifungal drugs.  
Validating in vitro observed synergy may provide a synergistic outcome in 
vivo, as have been observed in the case of an experimental therapy based in a 
combination of spectinamide and clarithromycin against tuberculosis infection in 
animal models (26). 
Commonly, synergy is defined for a combination of two drugs but synergy 
also can be considered when several (more than two) drugs are included in a 
treatment (27). 
AMP’s have shown synergy together with common drugs against M. 
smegmatis either in axenic culture or within the infected macrophages (28). Also, 
the combination of the AMP HNP-1 with isoniazid and rifampicin decreased the 
MIC of the drugs (rifampicin and isoniazid) and reduced the mycobacterial load 
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in vivo (29). Then, we consider synergy strategy for AMPs as a simple and effective 
approach that would help to find new alternatives to conventional antimicrobial 
compounds. 
In this chapter we present the antimicrobial activity of AS-48 against several 
M.tuberculosis strains and Non-tuberculous Mycobacteria, we have explored the 
differences of activity in porins mutants strains and also with some variants of the 
bacteriocin AS-48 engineered for improving the antimicrobial activity. Moreover, 
we assayed the cytotoxicity of the bacteriocin in human and murine macrophages. 
And finally, its antimicrobial activity in a model of infected macrophages. 
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OBJECTIVES 
Given the high concern raised globally on the increase of drug resistant 
variants of M. tuberculosis, to characterise novel compounds with new bacterial 
targets is a priority of biomedical research in our days. Bacteriocin AS-48 is an 
AMP with great biotechnological applications, although its potential biomedical 
uses have been little explored. For this, the objectives of this work have been the 
following: 
1) To characterise antimycobacterial activity of AS-48 in vitro 
2) To identify and characterise potential synergistic combinations of 
AS-48 and drugs or hydrolytic enzymes 
3) To assess cytotoxicity of AS-48 against macrophage cell lines 
4) To determine the antituberculosis activity of AS-48 against 
intracellular mycobacteria. 
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MATERIALS AND METHODS 
BACTERIAL STRAINS AND CULTURE CONDITIONS 
Mycobacterial strains used in this work for in vitro tests are listed in Table 
1 and Table 2. All strains were cultured in Middlebrook 7H9 media (Difco™) 
supplemented with 10% ADC (BD) and 0.05% Tween 80 in 25 cm2 flasks. For drug 
susceptibility testing, Tween 80 was replaced by 0.5% glycerol. Cultures on solid 
media were performed in Middlebrook 7H10 agar (Difco™) supplemented with 
10% ADC and 0.05% Tween 80. All cultures were incubated at 37°C until visible 
growth. 
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Table 1: Mycobacterium tuberculosis complex strains used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a= fast-growing strains, the rest of the strains have a slow growth. HMS= Clinical isolates 
provided by Hospital Miguel Servet, Zaragoza. 
 
 
Strain Source or reference 
M. tuberculosis H37Rv (30) 
M. tuberculosis H37Ra (31) 
M. bovis BCG Pasteur 1173 Laboratory collection 
M. tuberculosis Mt103 (32) 
M. tuberculosis CDC 1551 (33) 
M. tuberculosis GC 1237 (34) 
M. tuberculosis H37RvPhoP (35) 
M. tuberculosis SS18b (36) 
HMS 1500 HMS 
HMS 1555 HMS 
HMS 1531 HMS 
HMS 1536 HMS 
HMS 1546 HMS 
HMS 1547 HMS 
HMS 1548 HMS 
HMS 1292 HMS 
HMS 1543 HMS 
HMS 1278 HMS 
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Table 2: Non-Tuberculous Mycobacteria used. 
Strain Source or reference 
M. fortuitum a HCU 
M. mucogenicum a HCU 
M. xenopi HCU 
M. gordonae HCU 
M. avium a HCU 
M. abcesus a HCU 
M. lentiflavum HCU 
M. smegmatis mc2155 a (37) 
M. smegmatis SMR5 a (38) 
M. smegmatis MN01 a (39) 
M. smegmatis ML10 a (39) 
 
Note: a= fast-growing mycobacteria. HCU= Clinical isolates provided by the Hospital 
Clínico Universitario Lozano Blesa, Zaragoza. 
 
MINIMAL INHIBITORY CONCENTRATION (MIC) 
Serial broth microdilutions were made to determine the MIC of AS-48, 
lysozyme (Sigma-Aldrich L 3790) and other antimicrobials (isoniazid, rifampicin, 
moxifloxacin, streptomycin and ethambutol; Sigma-Aldrich). Bacteriocin AS-48, 
and its derivative mutants E4A, E20A, E49A, W70A, G13K, and L40K were 
purified to homogeneity from Enterococcus faecalis UGRA 10 strain (40) according 
to (41) (Annex I). 
Two-fold dilutions of compounds were made in 100 µl of culture medium 
for mycobacterial strains in sterile 96-well polypropylene flat bottom plates. Wells 
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were inoculated with 1x105 CFU in 100 µl of culture medium and incubated at 37°C 
during 7 days for slow-growing mycobacteria or 4 days for fast-growing species. 
Then, 30 μl of 0.1 mg/ml filter-sterilized resazurin (Sigma-Aldrich) was added. 
The colour change from blue (indicative of no bacterial growth) to pink (indicative 
of bacterial growth) was recorded after 48 hours in the case of slow-growing 
mycobacteria or after 24 hours for fast-growing species. The MIC was defined as 
the lowest concentration of compound capable of inhibiting bacterial growth. 
Positive and negative growth controls were added in all the experiments and 
moxifloxacin (Sigma) at 0.5 mg/ml was used in all the assays as a control (42). 
 
SYNERGY TEST 
This assay blends gradients of concentration of two compounds to evaluate 
their antimicrobial activity and the interaction between them. In fresh medium for 
culturing mycobacteria, solutions at 4x the highest concentration to be tested were 
prepared for each compound. Then, both compounds were serially two-fold 
diluted in a sterile 96-well flat bottom plates, one of the compounds was diluted 
along the columns and the other in rows. The MIC of one of the compounds alone 
will be tested in column one, and the MIC of the second compound will be tested 
in row H; the rest of the plate is a matrix of both gradients. Finally, wells were 
inoculated as described above, and incubated and treated with resazurin as in a 
conventional MIC assay (Image 10). 
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Image 10: Example of a 96-well plate for checkerboard assay. The illustration represents 
a hypothetical result of synergy. 
 
FRACTIONAL INHIBITORY CONCENTRATION INDEX ANALYSES 
After a synergy test is done, the determination of Fractional Inhibitory 
Concentration (FIC) index allows objective identification of any interaction 
between two compounds against a particular bacterial strain, indicating whether 
there is synergy, no interaction or antagonism. 
For each well in which there is no growth next to a well with bacterial 
growth, the FIC for each of the two compounds must be calculated using the 
following formula: 
FIC X = MIC of X in presence of Y / MIC de X alone. 
FIC Y = MIC de Y in presence X / MIC de Y alone. 
Both values, together with other points of inhibition can be represented 
graphically and a concave line will be indicative of synergy. Alternatively (or 
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additionally), the addition of FIC X and FIC Y results in the FICI value (Fractional 
Inhibitory Concentration Index). A FICI value up to 0.5 indicates synergy, when it 
is between 0.5 and 4 indicates there is no interaction between the compounds, and 
a FICI value over 4 indicates antagonism (43, 44). The relation between the two 
compounds could be represented graphically as is shown in the Image 11: 
Image 11: Graphic representation of the interaction between two compounds in the 
checkerboard assay. 
 
CELL CULTURES 
The following cell lines were used: murine macrophages MHS (HPA 
Culture Collections, 95090612), J774.2 (ECACC, 85011428), Raw 264.7 (TIB-71) and 
human monocytes THP-1 (ECACC, 88081201). MHS cells were cultured in DMEM 
and the rest were cultivated in RPMI-1640 Glutamax medium (Gibco) containing 
10% heat-inactivated Fetal Bovine Serum (FBS, Gibco). When cells were going to 
be used for cytotoxicity assays, antibiotics (penicillin, streptomycin and 
ciprofloxacin) were added to cell pre-cultures. Cells were cultured in a controlled 
5% CO2 atmosphere at 37°C. 
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CYTOTOXICITY ASSAYS 
The MTT assay and Neutral Red assay (45) were carried out to determine 
AS-48 cytotoxicity in MHS and J774.2 murine macrophages, and THP-1 human 
macrophages. Cells were cultured in 96-well flat bottom plates with the 
appropriate media. THP-1 monocytes were differentiated to macrophages by 
using 10 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich ref P1585-
1MG) for 72 hours. The concentrations of cells used for cytotoxicity assays for 
mouse lung macrophages were 15000 cells/well (MH-S) and 20000 cells/well 
(J774.2), and for human lung macrophages were 50000 cells/well (THP-1). They 
were cultured for 24 hours and then the compounds were added dissolved in fresh 
culture media and incubated, together with the cells, during 24 hours.  
After the time of incubation of cells with compounds, media was removed 
and 100 µl of MTT (1 mg/ml) or 100 µl of NR (0.05 mg/ml) was added. MTT and 
NR were incubated during 3 hours. Plate was centrifuged with a short spin, then 
media was removed and crystals of MTT were dissolved in 200 µl of pure 
isopropyl alcohol. After removing the NR media, cells were washed with PBS and 
finally NR was dissolved in ETOH/water/acetic acid 50:49:1 (v/v). Absorbance 
was measured in MTT assay at 570 and 650 nm and fluorescence in the case of NR 
at 530 and 645 nm excitation and emission wavelengths respectively. Percent of 
cell viability in comparison with untreated controls was determined, and 
treatments were considered to be cytotoxic or not according to (13). To check the 
absence of statistically significant differences between samples treated with lower 
concentrations of AS-48, we performed one-way ANOVA test. 
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M. TUBERCULOSIS MACROPHAGE INFECTION ASSAY 
For infection assays, a recombinant strain of M. tuberculosis H37Rv 
(ATCC#27294) constitutively expressing a green fluorescent protein (H37Rv-GFP) 
was used as a reporter for the intracellular mycobacterial replication assay (46). 
This strain was grown in Middlebrook 7H9 medium supplemented with 10% of 
oleic acid-albumin-dextrose-catalase (OADC, Difco), 0.05% of Tween 80 (Sigma-
Aldrich), 0.5% of glycerol (Euromedex) and 50 µg/ml of hygromycin B 
(Invitrogen). Cultures were maintained at 37°C in static conditions for up to 14 
days before being used for the intracellular mycobacterial replication assay, to 
reach the exponential phase of bacterial growth. Cultures of H37Rv-GFP were 
maintained under stirring during three days before the infection to ensure that 
bacterial cells were in exponential growth. Then, bacterial cells were washed twice 
with PBS without Mg2+ and Ca2+, followed by a third wash with RPMI 
supplemented with 10% FBS and centrifuged at 70 g during 2 min to pellet 
bacterial clumps; the supernatant corresponds to a homogenous suspension of 
bacteria.  
Bacterial titre was determined by measuring the optical density at 600 nm 
and by measuring EGFP fluorescence on a Victor Multilabel Counter (Perkin 
Elmer), and further diluted in RPMI 1640 supplemented with 10% FBS (RPMI-FBS) 
prior to infection. Raw 264.7 macrophages were used for the intracellular 
mycobacterial replication assay and harvested by using Versene solution 
(LifeTechnologies). Macrophages were prepared at a concentration of 5·105 
cells/ml, infected with a 1:2 MOI with M. tuberculosis H37Rv-GFP and incubated 
in RPMI-FBS cell culture media at 37°C under stirring at 120 rpm. After 2 hours, 
cells were centrifuged at 160 g during 5 min, resuspended in the same volume of 
fresh medium containing 50 µg/ml of amikacin to kill extracellular bacteria, and 
incubated during 1 hour at 37°C with shaking at 120 rpm. Cells were washed and 
resuspended in the same volume of fresh medium. Infected cells were seeded in 
384-wells plates (Greiner Bio-One) at 2·104 cells/well containing the compounds 
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(AS-48, ethambutol and lysozyme diluted in water). Plates were incubated for 5 
days at 37°C, 5% CO2.  
Infected cells were stained during 30 min with Syto60 dye (Invitrogen) at a 
final concentration of 5 µM. Finally, images were acquired (as described below), 
then cells were lysed with DPBS-0.1% Triton X-100 buffer for 1 min for releasing 
intracellular bacteria. The number of viable bacterial cells was determined by 
serially plate dilutions on Middlebrook 7H11 (Difco) agar plates, supplemented 
with 0.5% glycerol, 10% OADC and 50 µg/mL hygromycin B. After 3-weeks of 
incubation at 37°C with 5% CO2, the number of viable bacteria (CFUs) were 
calculated.  
 
IMAGE ACQUISITION AND ANALYSIS 
Images were performed on an automated fluorescent confocal microscope 
(Opera, PerkinElmer), using a 20X- water immersion lens. Syto60-labeled cells 
were detected using a 640 nm excitation laser coupled with a 690/70 detection 
filter and GFP-bacteria were detected using a 488 nm laser coupled with a 540/75 
detection filter. A series of 6 images was taken by well and each one was analysed 
using the image-analysis software Columbus system (version 2.5.1, PerkinElmer). 
Briefly, the images were processed to determine the output image of GFP mask 
and remove background in that channel. Then, the output images corresponding 
to the Syto60 values were processed similarly to assess morphological parameters 
of cells. Properties of intensity and morphology were filtered to select the correct 
nuclei population. Spots corresponding to the bacteria that are infecting the cells 
were detected, and bacterial number and area in pixels were determined for each 
cell. The intracellular bacterial growth was quantified by the total intracellular 
bacterial area (pixel) per well.  In order to consider a cell as infected, the number 
of bacteria within the cell area should be ≥1. Efficiency of infection and effectivity 
of treatment with compounds was determined in terms of percentage of infected 
cells and mean of M. tuberculosis area per infected cell. 
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RESULTS 
BACTERIOCIN AS-48 SHOWED BACTERICIDAL ACTIVITY AGAINST M. 
TUBERCULOSIS COMPLEX 
The activity of AS-48 was determined against several mycobacteria 
including M. tuberculosis complex reference strains, clinical isolates, and other 
clinically relevant non-tuberculous mycobacteria (NTM). First of all, we tested AS-
48 activity against M. tuberculosis complex clinical and reference strains. The MIC 
of AS-48 was quite uniform, between 16 and 64 µg/ml (Table 3 and 4), and there 
was no difference in the MICs of AS-48 between active replicating cells and the 
non-replicative strain SS18b of M. tuberculosis. We observed a similar MIC of AS-
48 in M. smegmatis and the other NTM (see below).  
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Table 3: MICs of AS-48 and lysozyme of M. tuberculosis complex strains and clinical 
strains. 
 
Strain MIC AS48 
(µg/ml) 
MIC lysozyme  
(µg/ml) 
M. tuberculosis H37Rv 32-64 200-400 
M. tuberculosis H37Ra 32 400 
M. bovis BCG Pasteur 1173 32 200-400 
M. tuberculosis Mt103 64 400 
M. tuberculosis CDC 1551 64 400 
M. tuberculosis GC 1237 16-32 400 
M. tuberculosis H37RvPhoP 64 400 
M. tuberculosis SS18b 32-64 >1200 
HMS 1500 32 100-200 
HMS 1555 32 >400 
HMS 1531 8 50-100 
HMS 1536 32 200-400 
HMS 1546 32 100 
HMS 1547 32 200 
HMS 1548 32 400 
HMS 1292 32 100-200 
HMS 1543 >32 >400 
HMS 1278 32 200 
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Table 4: MICs of AS-48 and lysozyme of NTM and porins mutans of M. smegmatis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: a= fast-growing mycobacteria. 
 
The kill curve kinetics indicated that bacteriocin AS-48 is bactericidal since 
concentrations equal to the MIC and 2xMIC were capable of reducing the number 
of live bacteria in a culture of M. tuberculosis H37Rv. First, after one or two days of 
treatment, the number of CFU was reduced by almost 2 log in comparison with 
untreated cultures. After 6 days of treatment with 128 or 64 µg/ml of AS-48, no 
live bacteria could be detected (Image 12) and this was found to be statistically 
significant by linear regression test (p-value of 0.0005 and <0.0001 respectively).  
 
 
Strain MIC AS48 
(µg/ml) 
MIC lysozyme  
(µg/ml) 
M. fortuitum a 64 >1200-1200 
M. mucogenicum a 64 200-400 
M. xenopi <2 < 9.375 
M. gordonae <2 <9.375 
M. avium a 64 >1200 
M. abcesus a 64 >1200 
M. lentiflavum > 256 >1200 
M. smegmatis mc2155 a 64 400 
M. smegmatis SMR5 a 64 400 
M. smegmatis MN01 a 128 >800 
M. smegmatis ML10 a 64 50 
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Image 12: Kill curve kinetics of bacteriocin AS-48 at 64 and 128 µg/ml against cultures of 
M. tuberculosis H37Rv. Untreated cultures have been used as a control. 
 
SYNERGY BETWEEN BACTERIOCIN AS-48 AND OTHER ANTIMICROBIAL 
COMPOUNDS 
Synergy interaction between lysozyme and the bacteriocin nisin was 
already observed in Gram-positive bacteria (47, 48). Similarly, we have observed 
that the presence of lysozyme resulted in an increase in the M. tuberculosis 
susceptibility to AS-48. First, we tested lysozyme activity against mycobacterial 
strains and found that different mycobacterial strains or species have more 
variability in the MIC of lysozyme (Table 1 and Table 2) than that obtained for 
AS-48. Notably, the non-replicating strain SS18b of M. tuberculosis was found to be 
greatly resistant to lysozyme. Secondly, we tested the susceptibility of 
mycobacterial strains to AS-48 in the presence of lysozyme. We found that, for 
most strains, susceptibility to AS-48 greatly increased (between 64 and 16-fold) in 
the presence of subinhibitory concentrations of lysozyme. In order to quantify the 
effect of lysozyme on growth inhibition by AS-48, we calculated the Fractional 
Inhibitory Concentration Index (FICI). The results of all strains assayed are 
indicated in Table 5. For reference strains, maximum synergism was observed for 
H37Rv and to a lesser extent to BCG, H37Ra, H37RvPhoP, GC 1237 (Beijing 
genotype), CDC1551, Mt103. Although technically the synergism is defined when 
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the FICI0.5, for the strains Mt103 and HMS 1548, which resulted in a FICI slightly 
over 0.5, we can consider it as a weak synergistic interaction. Even though, the 
synergy effect occurred in all the M. tuberculosis complex strains analysed.  
Table 5: MIC of AS-48 in the presence of different concentrations of lysozyme and the 
Fractional Inhibitory Concentration Index (FICI). 
Straina 
MIC of AS-48 (µg/ml) for mycobacterial strains in the 
presence of lysozyme 
FICIb 
Lysozyme concentration 
(µg/ml) 
400 200 100 50 25 12.5  
H37Rv <0.0312 0.0625 1 4 >32  0.25 
H37Ra <0.0312 2 4 16 >32  0.375 
M. bovis BCG Pasteur  <0.125 2 16 >32  0.312 
Mt103 <0.125 4 32 32 64 >64 0.562 
CDC 1551  <0.125 16 32 64 >64 0.5 
GC 1237 <0.0312 4 8 >32   0.375 
H37RvPhoP  <0.125 8 32 64 >64 0.375 
M. smegmatis mc2155 <0.125 32 64 >64   1 
M. smegmatis SMR5  <0.125 16 64    0.75 
M. smegmatis ML10     <0.125 0.5 16 0.5 
HMS 1500  <0.0312 8 >32   0.375 
HMS 1531   <0.0312 0.5 4 8 0.375 
HMS 1536  <0.0312 8 >32   0.5 
HMS 1546   <0.0312 2 8 >32 0.5 
HMS 1548 <0.03125 2 16 >32   0.531 
HMS 1292   <0.03125 4 16 >32 0.312 
HMS 1278  <0.03125 2 8 >32  0.5 
a: unless indicated, all strains are M. tuberculosis 
b: the fractional inhibitory index (FICI) is calculated as follows: FICI= (MICAS-48 in presence of 
lysozyme /MICAS-48 alone) + (MIClysozyme in presence of AS-48 /MIClysozyme alone); FICI 0.5 indicates 
synergism; FICI= 0.5-4, indicates no interaction and FICI> 4.0, indicates antagonism 
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ANTITUBERCULOSIS ACTIVITY OF VARIANTS OF AS-48 
A series of variants of AS-48 were obtained previously by site-directed 
mutagenesis within the structural as-48A gene. These mutants were performed 
with the aim of improving their activity and stability (49-51). 
We first tested antituberculosis activity of these mutant variants of AS-48 
and results are given in Table 6. The results were that no one of the mutants exhibit 
a greater MIC against M. tuberculosis than the wild type, AS-48. Only the mutants, 
G13K and L40K, have the same MIC value as AS-48. 
 
Table 6: MIC of each AS-48 mutant against M. tuberculosis. 
 
 
 
 
 
 
 
 
Additionally, synergy with lysozyme was assessed for AS-48 mutants. 
Synergy was observed only for the same mutants that have the same MIC of AS-
48, L40K and G13K, and the extent of the synergy effect was comparable to that of 
the wild type AS-48, reaching a FICI of 0.312. Image 13 represents the FIC of AS-
48 and lysozyme for these two mutants and for AS-48 
 
Mutant name MIC AS-48 mutant 
(µg/ml) 
E4A >64 
E20A >64 
E49A >64 
W70A >64 
G13K 64 
L40K 32 
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Image 13: FIC representation of AS-48, and the mutants L40K and G13K, with the FIC 
representation of lysozyme. 
 
A PORIN MUTANT OF M. SMEGMATIS ARE LESS SENSITIVE TO AS-48 
We have assayed three M. smegmatis mc2 porins mutants: ML10, MN01 and 
MNR5. In the Table 4, we show the results of the MIC of AS-48 against the mutants 
SMR5, MN01 and ML10. The SMR5 comes from the M. smegmatis mc2155 but 
Streptomycin resistant due to a mutation in the rpsL gene, in this case the result of 
the MIC is exactly the same as M. smegmatis mc2155 as expected. We also have 
assayed the activity of AS-48 against two porin mutants strains derived from 
SMR5, which are MN01 (∆mspA) and ML10 (∆mspA ∆mspC). In the case of the 
double mutant the MIC for AS-48 are the same as in the wildtype and lower in the 
case of lysozyme. However, in the case of the simple mutant the MIC is higher 
than the range assayed. 
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We analysed the synergy effect in strains with the cell wall altered, which 
is the case of the porins mutants (MN01 and ML10). The result was that for the 
wild type, M. smegmatis MNR5, the relation between lysozyme and AS-48 was of 
no-interaction (FICI=0.75); for the double mutant, ML10 there is synergy 
(FICI=0.5) but, for the single mutant, MN01, we could not reach a clear relation 
between the two components (Image 14). We could expect that as much 
modifications in the cell wall as much sensitive would be the strain to the effect of 
AS-48. The possible mode of action of AS-48 would not be related with the 
presence or absence of porins. 
Image 14: FIC representation of AS-48 and lysozyme against M. smegmatis porins 
mutants. 
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BACTERIOCIN AS-48 HAS VARIABLE ACTIVITY AGAINST NTM 
In most NTM, the MIC of AS-48 is the same as for M. tuberculosis, (i.e. 64 
µg/ml) with the exception of the slow-growing mycobacterial species such as 
M. xenopi, M. lentiflavum and M. gordonae. In M. xenopi and M. gordonae the value 
of the MIC of AS-48 was <2 µg/ml, and the MIC of lysozyme is < 9.375 µg/ml. In 
contrast, the MIC of AS-48 against M. lentiflavum was higher than 256 µg/ml and 
the MIC of lysozyme was also higher than 1200 µg/ml, being the mycobacterial 
species less susceptible to AS-48 and to the lysozyme (Table 4). 
 
SYNERGY TEST BETWEEN AS-48 AND FIRST-LINE ANTITUBERCULOSIS DRUGS 
AS-48 has been tested also in combination with the main first-line 
antituberculosis drugs, ethambutol, isoniazid, streptomycin and rifampicin. The 
combination of AS-48 and ethambutol was the only one to present synergistic 
relation with a FICI of 0.09375, being the lowest FICI obtained in all the assays 
(Image 15). 
Image 15: Synergism between AS-48 and ethambutol in H37Rv M. tuberculosis. For the 
reference strains: CDC1551, Mt103, H37Ra and H37Rv phoP, the synergy relationship 
between AS-48 and ethambutol was almost the same. 
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ANTIMICROBIAL CONCENTRATIONS OF AS-48 ARE NOT CYTOTOXIC FOR 
MACROPHAGE CELL LINES. 
The cytotoxicity of AS-48 on human and mouse lung macrophages cell lines 
was carried out by MTT and Neutral Red assays.  
In both protocols, > 70% cell viability was observed at concentrations of AS-
48 below 128 µg/ml which is considered as no cytotoxic effect by standard 
international protocols (52). Even when slight differences in cell viability were 
observed below 32 µg/ml of AS-48, they were no significant (Image 16). We did 
not observe a concentration-dependent cytotoxic effect in none of the cell lines 
assayed. At 128 µg/ml, <40% cell viability was observed (Image 16; p-value 
<0.0001). 
Image 16: Representative results of the cytotoxicity assays, as determined by Neutral Red 
Uptake technique in cell cultures of J774.2 murine macrophages. Concentration of 
compounds are expressed in µg/ml.  Cell suspensions with no compounds added were 
used as a positive control. 
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Lysozyme cytotoxicity was also analysed and, as expected, no cytotoxicity 
was observed in these cell lines. Finally, we assayed cytotoxicity of some of those 
synergistic combinations of AS-48 and lysozyme that showed great antimicrobial 
effect in M. tuberculosis, and we found that these combinations did not cause any 
significant cytotoxic effect (Image 16). 
 
SYNERGY BETWEEN ETHAMBUTOL AND AS-48 IN THE INFECTED 
MACROPHAGES. 
In the model of Raw 264.7 cells infected with M. tuberculosis H37Rv-GFP, 
we observed low FICI values (Table 7) ranging from 0.5 and 0.18, which is 
indicative of synergism. These FICI values were similar to those obtained in the in 
vitro antimycobacterial assays. The combination of 2 µg/ml AS-48 and 2 µg/ml 
ethambutol against M. tuberculosis infected macrophages resulted in the lowest 
FICI value, that was 0.18, and it is worth to remark that this concentration of AS-
48 (2 µg/ml) is well below the doses that were found to be toxic in macrophage 
cell lines.  
Other combinations also resulted in synergistic FICI values in infected 
macrophages, but to a lesser extent (Table 5). The determination of viable bacteria 
after treatment with ethambutol and AS-48 resulted in a reduction of CFUs 
between 90 and 99.9% in comparison with untreated controls. The efficacy of AS-
48 for killing intracellular pathogens was already proven by Abengózar et al.(53), 
when they showed the anti-leishmanial activity of AS-48 in Raw 264.7 infected 
macrophages. Despite the fact that the infection mechanism is different between 
Leishmania and mycobacteria, these experiments show that the AS-48 is active 
versus pathogens residing intracellularly in macrophages. 
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Table 7: Intracellular MICs of AS-48, ethambutol, and three combinations, related FIC 
values, and FICI data in Raw 264.7 cells infected with M. tuberculosis H37Rv-GFP. 
 
MIC (µg/ml)    
AS-48 EMB FIC AS-48 FIC EMB FICIa 
32 - - - - 
16 0.125 0.5 0.007 0.50 
8 0.5 0.25 0.03 0.28 
2 2 0.06 0.12 0.18 
- 16 - - - 
 
a: the fractional inhibitory index (FICI) is calculated as follows: FICI= (MICAS-48 in presence of 
ethambutol /MICAS-48 alone) + (MICethambutol in presence of AS-48 /MICethambutol alone); FICI 0.5 indicates 
synergism; FICI= 0.5-4, indicates no interaction and FICI> 4.0, indicates antagonism. EMB: 
Ethambutol.  
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DISCUSSION 
 
Bacteriocins have been highlighted as potential antimicrobial compounds 
in antituberculosis treatment, and in fact, several works have reported the 
antituberculosis activity of certain bacteriocins (14, 54, 55). Howerver, although 
antimicrobial and antiparasital activity of bacteriocin AS-48 has also reported in 
the literature (12, 13, 40, 48, 53, 56-64), to date, its antituberculosis activity had 
never been characterized before. 
Susceptibility of M. tuberculosis strains to bacteriocin AS-48 ranged from 16 
to 64 µg/ml, including reference strains and several clinical isolates of M. 
tuberculosis selected by their different spoligotype and RFLP profile. We found that 
AS-48 is bactericidal against M. tuberculosis. Several other bacteriocins have been 
reported as effective against M. tuberculosis in in vitro assays (14, 54, 65, 66): colistin 
has an MIC of 16 µg/ml (55), and nisin showed an MIC >60µg/ml against M. 
tuberculosis H37Ra (14). These authors described variants of nisin with an 
enhanced antimicrobial activity (65) against M. tuberculosis as well as other 
naturally occurring bacteriocin such as lacticin 3147 (MIC90 = 7.5 µg/ml) (14). In 
conclusion, when comparing antituberculosis activity of AS-48 with that of other 
bacteriocins, most values are in the range of 7.5 – 64 µg/ml. However other 
bacteriocins, such as B602, OR7, S760 and E50-52,  have a stronger effect  in 
inhibiting growth of M. tuberculosis at 0.1 µg/ml concentration, than the same 
concentration of rifampicin (15). 
The success in the improvement of antituberculosis activity of nisin 
derivatives (65) prompted us to explore whether variants of AS-48 (altered in 
residues important for maturation, conformation stability, etc.) could have 
reduced MICs in comparison with wild-type AS-48. However, none of these 
variants resulted in a significant change of their MICs against M. tuberculosis, 
similarly to what has been described for other bacterial species (11). The only two 
mutants that exhibit a similar inhibitory activity against M. tuberculosis were G13K 
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and L40K, they also have almost the same activity against the majority of the gram-
positive bacteria assayed (51). According to Maqueda M., et al. (67) the active site, 
where the maximum positive electrostatic potential (that will promote the peptide 
to its first approach to the membrane) is in the opposite site of the lysine residues 
of mutants G13K and L40K. The addition of an extra positive charge in mutants 
G13K and L40K did not improve the activity or stability of these mutants (11). 
From this experiments, we decided to continue exploring the activity of the wild-
type, AS-48, since these mutants do not exhibit a great advantage in the activity 
against M. tuberculosis. Nevertheless, other aspects could be considered for further 
studies, such us the cytotoxicity of the mutants or the bioavailability for in vivo 
experiments. 
We have also explored susceptibility of other mycobacterial species to AS-
48 and found that for some species (M. smegmatis, M. fortuitum and M. 
mucogenicum; all three fast-growing mycobacteria) the MIC of AS-48 does not 
change significantly in comparison with that of M. tuberculosis. Carroll et al. (65) 
also described a rather uniform susceptibility of nisin derivatives between M. 
tuberculosis, M. kansasii, and M. avium. For other mycobacterial species (slow-
growing and chromogenic species), however, we obtained either very low MICs 
(<2 µg/ml for M. xenopi and M. gordonae) or we could not detect any inhibition of 
growth up to 256 µg/ml (M. lentiflavum). 
Lysozyme is an enzyme present in respiratory tract secretions as a part of 
the body defense mechanisms against microbes. It has been reported that the 
combination of lysozyme and bacteriocins such as nisin results in a synergistic 
effect against many bacterial pathogens such as C. difficile (68). This synergistic 
effect of lysozyme has also been described for AS-48 (48). The lysozyme, acting in 
the cell wall, could facilitate the access of AS-48 into the bacteria and increase its 
bactericidal effect. Through synergy tests, we have found that AS-48 strongly 
synergizes with lysozyme, as it has been reported for other bacterial species (48). 
Moreover, the combination of drugs with cell wall hydrolytic enzymes (i.e. 
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lysozyme) augment the efficacy of the drugs, and reveal a synergistic effect and an 
enhancement of the bactericidal activity in mycobacterial strains (69). 
From the early dates of antituberculosis treatment, it became evident that 
monotherapy results in the selection of drug-resistant strains, so a combination 
therapy was established as a gold-standard for antituberculosis treatment with 
decreased probabilities to develop resistance. Then, for any new antituberculosis 
agent, it is interesting to investigate not only its own antimicrobial activity but also 
how it may interact with other drugs in use against tuberculosis. We have 
investigated the interaction between AS-48 and first-line antituberculosis drugs by 
using the checkerboard assay, considered as an accurate drug-combination 
analysis method (20), that has been used for demonstrating synergism of drugs 
and drug candidates in M. tuberculosis (70, 71). We found that there is a synergism 
between AS-48 and ethambutol. In fact, the synergism between AS-48 and 
ethambutol was stronger than that of AS-48 and lysozyme. We can hypothesize 
that ethambutol, by inhibiting biosynthesis of arabinogalactan in cell wall, this 
would increase the permeability of mycobacterial cells, and this could facilitate the 
access of AS-48 to its potential target, the mycobacterial membrane. The work by 
Kalita et al. (29) reported synergism between the antimicrobial human neutrophil 
peptide 1 (HNP-1) and the antituberculosis drugs isoniazid and rifampicin, and 
hence proposed the use of this AMP as an adjuvant in antituberculosis 
chemotherapy. 
In the intracellular M. tuberculosis growth assays in macrophages, the 
combination between AS-48 and ethambutol readily shows strong synergism, and 
the FICI values obtained are similar to the ones found in in vitro cultures. However, 
when we tested the interaction between AS-48 and lysozyme in the intracellular 
model of infection, no synergistic effect was observed in any of the conditions 
tested, in contrast with what we have observed in in vitro cultures. We can 
speculate that either lysozyme could not get inside the macrophages, hence it 
could not reach the intracellular bacteria residing in the phagosome, or it could be 
degraded by the macrophage. 
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In summary, we have reported here the antituberculosis activity in vitro of 
circular bacteriocin AS-48, both on extracellular and intracellular bacteria. 
Interestingly, we have found that in both systems, AS-48 strongly synergizes with 
ethambutol, hence opening the way to further explore the interaction of other 
AMPs with antituberculosis drugs and their future potential use as adjuvants of 
current antituberculosis treatments or as part of a new alternative therapeutic 
regimen. 
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INTRODUCTION 
 
In the study of drug discovery, it is crucial to know which are the 
mechanisms of resistance that microorganism have, either intrinsic or acquired. 
Knowing this, would help to prevent the development of new resistant strains. 
MECHANISMS OF RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS 
In the search of new antimicrobials to fight tuberculosis, the knowledge of 
how the different drugs interact with the bacteria, and the strategies that 
M. tuberculosis has to avoid their harmful effect, seem to be crucial for the 
development of new antituberculosis compounds and new therapeutic strategies. 
The fast development of drug resistance in M. tuberculosis strains, is causing a 
heavy burden in the global health panorama. Again, it is very important the 
understanding of the different molecular mechanisms that are involved in the 
appearance of drug resistance, especially in those cases where a single strain 
presents resistance against different kinds of antimicrobials, i.e. multi-drug-
resistant (MDR), extensively-drug-resistant (XDR) and totally-drug-resistant 
(TDR) strains (1, 2). 
In M. tuberculosis, horizontal gene transfer, through plasmids, transposon 
or phages has not been registered, so the acquired resistance is due to 
chromosomal mutations. Selection of resistant mutants can be enhanced by the 
environmental pressure caused by the use of antimicrobial drugs, especially when 
a non-effective concentration is given (3), or when there is non-adherence to the 
treatment during such as long periods of regimens that are used in tuberculosis 
treatment. Under these conditions, most of susceptible populations will be 
eliminated, and those microorganisms that have got an advantage through the 
selection of a resistance mutation will survive. With a combined therapy of more 
than one drug given simultaneously, the appearance of resistance is less probable 
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but is still possible, and nowadays, multi-drug resistant strains constitute a social 
problem that has to be solved by different approaches. 
 
Intrinsic resistance 
One of the reasons why the number of antimicrobials available for treating 
tuberculosis is lower than for other pathogens is its intrinsic resistance. Besides, it 
makes harder to discover or find new strategies or antimicrobials. Cell 
permeability is a factor contributing to intrinsic resistance, mainly mediated by the 
existence of the multi-layered cell wall. The intrinsic resistance due to the cell wall 
has been demonstrated in several occasions by studying mutations that affect the 
cell wall biosynthesis (4, 5). 
Of course, this intrinsic resistance due to the cell wall could be overcame by 
the existence of porins (proteins causing hydrophilic channels in the cell wall), that 
could allow the entrance of antimicrobial drugs through them, although this could 
be compensated with porin mutations or with the efflux of the drug by the efflux 
pumps. The efflux pumps are transmembrane proteins that have several functions 
such as transporting wastes or signalling molecules out of the bacterial cell. They 
transport specifically several antimicrobial drugs outside the cell, even when they 
could not be structurally related. Mutations in regulators of efflux pump genes 
confer in some cases antibiotic resistance. For example, in M. tuberculosis the 
transporter Tap, which is regulated by WhiB7, is able to export p-aminosalicylic 
acid (PAS), conferring a low level of resistance to this drug. It has been proposed 
that an efflux inhibitor could be a valuable tool for fighting tuberculosis as well as 
infections caused by other multi-drug resistant pathogens (6). It has been 
demonstrated that the porins MspA and MspC play a role in the resistance to 
fluoroquinolones and chloramphenicol in M. smegmatis (7).  
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Target alteration 
One of the mechanisms of resistance is the modification of the target, which 
can take place directly by altering the target sequence through gene mutations or 
indirectly through other mechanisms that control the access of the drug to the 
target. This is the case of the resistance to capreomycin and viomycin, two peptides 
that bind 16S and 23S of rRNA in a region methylated by the enzyme TlyA; a loss 
of function of TlyA confers resistance to capreomycin and viomycin (8, 9). 
 
Target mimicry 
The target of fluoroquinolones is the inhibition of DNA replication, 
transcription and repair by blocking the DNA gyrase. However, M. tuberculosis has 
an interesting mechanism that confers resistance to fluoroquinolones: it consists in 
producing a protein called MfpA that mimic the structure of the DNA molecule, it 
is though that MfpA can capture fluoroquinolones avoiding the binding to the 
natural DNA (10). 
 
Compensatory mutations 
The appearance of these mutations implies an energetic (or fitness) cost that 
may act against the development of the emerging resistance. For this reason, 
M. tuberculosis, as well as other pathogens, is able to compensate this fitness cost 
with secondary mutations called “compensatory mutations”, which allow 
resistant bacteria to restore their fitness after a long exposure to antimicrobials. 
Comas et al. (11) demonstrate that the fitness of rifampicin-resistant strains of M. 
tuberculosis was recovered when they performed growth competition assays. They 
concluded that recovering the fitness by compensatory mutations would had 
allow to some MDR strains to prevail in the population. We can appreciate that 
M. tuberculosis has a great versatility and capability of adaptation to the drug-
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mediated aggressions of the environment, and also it has the ability to modify or 
counteract the external drug attack.  
 
Drug modification 
In the resistance against aminoglycosides (such as kanamycin) a protein 
called Eis plays and important role. This mycobacterial protein is able to inactivate 
certain aminoglycosides by acetylation of the amine groups (12), also has been 
demonstrated by Houghton et al. (13), that Eis, could also play a role in the 
inactivation of capreomycin, which is a circular antimicrobial peptide. Also, 
mutations in the Eis protein turns M. tuberculosis resistant to kanamycin A but not 
in amikacin.  
 
Image 1: Schematic representation of the different mechanisms of resistance in M. 
tuberculosis. 
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DRUGS, DRUG TARGETS AND MODE OF ACTION 
Historically, gene products that are essential for maintaining bacterial 
structures or contribute to essential metabolic processes like DNA replication, 
RNA synthesis, protein synthesis, energy metabolism, cell wall synthesis or folate 
metabolism have been attractive targets for the discovery of new drugs capable of 
inhibiting them (14). Consequently, antimicrobial drug resistance often arises 
through the acquisition of mutations in the genes encoding such drug targets. A 
few well known examples are: 
1. Fluoroquinolones are broad-spectrum antimicrobials that interfere 
with bacterial DNA replication. In the case of M. tuberculosis, like in all other 
bacteria, they block the activity of DNA gyrase, then the DNA is unable to initiate 
the replication. DNA gyrase is encoded by gyrA and gyrB genes, and resistance to 
fluoroquinolones are often due to mutations in the coding region of these genes 
(15). Currently, fluoroquinolones are used as a second-line drugs for the treatment 
of MDR tuberculosis. 
2. Rifamycins act at the transcription level, since they inhibit the action 
of RNA polymerase by forming a complex with its β-subunit. Rifampicin (RIF) is 
one of the most effective drugs used in the treatment of tuberculosis. The most 
common mutations that produces resistance are located in rpoB gen, which 
encodes the β-subunit of the RNA polymerase. The M. tuberculosis strains called 
multi-drug resistant (MDR) are resistant to RIF (16). 
3. Protein synthesis is another classical drug target. Streptomycin, 
which was the first antitubercular antibiotic discovered, binds to the 30S subunit 
of the ribosome, thus inhibiting the normal protein synthesis. Mutations in rpsL or 
rrs genes, which encode 30S ribosome components, are associated with 
streptomycin-resistance (17). Currently, streptomycin is used as a first-line drug 
against tuberculosis. The oxazolidinone drug linezolid binds to the 50S ribosomal 
subunit altering the protein synthesis and having a bacteriostatic effect. Although 
resistance to linezolid is not very common, mutations in the 23S rRNA and in the 
rplC gene have been related with resistance to this drug (18); also, the effect of 
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efflux pumps has been suggested as a possible mechanism of resistance to 
linezolid in M. abscessus (19). Linezolid is very toxic in prolonged treatments; for 
this reason, it is not commonly used to treat tuberculosis. 
4. Pyrazinamide (PZA) is one of the first-line drugs against tuberculosis 
that plays an important role in the shortening the disease treatment from 9-12 
months to 6 months. It is targeting the energy metabolism by disrupting the 
membrane potential, interfering with the energy production and the synthesis of 
mycolic acids. The majority of the M. tuberculosis resistant strains to PZA has 
mutations in the gene pncA. Also other genes, such as rpsaA, panD and hadC have 
been reported to play a role in the PZA resistance adquisition. This has suggested 
that PZA could target the trans-translation process, the acidification of the 
cytoplasm and the synthesis of coenzyme A in M. tuberculosis (20).  
Image 17: Classical targets of antimicrobials against M. tuberculosis (14). 
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DRUGS ACTING AT THE CELL WALL 
The bacterial cell wall is one of the most explored drug targets, with several 
families of drugs acting on it. The mycobacterial cell wall plays an important role 
in tuberculosis survival, interaction with the host and virulence, and also is a 
significant barrier for antimicrobial drugs (21). Due to its high content of lipids, 
most of the hydrophilic agents cannot permeate the cell wall. Some of the drugs 
that target the cell wall are: isoniazid (INH), ethambutol (EMB), ethionamide 
(ETH), ethylenediamine, pyrazinamide (PZA) and cycloserine. From these, INH, 
PZA and EMB are first-line drugs used in combination with RIF in the tuberculosis 
treatment for drug susceptible strains. 
INH is a pro-drug that is activated by catalase-peroxidase and inhibits InhA 
(enoyl-ACP reductase) that acts in the synthesis of mycolic acids. There are several 
genes implied in resistance to INH (katG, inhA, ahpC, kasA and ndh), and efflux 
pumps are also involved in the acquisition of the resistance to INH (22). EMB is a 
bacteriostatic agent that has activity against actively replicating bacilli, it is also 
used for treating infections with M. avium and M. kansasii. It interferes in the 
formation of mycolyl-arabinogalactan-peptidoglycan complex by disrupting the 
synthesis of arabinogalactan, since it inhibits the enzyme arabinosyl transferase. 
Recently, Pawar A. et al, have suggested that EMB is also targeting glutamate 
racemase (MurI), an enzyme implied in the synthesis of peptidoglycan (23). 
The recently discovered antituberculosis drugs delamanid and pretomanid, 
have an interesting mode of action, since they act in multiple targets, which is an 
advantage in order to avoid the selection of resistant mutants. In the case of 
delamanid, it has a strong activity against M. tuberculosis including rifampicin 
resistant and MDR strains (24).  Delamanid inhibits the biosynthetic pathways of 
two mycolic acids, methoxy and ketomycolic acids. It has been recently published 
that delamanid exert a great activity against dormant tuberculosis in vitro and in 
guinea pig animal model (25). In the case of pretomanid, after being activated by 
a nitroreductase, it is able to inhibit the protein synthesis and also disrupts the cell 
wall lipid biosynthesis (26). Despite the fact that, multi-target drugs are less likely 
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to select resistance, it has been found that a mutation in the rv3547 gene generate 
delamanid-resistant strains of M. tuberculosis (27), and pretomanid-resistance 
seems to be caused by the loss of a specific glucose-phosphate dehydrogenase (28).  
Moreover, finding new multi-target drugs offer the possibility to reduce the 
development of resistance (29). Concurrence of multiple targets could be classified 
as series inhibition: when targets are in the same pathway; parallel inhibition: 
targets are unrelated; or network inhibition when many targets are in series or in 
parallel (30). 
 
TARGETING THE MEMBRANE AND MEMBRANE PROTEINS 
Recently, the interest on new drugs with unexpected targets has arisen, 
such as the InhA (enoyl-acyl carrier protein reductase) in 
methylthiazoles,pirrolydine carboxamides or diaryl ethers; the transmembrane 
transporter MmpL3 in ethambutol or in adamantly ureas; DprE1 
(decaprenylphospho-beta-D-ribofuranose 2-oxidase) in benzothiazoles and the 
QcrB (ubiquinol-cytrochrome C reductase) in lansoprazole (31).  They have in 
common that they are membrane proteins, thus the membrane could be an 
underexploited target for the developing of new antituberculosis drugs.  
Apart from the drugs that disrupt the function of membrane proteins, there 
are other agents that interact directly with the structure of the membrane itself.  
Most of these interactions are due to the  charge of the membrane, which is 
negatively charged due to the phospholipids and polyanionic groups, so that it 
binds positively charged drugs (32). 
In this context, antimicrobial peptides (AMP) interact electrostatically with 
the mycobacterial membrane and can cross the different layers disrupting some 
components of the cell envelope. The insertion of AMP in the inner membrane 
results in a loss of membrane permeability, but also allows pore formation. Pore 
formation not only affect the permeability of the bacillus membrane; it also alters 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
97 
the transmembrane potential, and other intracellular processes could result 
indirectly altered. Targeting the membrane present an advantage: membrane 
integrity is vital for both replicating and latent bacteria, and this feature is one of 
the goals for developing new drugs against tuberculosis. 
In this work we have explored the activity of AS-48, a circular bacteriocin, 
that in previous studies has been proposed to have a mode of action by disrupting 
the plasma membrane (33). However, due to the special composition of the cell 
wall in M. tuberculosis we wanted to explore if the same mode of action that, AS-
48 present against other species, is also happening in our microorganism of 
interest.  
 
THE OMICS IN DRUG RESISTANCE AND DRUG DISCOVERY 
In the last years, research on the acquisition of resistance genes has moved 
from the study of individual genes to the entire genome, the whole-genome 
sequencing (WGS). The comparative study of different genomes, either resistant 
strains or not, has become a good tool for the identification of resistance 
mechanisms. Along with that, further confirmatory studies should be done, such 
as generation of knockout mutants and phenotypic studies.  
In this context, RNAseq analysis seems a very appropriate technique for the 
evaluation of the interaction of different genes that confer resistance to 
antimicrobials. 
The RNAseq is a quantitative technique, it can provide levels of gene 
expression more accurately than former microarrays systems. One advantage of 
RNAseq is the possibility to track gene expression during a dynamic process (34). 
Other advantages over hybridization-based techniques are the high sensitivity for 
detecting low abundance transcripts, singles nucleotide resolution and the means 
to profile gene expression for those strains whose genome sequence is not 
annotated (35). RNAseq analysis provides the information of differentially 
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expressed genes (DEG), changes in gene expression under several experimental 
conditions, etc. This technology is also used to investigate which genes are 
expressed differentially when an infectious process is happening, and to quantify 
the levels of expression of each transcript under different conditions (36). DEG 
identified in vivo could help in the design of novel antimicrobials or therapies with 
different targets (37), this tool could help to avoid the gap between in vitro analysis 
and the in vivo approach. By the use of WGS, Winglee et al. (38) described the 
evidence of a mutation in the gene rv2887, with a loss of function, in mutants 
resistant to imidazo[1,2-a]pyridine-4-carbonitrile-based (MP-III-71) compounds. 
By the use of RNAseq analysis, they identified which genes were differentially 
expressed in the resistant mutant or in the wild type in the presence of MP-III-71. 
Gene expression analysis have been used not only for understanding the 
mechanism of action of antimicrobial drugs but also could be an interesting tool 
for determining new diagnostic biomarkers in the tuberculosis disease (39). By 
using RNAseq, it was possible to observe the difference of the immune response 
when the bacilli are adapted to its host. Malone K.M. et al. identified the 
mechanisms of the innate immune response during the early infection of 
M. tuberculosis and differentiated them from the infection of M. bovis when they 
are infecting cows (40, 41). In order to analyse the interaction of cholesterol, 
palmitic and oleic acids with M. tuberculosis during the infectious process, Aguilar-
Ayala D.A. et al. (42) demonstrated the implications of lipid pathways, efflux 
pumps and iron and sulphur caption, by RNAseq technique. They suggested that 
the response to these fatty acids, could be the machinery that confers drug 
tolerance to drugs and proposed the differentially expressed pathways as a 
therapeutic target. 
Finally, in the fight against tuberculosis exploring new molecules or 
searching new targets are the best weapon to lead the new emerging resistance 
and the spread of the multidrug resistance strains. 
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OBJECTIVE 
In the previous chapter, we have characterised the antimicrobial activity of 
bacteriocin AS-48, against mycobacterial strains, mostly M. tuberculosis, and 
discovered its synergism with a lytic enzyme (lysozyme) and with the first line 
antituberculosis drug ethambutol. We wanted to get further knowledge on how 
this bacteriocin acts on mycobacterial cells. For exploring this, we have followed 
two main approaches: first, assays aimed at determining the integrity and 
functionality of the bacterial membrane have been done, given that for many other 
bacteriocins, the bacterial membrane is proposed as a target; in parallel, we have 
followed a global approach by using transcriptomic techniques, in order to get a 
complete picture on how the bacterial react to the treatment of AS-48. 
The specific objectives have been the following: 
1) To determine if mycobacterial cells treated with AS-48 can 
accumulate increased quantities of ethidium bromide 
2) To explore whether AS-48 is able to depolarize the membrane of 
mycobacterial cells 
3) To analyse global transcriptome of M. tuberculosis after treatment 
with AS-48 at several time points 
4) To validate candidate genes that could be relevant for the response of 
mycobacterial cells to treatment with AS-48 
5) To build up a hypothesis on how this bacteriocin acts and how the 
bacteria can response to treatment with AS-48 
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MATERIALS AND METHODS 
ETHIDIUM BROMIDE ACCUMULATION ASSAY 
This assay assesses the capacity of M. smegmatis cells for accumulating 
ethidium bromide in the presence of increasing concentrations of bacteriocin AS-
48. M. smegmatis was cultivated until an O.D.600 of 0.6-0.8 at 37ºC in Middlebrook 
7H9 broth supplemented with Tween 80 at 0.05% and 10% of ADC enrichment. 
The culture was centrifuged and the pellet washed in PBS buffer supplemented 
with 0.05% Tween 80, then the O.D.600 was adjusted to 0.8 in the same buffer 
further supplemented with glucose 0.4%. The ethidium bromide was used at 1 
µg/ml combined with inhibitory and subinhibitory concentrations of AS-48. 
Verapamil at 75 µg/ml was used as a positive control showing the highest 
accumulation of ethidium bromide. A control experiment was done with PBS-
Tween 80 buffer and no bacterial inoculum, to set the values of fluorescence of the 
compounds by themselves. Other controls were done without ethidium bromide, 
to set the values of fluorescence of the bacterial cells. Accumulation of ethidium 
bromide was measured by recording fluorescence at 530 nm excitation and the 590 
nm detection during an hour (43).  
 
ANALYSIS OF THE BACTERIAL MEMBRANE POTENTIAL 
M. smegmatis and M. bovis BCG membrane potential was measured by the 
Baclight Bacterial Membrane Potential Kit (BacLightTM, B34950, Thermo Fisher 
Scientific) according to manufacturer instructions; integrity of the membrane 
potential results in fluorescence due to the accumulation of DiOC2(3) (Ex/Em of 
482/497 nm) inside bacterial cells. Bacterial cells were treated with several 
concentrations of AS-48 during 24 hours to assess its effect in the membrane 
potential. The samples were analysed by flow cytometry (Gallios, Beckman 
Coulter, Inc). Parameters, Forward Scatter (FSC) and side Scatter (SSC), were 
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adjusted according to the size of bacteria. For detecting DiOC2(3) a emission laser 
of 488 nm was used. For collecting the signal the filter FL1 was used that collect 
the wavelength at 505-545 nm. 
 
SAMPLES FOR SCANNING ELECTRON MICROSCOPY (SEM) 
The effect of AS-48 in morphology of M. tuberculosis H37Rv was analysed 
by Scanning Electron Microscopy (SEM). SEM images were acquired using an SEM 
Inspect™ F50 (FEI Company, Eindhoven, The Netherlands). Bacterial cultures 
treated with AS-48 at 64 µg/ml or with 8 µg/ml of AS-48 plus 25 µg/ml of 
lysozyme, were diluted to 105 cfu/ml, and samples were firstly fixed with 
glutaraldehyde. Then, samples were washed three times with 10x PBS and filtered 
through 0.1 μm filter (IsoporeTM Membrane Filters 0.1µm VCTP, Millipore) and 
finally dehydrated with a graded ethanol series, and kept in 100% ethanol. Finally, 
ethanol was evaporated at room temperature, and samples were covered with a 
thin layer of metal (Pt, 15 nm) and examined at 15 keV and at different 
magnifications. 
 
RNA EXTRACTION 
For RNA extraction, M. tuberculosis H37Rv was cultured in a minimum of 
10 ml volume up to and O.D. of 0.3-0.5. Cultures were then centrifuged at 3220x g 
during 5 min and supernatants were discarded. Then, 500µl of wash buffer (a 
solution of 1.5 ml of 8% NaCl and 75µl of Tween 80 in a final volume of 15 ml of 
nuclease-free water) and 1ml of RNA protect reagent (Quiagen) were added and 
homogenized. The samples were incubated at room temperature during 5 min and 
centrifuged at 20817x g during 5 min. The supernatants were discarded and the 
last drops were removed with a micropipette. At this point, pellets were stored at 
-80ºC until all samples were collected. Mycobacterial pellets were defrosted and 
resuspended in 400 µl of fresh lysis buffer (solution of 67 µl of sodium acetate 3M 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
103 
pH 5.5 (Ambion), 500 µl of SDS 10%, 5 µl EDTA 0.2M in 10 ml of nuclease-free 
water) and 1 ml of acid-phenol:chloroform (5:1). Mycobacterial cells were lysed in 
a screw tube with glass beads (lising matrix B, MP BiomedicalsTM) using Fast-
Prep® equipment, with two 45 second cycles at 6.5 m/s. Samples must be cooled 
on ice for 5 min between pulses. Then, samples were centrifuged at 20817x g 
during 5 minutes at 4 ºC. The bacterial pellets went again through the Fast-Prep® 
step in order to recover as much RNA as possible; the upper aqueous phase was 
recovered and transferred to a fresh tube and extracted with 900 µl of 
isoamilic:chloroform (24:1). Samples were kept on ice all the time. Again, samples 
were centrifuged for 5 minutes at 20817x g at 4 ºC. The final supernatant was 
placed in a new tube with 900 µl of isopropyl alcohol and 90 µl of sodium acetate 
3M pH 5.5 for precipitating RNA. Tubes were incubated at -20 ºC over night for 
RNA precipitation. Up to this point, the experiments were carried out in the BSL3 
facilities. 
For recovering RNA, tubes were centrifuged at 20817x g during 30 min at 4 
ºC. Pellet was washed with 1 ml of 70% ethanol and centrifuged again during 5 
min at 20817x g and 4 ºC. Supernatants were discarded and finally the pellets 
containing RNA were resuspended in 100 µl of nuclease-free water. 
Treatment with DNase was done to avoid DNA contamination. Two 
incubations with Turbo DNA-free DNAse (Ambion) were done at 37 ºC for one 
hour each of them. A second purification process was performed by adding 200 µl 
of acid-phenol:chloroform and 50 µl of nuclease-free water, samples were 
homogenized and centrifuged 5 min at maximum speed. The aqueous phase was 
precipitated again with 400 µl of isopropyl alcohol and 20 µl of sodium acetate 
(3M, pH 5.5) and incubated over night at -20 ºC. 
After the second purification, RNA pellets were rinsed with 200 µl of 
ethanol (70%) and resuspended in 50 µl nuclease-free water. RNA integrity was 
assessed by agarose gel electrophoresis and absence of DNA contamination was 
checked by PCR amplification. 
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Concentration of RNA was assessed using ND-1000 spectrophotometer 
(NanoDrop technologies) reading at 260/280 nm. 
 
RNASEQ ANALYSIS 
Bacterial cultures were grown with and without 64 µg/ml of AS-48. RNA 
extraction was done at time 0, after 4 hours and after 24 hours. RNA samples were 
sent to FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica 
de la Comunitat Valenciana) where cDNA libraries were prepared and sequenced 
by NextSeq RUN High Output 1x150pb by Illumina Technology. 
 
BIOINFORMATIC ANALYSIS 
The bioinformatics analysis was performed in FISABIO where the 
normalized count values were faced for each sample and plotted in a biplot. The 
relative expression (Sample 1/Sample 2) for each comparison were presented in a 
distribution in order to show the variability within each comparison. From this 
distribution, only those values that overcome the quintiles 0.95 and 0.05 of the 
relative expression were taken into account as a differentially expressed. All 
statistics have been obtained using The RStatistics software making use of several 
Open Source libraries such as rtracklayer, GenomicFeatures, etc. Infering the 
transcripts and its expression has been done using Cufflinks (44) and R libraries: 
Rsamtools, GenomicFeatures, GenomicAlignments and NOISeq (45) program 
suite. BAM files from TopHat alignment program has been processed by Cufflinks 
to assembly transcriptomes from the alignment to reference genome. Computation 
of gene and transcript expression profiles is given in two formats: count tables and 
FPKM tables.  
Density distribution of expression levels relationship using as reference 
sample. For samples with different RNA composition, it is expected a different 
distribution in sequencing reads across genomic features, in such a way that 
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although a feature had the same number of read counts in both samples, it would 
not mean that it was equally expressed in both. To check if this bias is present in 
the data, RNA composition distribution plot and the corresponding diagnostic test 
can be used. In this case, each sample is compared to the reference sample (which 
is randomly chosen). To do that, log2 (counts sample / counts reference) are 
computed. If no bias is present, it should be expected that the median of log2 
(counts sample / counts reference) for each comparison is 0. Otherwise, it would 
be indicating that expression levels in one of the samples tend to be higher than in 
the other, and this could lead to false discoveries when computing differencial 
expression.  
Therefore, a normalization procedure should be used to correct this effect 
and make the samples comparable before computing differential expression. 
Differential expression comparison has been based on relative expression ratio 
(REi) between normalized reads counts from pairs samples of interest. 
Normalization of counts are obtained by library or size factor measuring 
differences between samples in terms of coverage or number of reads and 
recalibrating counts with this factor to make them comparable (46). Once 
normalized counts are obtained, relative expression ratio is calculated for each 
gene as the formula below: 
𝑅𝐸𝑖 =
𝑆𝑎𝑚𝑝𝑙𝑒 1𝑖
𝑆𝑎𝑚𝑝𝑙𝑒 2𝑖
 
Being i each of consider genes into the analysis. Biplots confronting 
normalized counts and distribution of relative expression ratios are show bellow 
for each sample and gene pair considered. Finally, for each comparison high and 
low relative expressed genes are shown in table format, using quantiles 0.95 (high 
relative expressed genes: higher sample1 vs lower sample2 normalized counts) 
and 0.05 (low relative expressed genes: lower sample1 vs higher sample2 
normalized counts) of relative expression ratio distributions as threshold criteria. 
 
CHAPTER 2 
 
 106 
REAL TIME QUANTITATIVE REVERSE TRANSCRIPTION PCR 
A real-time quantitative reverse transcription PCR (qRT-PCR) were carried 
out to check the expression levels of genes selected after the RNAseq analysis. 
First, reverse transcription was done with 500 ng of RNA and 2 µl of Prime 
Script RT Master Mix (Takara) in a final volume of 10 µl of nuclease-free water. 
The Mix included Pimer Script Rtase, RNase inhibitor, Random Hexamers, dNTP 
Mixture and Mg2+ buffer. Actinomycin D (Sigma) was added to each sample to 
avoid second-strand cDNA synthesis during reverse transcription. The reverse 
transcription reaction was performed at 37 ºC during 15 minutes, 85ºC during 5 
seconds and finally kept at 4ºC. Next, the resulting cDNA was diluted 1/10 for the 
qRT-PCR amplification in presence of the different gene primers (Table 8); 5 µl of 
SYBR green Master Mix (Takara) were added by each cDNA sample. This Mix also 
contains ROX dye which is used for normalize the non-PCR-related fluctuations 
in fluorescence signal, 0.2 µl of ROX was added by each cDNA sample.  
The qRT-PCR reactions were performed as recommended by the 
manufacturer (95ºC for 10 minutes, followed by 40 cycles of: 95ºC for 15 seconds 
and 60ºC for 1 minute, and finished with sample storage at 4ºC). The amplifications 
were carried out in the StepOne Plus Real Time PCR System (Applied Biosystems). 
All primers were designed using the Primer Express Software (Applied 
Biosystems). 
Finally, for assessing the specificity and amplification of one single product 
per each primer pair, a melting curve were done. Two housekeeping genes were 
used to normalize the gene expression between samples: sigA (encoding sigma 
factor A) and rrs (encoding 16S rRNA) because they both have a stable expression 
level under different experimental conditions. 
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 Table 8: Target genes and primers (5’ to 3’) for qRT-PCR reactions. 
GEN RV Forward Reverse 
hycQ Rv0086 TCTTTGCGCGATGGTTCTG ACCGTGGTGGCCTCGAT 
fadD10 Rv0099 CGGCGGGTTGTGTGTCA GGTGAGAATCTCCAGCAACGA 
hsp Rv0251c CGGTGGTCCGTTTGGAACT GGGTCAAGCTCGACGTTGA 
secE2 Rv0379 CGGGTCATTGAGCAGGACAT CTTGATGCGGTAGGTGATCTTG 
mce2D Rv0592 AGGCGCTCGCGCTGTAC ACCCGCACACCCATGATC 
vapC7 Rv0661c CTGGGCCGTGTGACTATGC GGTGGCCTCGATTGATGGT 
rpmD Rv0722 CACTCTGGGCTTACGAAGGATT CGAGTCGCTGCGTTGTCTT 
fadE9 Rv0752c GCGCATCTTCGAGCAGTTG ATGTTGTGGATGGACAAAAACG 
ephC Rv1124 CGGCGAACGGGAGTCA ACGTCAATCCAGTGTGGTTCAG 
prpC Rv1131 CACCGCCATCTCCAAGGT TCCCCGGTAGGTCAACGA 
mbtN Rv1346 AAGCGCAGGAACGTTTTCC TCGAATACGCCGCAGACA 
cydD Rv1621c CGGCTATTTGCCCACGTT GGCAGTGTGATCACCACAATG 
vapB12 Rv1721c GATGAGCCTGAGCGATTTCC CCGGTTCTTCCGCGATCT 
vapC34 Rv1741 TGATGTCGACGGCGTCATAT CCCGAAGCGTGTTTCGAT 
vapC14 Rv1953 TGCAAGTCGCCGAACAGTT TCACGCCTCGCTCAATCTC 
higB Rv1955 CCGGCCGGTATTCAAGAAG GCCCGGGCCTGATCA 
parD1 Rv1960c TGGGTAAGAACACGTCCTTCGT GCGATCTCGCCGTCGAT 
vapC36 Rv1982c TCTTTCACCGCCGAGCAT TTGCCGTATCGCAGAAAGG 
rpsN2 Rv2056c AAGAAGTCCAAGATCGTCAAGAATC GGGATCGGATGATGTCTTTGAG 
mazE7 Rv2063 TCCACGACGATTAGGGTTTCA AGCAGAGCCGACATCGAGAT 
vapB16 Rv2231B CGATGATCGCGAAGTTTGGT GCAGGCGCCCAGACTTT 
cyp121 Rv2276 GGCTCGTCTCCTCGTATGCA ATGGAAAAACGCCGATCCT 
uspB Rv2317 TCACGCTGTCCCCCTTCTT GAACTGGTGTGCGGAAGTGAA 
lppQ Rv2341 GTCGACGAAGGCCAGATCTC CAACCATCGCCGCTTGATA 
plcA Rv2351c GGTCAGCTGGAAGGTGTACCA TGATGGGCGTGTTGATGAAT 
mbtH Rv2377c TTCTTCGTGCTGGTCAACGA CGGGATATCGGCGAACAC 
mbtA Rv2384 TTCGCTGGAGCTCCGATTAC ACCACGCCGGTCAAGGTA 
accD1 Rv2502c CCCCGGGTCCCTTACG GAATTCGCTGCCGTCAACA 
fas Rv2524c CGTGCACCCGAGTTTGGT GCAATGATATTCGGCAAGACTTC 
vapB17 Rv2526 ATTGAGCTGGACGAAGATCTTGT ACCGTCGCTCGCAATGTT 
vapC42 Rv2759c GGTCACCGAACTCCCGAAT TGATCGCGCACAGTTCGA 
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GEN RV Forward Reverse 
vapB22 Rv2830c TGACCGCTACGGAGGTGAA CGCCCTGGGCCACTTC 
ugpE Rv2834c GGGCCGTTGCTGTTCGT CGCATAGATGTCGGGCTGAT 
esxS Rv3020c GCCGCCAAGGTCAATACCT GCGGCCTCACCCAAATT 
metA Rv3341 GCCCGCGACGGAAAG GCCTGCACCTGGTCACGTA 
relK Rv3358 CCTGGGAGGACTTCTTGTTCTG ATCCGACGGGCCGTTTT 
dppC Rv3664c GGATCGATGCGGTGGTTTC CAACGGCAAGCCGAGAA 
 
MATHEMATICAL ANALYSIS OF QRT-PCR 
The data generated by StepOne Plus Real Time PCR System provide the CT 
value of each reaction; all gene amplifications were performed in triplicate, and for 
each gene, arithmetic average of the triplicates was done. For calculating delta CT, 
the geometric average of the different arithmetic average of each housekeeping 
(HK) gene was subtracted from the arithmetic average of the genes of interest 
(GOI): 
∆𝐶𝑇 = 𝑎𝑟𝑖𝑡ℎ𝑚𝑒𝑡𝑖𝑐 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐺𝑂𝐼 −
𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑎𝑟𝑖𝑡ℎ𝑚𝑒𝑡𝑖𝑐 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑡ℎ𝑒 𝐻𝐾  
We considered the expression genes of the positive control at time 0 as the 
calibrator, so for calculating the Delta Delta CT : 
∆∆𝐶𝑇 = ∆𝐶𝑇 𝑠𝑎𝑚𝑝𝑙𝑒 − ∆𝐶𝑇 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟 
And then the relative quantification (RQ) was calculated as follows from 
the Delta Delta CT : 
𝑅𝑄 = 2−∆∆𝐶𝑇 
Finally, the fold change of each gene was calculated as the ratio of the RQ 
of each gene when the sample was treated with AS-48 and the RQ of each gene 
when the sample was untreated (positive control): 
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 =
𝑅𝑄 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑡𝑖𝑚𝑒)
𝑅𝑄 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑡𝑖𝑚𝑒)
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Graphic representation of the Fold Change allowed to identify whether any 
specific gene has been differentially expressed between both conditions. 
MYCOBACTERIAL DNA EXTRACTION 
The method used for genomic mycobacterial DNA extraction was based on 
CTAB method (47). Mycobacterial cultures were centrifuged, the pellets 
resuspended in 400µl of TE (100 mM Tris/HCl, 10 mM EDTA, pH 8) and 
inactivated by heat during 15 minutes at 85°C. Then, 50µl of lysozyme solution (10 
mg/ml) were added and incubated at 37°C at least one hour. Next, 75 µl of the mix 
composed by SDS (72.5 µl, 10%) and Protein K (2.5 µl, 20mg/ml) were added and 
mixed by inversion, then incubated at 65°C during 10 minutes. After this, 100 µl of 
a prewarmed solution of NaCl (5M) and 100 µl of CETAB/NaCl (10% CETAB in 
0.7M NaCl) were added and incubated during 10 minutes at 65°C. Then, 750 µl of 
chloroform/isoamyl alcohol (24:1) were added to extract genomic DNA. After 
centrifugation (5 minutes at 15294x g) the upper aqueous phase was transferred 
into a new tube containing 420 µl of isopropanol and kept at -20°C during at least 
30 minutes for DNA precipitation. Precipitated DNA was pelleted by 
centrifugation (5 minutes at15294x g) and washed by 500 µl of ethanol 70%, mixed 
by inversion. After centrifugation, pellet was vacuum dried and finally 
resuspended in 50µl of MilliQ water. DNA was quantified by absorbance readings 
at 260 nm using a ND-1000 spectrophotometer (NanoDrop technologies). 
ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
To evaluate the ability of AS-48 to bind bacterial DNA, an electrophoretic 
mobility shift assay (EMSA) was done.  For this, 250 ng of DNA extracted from 
M. tuberculosis H37Rv were used in a final reaction volume of 12 µl. Serial dilutions 
of AS-48, from 1300 to 2.5 µg/ml, were incubated during 10 minutes at room 
temperature with the DNA samples and load in 0.8% agarose gel at 130V and 
detected by the fluorescence of ethidium bromide. In the first well was loaded the 
molecular weight marker of 100bp (GeneRuler 100bp Plus DNA Ladder. 
ThermoFisher). 
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RESULTS 
 
IS AS-48 TARGETING THE MYCOBACTERIAL MEMBRANE? 
In order to explore whether bacteriocin AS-48 could be targeting the 
mycobacterial membrane, we carried out experiments of ethidium bromide 
accumulation using M. smegmatis mc2155 and we determined the ability of AS-48 
for depolarising the mycobacterial membrane. 
It is assumed that AS-48 forms pores in the membrane (48), thus making the 
cell more permeable to compounds such as ethidium bromide. Therefore, in an 
ethidium bromide accumulation assays, we would expect that the fluorescence 
detected would be higher in the presence of AS-48, reflecting the increased 
accumulation of ethidium bromide as a result of the effect of AS-48 in the bacterial 
membrane. We compared the effect of AS-48 with verapamil, a well-known efflux 
inhibitor (43), which produces an increase in the accumulation of ethidium 
bromide. In the presence of AS-48, fluorescence due to accumulated ethidium 
bromide increased upon time in a concentration dependent manner, although the 
kinetics of accumulation was rather distinct to that observed with verapamil 
(Image 17).  
Image 17: Measure of fluorescence in the Ethidium Bromide accumulation assay when 
treating M. tuberculosis with different AS-48 concentrations and with Verapamil as an 
efflux inhibitor. 
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The determination of membrane potential was carried out following the 
BacLightTM Kit instructions, using M. smegmatis mc2155 and M. bovis BCG cells. In 
a representative control experiment, in the untreated cells, a 3.4% of cells were 
depolarized, whereas in the cells treated with the protonophore CCCP the 
percentage of depolarized cells was 94.93%. We have assessed the effect of AS-48 
in several concentrations and after different times of incubation (1 or 24 hours). 
We have observed that AS-48 depolarized cells in a concentration-dependent 
manner, and this effect was much higher in the cells incubated with AS-48 during 
24 hours than in those tested after one hour of incubation. Figure 4 shows that the 
percentage of depolarized cells after 24 hours is 67.04% in presence of 128 µg/ml 
of AS-48, 26.34% with 64 µg/ml and, 18.68% with 32 µg/ml. Again, this 
demonstrate that the depolarization of the cells is dependent on the concentration 
of AS-48 and increases with time (Image 18). 
Image 18: Percentage of depolarization when treating M. smegmatis with a gradient of 
AS-48 at different time points. Compared with positive control of depolarization: CCCP 
(Carbonyl cyanide m-chlorophenyl hydrazone). 
 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
113 
TREATMENT WITH AS-48 RESULTS IN MORPHOLOGICAL CHANGES IN M. 
TUBERCULOSIS. 
We treated M. tuberculosis cells with AS-48, along with untreated cells as a 
control, and samples were taken at several time points for microscopic 
observation. We found that after short time exposures (48-72 hours), cells were 
affected by AS-48 as the morphology of cells treated with a concentration of AS-48 
equal to the MIC, were rougher than the control (Image 19). 
Image 19: Scanning Electron Microscopy (SEM) images of M. tuberculosis H37Rv under 
different conditions. A) Untreated cells after 48 hours of growth. B) Untreated cells after 
72 hours of growth. C) Cells treated with 64 µg/ml of AS-48 during 48 hours. D) Cells 
treated with  64 µg/ml of AS-48 during 72 hours. 
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Moreover, we analysed the effect of a combination of 8 µg/ml of AS-48 with 
25 µg/ml of lysozyme on cell morphology after 24, 48 and 96 hours after treatment. 
When bacterial cells were treated with a synergistic combination of AS-48 and 
lysozyme, they exhibited greater morphological damages (Image 20), in 
comparison with cells treated with AS-48 alone (Image 19).  
Image 20: Scanning Electron Microscopy (SEM) images of M. tuberculosis H37Rv treated 
with a synergistic combination of 8 µg/ml of AS-48 and 25 µg/ml of lysozyme; A) after 24 
hours of treatment; B) after 48 hours of treatment and C) after 96 hours of treatment. 
 
RESISTANT MUTANTS 
For elucidate the mode of action, we have tried to get resistant strains to AS-
48 but we could not reach any. We have cultured M. tuberculosis under the 
conditions described in Chapter 1, and treated the inoculum with a concentration 
of 8 x MIC. After that, we plated the culture and got 57 colonies. The MIC was 
performed comparing with the wild type strain and the result was that there were 
not any variation between them. 
This suggested that M. tuberculosis could present a transitory tolerance to 
AS-48 but when cultivating again turns into the same susceptibility that we have 
observed for the MIC determination.  
We could not predict which other changes (besides the already described 
above) AS-48 is causing in M. tuberculosis, so, for that reason we decided to 
perform a transcriptomic assay by RNAseq. 
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TRANSCRIPTOMICS 
In order to get a global impression of the impact of bacteriocin AS-48 on M. 
tuberculosis, we analysed the transcriptome of M. tuberculosis H37Rv cultures 
treated with AS-48 after 4 and 24 hours. We expected that potential mechanisms 
of resistance or response to the treatment with bacteriocin, or genes related with 
bacteriocin mode of action would be identified. From the data obtained from the 
RNAseq analysis, we got a biplot comparison between treated and untreated 
bacterial cells after the two selected time-points (Image 21). 
Image 21: Transcriptomics expression bit plots comparisons among treated and 
untreated cultures after 4hours (A) and 24 hours (B) of treatment with AS-48 
 
The biplot shown in Figure 5 is a density distribution of the relative 
expression. Those dots that are distant from the diagonal represent genes that 
change their expression level between treated and untreated cells. It is evident that 
after 24 hours of treatment, the number of differentially expressed genes is higher 
than after 4 hours of treatment. 
Those genes that have a relative expression values that overcome the 
quintiles 0.95 (high) and 0.05 (low) were selected for further studies and listed. 
These are the genes that shows a higher differential expression in the bacteriocin 
AS-48 treated samples in comparison with the untreated control. According to this 
A) B) 
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analysis, we obtained four lists, two lists for the genes over- and under-expressed 
after 4 hours of treatment and two other lists for the same comparison after 24 
hours of treatment. These four lists of genes are recorded in the Tables 9-12, as 
follows:  
Table 9: Differentially over-expressed genes after 4 hours of treatment with AS-48 (list A). 
Gene name control-4h AS-48-4h Relative Expression 
vapB16 0.000 1.011 0.000 
vapB7 3.656 4.775 0.766 
PPE40 12.728 15.641 0.814 
PE20 8.461 10.347 0.818 
mmpL9 13.424 15.724 0.854 
PPE48-1 5.408 6.230 0.868 
PE29 3.558 4.020 0.885 
PE7 5.259 5.903 0.891 
moaD1 4.985 5.544 0.899 
narK1 13.220 14.671 0.901 
PPE31 8.359 9.247 0.904 
fadE9 9.814 10.740 0.914 
vapB17 6.125 6.650 0.921 
PPE1 9.286 10.059 0.923 
mazE7 4.385 4.721 0.929 
relK 5.617 6.043 0.929 
mbtH 11.859 12.721 0.932 
 
 
 
 
 
 
 
 
 
 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
117 
Table 10: Differentially infra-expressed genes after 4 hours of treatment with AS-48 (list 
B). 
Gene name control-4h AS-48-4h Relative Expression 
nusB 16.705 10.388 1.608 
thiS 3.656 2.339 1.563 
aroD 15.550 10.208 1.523 
aglA 17.002 12.185 1.395 
galK 5.688 4.721 1.205 
esxE 6.776 5.802 1.168 
PE_PGRS49 5.863 5.108 1.148 
vapC7 5.756 5.065 1.137 
moaB1 5.734 5.065 1.132 
vapB42 7.396 6.575 1.125 
uspB 5.641 5.020 1.124 
dosT 13.632 12.230 1.115 
PE_PGRS36-1 6.446 5.802 1.111 
lppQ 8.101 7.352 1.102 
PE10 6.073 5.512 1.102 
cut1 7.323 6.650 1.101 
esxF 7.247 6.591 1.100 
vapB22 7.973 7.269 1.097 
rpmD 12.853 11.797 1.090 
parD1 12.159 11.163 1.089 
PE_PGRS10 11.525 10.592 1.088 
pfkB 13.858 12.838 1.079 
pabB 13.808 12.804 1.078 
PE_PGRS3 8.738 8.130 1.075 
vapB27 8.867 8.259 1.074 
moaR1 10.913 10.191 1.071 
PE_PGRS61 6.787 6.343 1.070 
PE_PGRS15 11.669 10.910 1.070 
vapC34 7.880 7.370 1.069 
vapB12 7.140 6.679 1.069 
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Table 11: Differentially over-expressed genes after 24 hours of treatment with AS-48 (list 
C). 
Gene name control-24h AS-48-24h Relative Expression 
mazE7 3.449 5.445 0.633 
PE20 9.068 12.901 0.703 
PPE31 8.210 11.099 0.740 
cyp121 11.060 14.703 0.752 
PPE42 11.759 15.606 0.753 
cdh 13.213 16.553 0.798 
PPE29 8.010 9.788 0.818 
phoH1 15.857 18.223 0.870 
vapC42 7.489 8.578 0.873 
cdd 5.920 6.767 0.875 
PPE32 9.505 10.858 0.875 
accD1 12.631 14.429 0.875 
relK 5.208 5.917 0.880 
PPE48-1 4.689 5.308 0.883 
papA4 9.143 10.324 0.886 
mazF7 5.108 5.767 0.886 
accA1 12.634 14.259 0.886 
dppC 7.227 8.079 0.895 
moaC1 5.949 6.586 0.903 
celA1 9.637 10.596 0.909 
esxS 6.592 7.195 0.916 
yrbE4B 9.400 10.250 0.917 
mtc28 10.674 11.637 0.917 
PPE33 10.751 11.679 0.921 
mpg 6.394 6.928 0.923 
thrB 11.064 11.962 0.925 
lprJ 11.599 12.517 0.927 
prpC 12.672 13.662 0.928 
ctpJ 9.101 9.796 0.929 
ugpE 7.489 8.041 0.931 
mpt83 9.692 10.390 0.933 
secE2 10.007 10.726 0.933 
PE_PGRS29 10.286 11.016 0.934 
prpD 14.191 15.184 0.935 
galK 5.159 5.510 0.936 
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Gene name control-24h AS-48-24h Relative Expression 
ephC 8.814 9.399 0.938 
uspA 7.887 8.408 0.938 
PE_PGRS9 7.856 8.369 0.939 
PPE39 6.213 6.615 0.939 
mce2D 8.321 8.853 0.940 
lpqC 9.967 10.598 0.940 
 
Table 12: Differentially infra-expressed genes after 24 hours of treatment with AS-48 (list 
D). 
Gene name control-24h AS-48-24h Relative Expression 
aglA 17.585 11.780 1.493 
plcA 14.873 11.048 1.346 
lipP 17.064 13.630 1.252 
mbtI 11.737 9.567 1.227 
vapB7 4.293 3.572 1.202 
mbtL 9.467 7.905 1.198 
hisE 7.364 6.290 1.171 
dosT 13.873 11.871 1.169 
mbtA 10.156 8.727 1.164 
mbtD 11.195 9.633 1.162 
mbtC 11.272 9.756 1.155 
mbtB 13.404 11.636 1.152 
mbtJ 10.024 8.717 1.150 
vapC7 5.512 4.794 1.150 
cydD 11.155 9.980 1.118 
iniB 11.995 10.769 1.114 
hycP 9.806 8.853 1.108 
lprD 12.483 11.287 1.106 
fas 17.614 15.963 1.103 
hsp 13.610 12.339 1.103 
cydB 10.606 9.621 1.102 
PPE1 9.482 8.611 1.101 
hycE 12.786 11.644 1.098 
argD 10.673 9.761 1.094 
mbtK 10.932 10.008 1.092 
hycQ 12.505 11.474 1.090 
cydC 11.490 10.587 1.085 
PE10 5.551 5.115 1.085 
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Gene name control-24h AS-48-24h Relative Expression 
rpmG1 5.551 5.115 1.085 
blaI 14.224 13.194 1.078 
higB 12.278 11.425 1.075 
sigC 10.849 10.102 1.074 
PE25 15.060 14.038 1.073 
vapC17 7.479 6.975 1.072 
argR 8.961 8.365 1.071 
PPE3 14.209 13.268 1.071 
vapC14 11.335 10.589 1.070 
ctpC 14.889 13.931 1.069 
cobU 8.723 8.176 1.067 
fadD10 11.127 10.439 1.066 
hycD 11.612 10.897 1.066 
ureA 10.395 9.762 1.065 
rpsN2 6.994 6.571 1.064 
vapC36 10.647 10.009 1.064 
vapB4 8.744 8.224 1.063 
PE34 14.489 13.637 1.062 
mbtN 12.434 11.731 1.060 
metA 13.018 12.285 1.060 
 
In the four tables above, the second and third column contain the expression 
level of the gene normalized. And the fourth column contains the ratio between 
the expression level in cultures treated with AS-48 in comparison with expression 
levels in untreated cultures. This ratio is <1 for genes over-expressed after AS-48 
treatment and >1 for genes under-expressed after AS-48 treatment. 
We compared the four lists of differentially expressed genes during time. 
The number of genes that appeared in one single list or in two lists simultaneously 
(obviously there was no gene in common between three or the four lists) were 
represented in the following Venn diagram (Image 22). Considering this 
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comparison, we selected some genes for further qRT-PCR analysis to validate and 
quantify the relative level of expression. 
Image 22: Venn diagram with the four list of differentially expressed genes when 
M. tuberculosis is treated with AS-48. A) genes over-expressed after 4 hours of treatment 
with AS-48; B) genes infra-expressed after 4 hours of treatment with AS-48; C) genes over-
expressed after 24 hours of treatment with AS-48; D) genes infra-expressed after 24 hours 
of treatment with AS-48. 
The first group of pre-selected genes comprised those four genes that were 
found infra-expressed at both time points (i.e. common to lists B and D): aglA, 
vapC7, dosT and PE10. Also, we pre-selected the five genes that are commonly 
over-expressed at the two-time points (i.e. common to lists A and C): PE20, PPE48-
1, PPE31, mazE7 and relK. 
Second, we were intrigued by those genes that apparently inverted their 
expression upon time: the gen galK, seems infra-expressed after 4 hour of 
treatment but after 24 hours of treatment is over-expressed. In addition, genes 
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PPE1 and vapB7 appeared over-expressed after 4 hours of treatment and infra-
expressed after 24 hours. 
Third, we have pre-selected other genes that were differentially expressed 
greatly in any single condition. This included a large number of genes; for 
example, we realized that there were 19 genes belonging to the Toxin-Antitoxin 
systems so we pre-selected at least one for each family (maz, hig, par, rel and vap); 
other genes, predicted to be in operons, were pre-selected also. 
Finally, we added the rrs gene (encoding the 16S rRNA) as an internal 
control. 
From the lists of pre-selected genes, PE and PPE genes were excluded from 
further analysis, since its function is still little known, so we could not relate with 
a possible mode of action of AS-48. We ended up with a list of 30 genes, selected 
for quantification of their relative expression by qRT-PCR (Table 13). 
Table 13: List of genes selected from the RNAseq analysis for qRT-PCR.     
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Out of the 30 selected genes, four of them resulted in nonspecific retro-
transcription amplification reaction (metA, vapC42, fadD10 and fadE9), so they were 
left apart and the qRT-PCR validations for the different RNA extraction samples 
were done for remaining 26 genes. Technical triplicates were within 0.5 cycles and 
all the CTs values were under 35 cycles. In Image 23, we have compared the 
Relative Quantification (RQ) of each condition to the calibrator (Control 0 hours). 
An RQ value was considered as significant when there were more than 1.5 or less 
than 0.5, which is within the variations of the technique (49). 
As we can observe in Image 23, the expression of rrs gene remains stable in 
all the conditions, so this housekeeping gene can be used to normalise the 
expression levels of the rest of the genes. Then when comparing the level of 
expression of genes obtained after the RNAseq analysis with those of relative 
quantification of qRT-PCR, the expected results should be: 
1) We see that those genes that show over-expression or infra-expression 
(RQ<0.5 and RQ>1.5) in all the conditions are not reliable. 
2) Those genes that appears in list A should be enhanced in the RQ of 
samples treated with AS-48 at 4 hours and diminished in the samples 
of control at 4 hours. 
3) Genes in list B should be enhanced in the control at 4 hours and 
diminished in sample treated with AS-48 at 4 hours. 
4) For list C, genes with a high RQ must be the ones highly expressed 
when treating with AS-48 during 24 hours and decreased in the 
control sample untreated after 24 hours. 
5) And for the genes that appears in list D we expected an increase in the 
RQ of the untreated samples after 24 hours and a reduction in the ones 
treated with AS-48 during 24 hours. 
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Image 23: Quantification of gene expression levels by qRT-PCR of those genes selected 
after the RNAseq analysis. 
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The final analysis obtained from the results of RNAseq was comparing the 
treatment with AS-48 in relation to its time control. In this way, we could be able 
to determinate which genes are really differentially expressed. In Image 24 is 
represented the fold change of the treatment with AS-48 after 4 hours and after 24 
hours normalized with the control at its respective time. 
 
Image 24: Fold change of RQ (Relative Quantification) of treatment with AS-48 at different 
time points compared with its untreated time-dependent control sample. 
 
From the Fold Change analysis, those genes that its fold change expression 
is higher than 1.5 and lower than 0.5 have been considered as differentially 
expressed. However, the fold change of the relative expression after 24 hours of 
treatment seems to be much lower than after 4 hours of treatment. We can 
speculate that the RNA samples obtained after 24 hours of treatment with AS-48 
could start to be effected by the bactericidal action of AS-48, despite the fact that 
the O.D. of the culture correspond to a bacterial concentration higher than the used 
for the MIC.  
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As we have seen in CHAPTER 1, from the time-kill curve, AS-48 has a 
bactericidal effect after 48 hours of treatment, nevertheless a significant part of the 
bacterial population could be affected already after 24 hours. It is worth to remark 
that, the MIC of AS-48 is inoculum-dependent so the concentration of AS-48 used 
for treating the cultures prior to RNA extraction may not affect tuberculosis 
viability. In addition, the Fold Change and the RQ expression of the rrs 
housekeeping gene allow us to normalize the relative expression of each gene. 
Those genes that are differentially expressed by both methods, RNAseq and 
qRT-PCR, could be modulating its expression due to the AS-48 effect, and we 
could consider that if a mutation in those genes happen could generate resistant 
bacilli to AS-48. In Table 14 is shown the concordance of the results of both 
methods, if the result of qRT-PCR in terms of the relative expression of the Fold 
Change match with the RNAseq. 
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Table 14: Comparison of the Relative Gen expression of the selected genes by RNAseq and qRT-
PCR. 
  RNAseq qRT-PCR   
Gene OE_4h IE_4h OE_24h IE_24h OE_4h IE_4h OE_24h IE_24h Concordance 
accD1   
 
X   X 
  
X NO 
cydD   
  
X   
  
X YES 
cyp121   
 
X     
  
X NO 
dppC   
 
X   X 
  
X NO 
ephC   
 
X   X 
  
X NO 
esxS   
 
X   X 
  
X NO 
fas   
  
X   
  
X YES 
higB   
  
X   
  
X YES 
hsp   
  
X   
  
X YES 
hycQ   
  
X   
  
X YES 
lppQ   X 
 
  X 
  
X NO 
mazE7 X 
 
X     
  
X NO 
mbtA   
  
X X 
  
X NO(4h) YES(24h) 
mbtN   
  
X   
  
X YES 
mce2D   
 
X     X 
 
X NO 
parD1   X 
 
  X 
  
X NO 
plcA   
  
X   
  
X YES 
prpC   
 
X   X 
  
X NO 
relK X 
 
X   X 
  
X YES(4h) NO(24h) 
rpmD   X 
 
    
  
   - 
rpsN2   
  
X   
  
X YES 
secE2   
 
X   X 
  
X NO 
ugpE   
 
X   X 
  
X NO 
uspB   X 
 
    
  
X NO 
vapB17 X 
  
    
  
X NO 
vapC7   X   X X     X NO(4h) YES(24h) 
Note: OE_4h: Over Expression at 4h hours; IE_4h: Infra Expression at 4h; OE_24h: Over 
Expression at 24h hours; IE_24h: Infra Expression at 24h. 
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The genes that show a differential expression by the two methods are: cydD, 
fas, higB, hsp, hycQ, mbtN, plcA and rspN2. For mbtA and vapC7 there are 
concordance but only confirmed after 24 hours, and for relK only after 4 hours of 
treatment. We can see that the expression of these genes appears to be changed 
due to the effect of AS-48. For the other genes we cannot confirm the results 
obtained by RNAseq. 
TARGETING DNA MOBILITY 
It has been proposed that antimicrobial peptides could interact not only 
with the microbial membrane but also with its genetic material (50). In order to 
test this possibility, we performed a mobility shift assay to check if AS-48 is able 
to bind directly bacterial DNA. Image 25 shows the electrophoresis gel with the 
samples of M. tuberculosis DNA treated with a concentration gradient of AS-48 to 
allow its interaction and binding with the DNA. 
At concentrations below 40.625 µg/ml of AS-48, there is a normal migration 
of the DNA, equal to the one in the untreated control. But at concentrations of AS-
48 from 81.25 µg/ml and above, the DNA stayed in the well. These concentrations 
of AS-48 are in the range of the MIC of AS-48 in in vitro cultures (64 µg/ml). We 
can hypothesize that bacteriocin AS-48 is binding the DNA due to electrostatic 
interactions, given that DNA is negatively charged and AS-48 is positively 
charged. If this were the case, after its interaction with AS-48, the DNA would have 
a reduced negative charge, which in turn would explain its reduced mobility in 
the electric field within the agarose gel. Then, we can consider that AS-48 may be 
targeting the membrane as well as the bacterial DNA.  
 
 
 
Image 25: DNA migration in 
electrophoretic gel with different 
concentrations of AS-48. 
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DISCUSSION 
Natural or synthetic peptides are emerging as a promising source of novel 
antimicrobials (51). Currently, there are two AMPs in phase 2 of clinical 
development (murepavidin and brilacidin) for treating respectively Pseudomonas 
aeruginosa and S. aureus infections. As most AMPs, they both are targeting the 
bacterial membrane, an interesting new target for treating persistent infections as 
it is the case for tuberculosis (52). Other membrane-targeting compounds have 
been shown to be effective in vitro against Clostridium difficile (53). The interest of a 
possible application of AMPs in tuberculosis treatment has arisen since it was 
demonstrated that a high proportion of AMPs active against P. aeruginosa also 
showed activity against M. tuberculosis (54).  
We conducted two experiments aimed at investigating the potential effect 
of AS-48 in the cell membrane. On the one hand, by determining the proportion of 
depolarized cells after AS-48 treatment, we found that this effect was both 
concentration and time dependent. On the other hand, in ethidium bromide 
accumulation assays, we monitored a time-course increase in fluorescence, and 
also an AS-48 concentration dependent effect. Then, we have demonstrated that 
AS-48 is acting on mycobacterial membranes, by using two independent methods. 
We have also observed the changes in the architecture of the bacilli by Electron 
Microscopy, however, to elucidate if the damage is either in the membrane or in 
the cell wall an analysis with Transmission Electron Microscopy could give a more 
precise image, as has been described in M. marinum by Smith J. et al (55). 
Transcriptomics has evolved the study of the different molecular process in 
Mycobacterium tuberculosis but also has become an interesting and a useful tool for 
drug discovery and for getting a better understanding of the possible mechanism 
of resistance and its mode of action. Further validation is still needed to 
corroborate the vast information provided by the omics techniques, as well as the 
integration of phenotypic studies related with the role of the genes and proteins 
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being targeted. At this concern, bioinformatics tools and computer modelling are 
essential in order to make easy predictions, fast analysis of the massive data 
provided by omics techniques and consequently, improved drug discovery 
studies (56, 57). It could be also interesting to include the study of Tn-seq 
(phenotypic) data analysis, since it shows that there is a significant difference 
between transcriptionally relevant genes and the phenotypically important genes, 
i.e. those genes that the bacteria needs in order to keep its fitness when an 
environmental change happens (58). 
From the transcriptomical analysis with RNAseq we noticed that those 
genes belonging to the antitoxin-toxin (TA) systems seem to be differentially 
expressed (in a ratio between 2 to 5 or even higher), when the M. tuberculosis 
cultures were treated with AS-48, in comparison with untreated control cultures. 
TA systems are composed of a stable protein, toxin, and a more labile antagonistic, 
antitoxin. M. tuberculosis has a very high number of TA systems, 79 in total, much 
higher than other mycobacteria. The systems belong to different families: VapBC 
(50 systems), MazEF (10 systems), YefM/YoeB (one system), RelBE (two systems), 
HigBA (two systems) and ParDE (two systems), one tripartite type II TAC (Toxin-
Antitoxin-Chaperone) controlled by SecB-like chaperone, three potentially type IV 
systems and eight uncharacterized putative TA systems (59). It is thought that TA 
systems are involved in the control of growth, and in the persistence of M. 
tuberculosis, even though the signals that trigger activation of toxins are yet 
unknown (60). When M. tuberculosis persisters were induced by common 
antimicrobials, it was seen that TA systems were up-regulated (59), indeed the 
over-expression of relE has been shown that is related with the persister formation 
in vivo and the increase of the survival in the presence of rifampicin in vitro (61). 
From the list of 11 genes that we have confirmed the expression by RNAseq 
and qRT-PCR, three of them are toxin producers (higB, vapC7 and relK). In the case 
of mbtN and mbtA both genes could be repressed by iron and IdeR (62), then AS-48 
could also be affecting this metabolic route. According to DeJesus et al. (63)  a 
disruption of the genes, rpsN2 and higB, provides a growth advantage in H37Rv. 
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Besides higB has been identified by DNA microarrays to be up-regulated at high 
temperatures as well as hsp (64), in this case we have not change any 
environmental condition.  
However, higB is also up-regulated after 24 hours and 96 hours of starvation 
and fas is down regulated under the same conditions (65); some mechanism that 
happens in the cell under starvation conditions are similar to those when we have 
persister cells (59). From this we can hypothesize that AS-48, at short times 
exposures, is able to activate some mechanism that alters the production of 
persisters bacteria. We could also speculate about the infra expression of cydD, 
which is thought to be involved in the translocation of the substrate transport 
across the membrane, then the alteration of the membrane caused by AS-48 could 
also trigger the lack of nutrients and metabolic substrates for the normal growth 
of M. tuberculosis. 
Besides the effect in the cell membrane we have demonstrated that AS-48 is 
a multitarget drug thus the possibility to acquire resistances is lower than targeting 
a unique mechanism. Indeed, we could not get any resistant mutants that is why 
we used a transcriptional analysis to assess the mode of action. We have validated 
the interaction of AS-48 with the mycobacterial membrane and with the DNA, 
nevertheless, other modes of action could be considered. We cannot decline the 
idea that AS-48 could be binding some regions of the DNA and the relative 
expression of genes would be modulated by the effect in the DNA instead by the 
effect of As-48 in the membrane.  
To validate this hypothesis further transcriptomic studies should be 
needed, for example changing some of the culture conditions and time extraction. 
Moreover, the next step could be studying the combined effect of AS-48 and 
ethambutol and its transcriptomic changes in the cultures. The result of 
phenotipyc studies, generating knockouts, will give a precise idea of the real 
mechanism of action of AS-48. 
 
CHAPTER 2 
 
 132 
 
 
 
  
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
133 
REFERENCES 
 
1. Nguyen L. 2016. Antibiotic resistance mechanisms in M-tuberculosis: an update. 
Archives of Toxicology 90:1585-1604. 
2. Gygli SM, Borrell S, Trauner A, Gagneux S. 2017. Antimicrobial resistance in 
Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. Fems 
Microbiology Reviews 41:354-373. 
3. Kohanski MA, DePristo MA, Collins JJ. 2010. Sublethal Antibiotic Treatment Leads to 
Multidrug Resistance via Radical-Induced Mutagenesis. Molecular Cell 37:311-320. 
4. Gao F, Hua Y, Korepanova A, Peskova Y, Rohal K, Nakamoto RK, Cross TA. 2003. 
Membrane protein structural genomics: Mycobacterium tuberculosis. Biophysical 
Journal 84:349a-349a. 
5. Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA. 2004. Genes required for 
intrinsic multidrug resistance in Mycobacterium avium. Antimicrobial Agents and 
Chemotherapy 48:3412-3418. 
6. Ramon-Garcia S, Mick V, Dainese E, Martin C, Thompson CJ, De Rossi E, Manganelli R, 
Ainsa JA. 2012. Functional and Genetic Characterization of the Tap Efflux Pump in 
Mycobacterium bovis BCG. Antimicrobial Agents and Chemotherapy 56:2074-2083. 
7. Danilchanka O, Pavlenok M, Niederweis M. 2008. Role of porins for uptake of antibiotics 
by Mycobacterium smegmatis. Antimicrob Agents Chemother 52:3127-34. 
8. Monshupanee T, Johansen SK, Dahlberg AE, Douthwaite S. 2012. Capreomycin 
susceptibility is increased by TlyA-directed 2'-O-methylation on both ribosomal subunits. 
Mol Microbiol 85:1194-203. 
9. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin 
resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 
49:571-577. 
10. Ferber D. 2005. Biochemistry. Protein that mimics DNA helps tuberculosis bacteria resist 
antibiotics. Science 308:1393. 
11. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, 
Gagneux S. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium 
tuberculosis strains identifies compensatory mutations in RNA polymerase genes. 
Nature Genetics 44:106-U147. 
12. Chen WJ, Biswas T, Porter VR, Tsodikov OV, Garneau-Tsodikova S. 2011. Unusual 
regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. 
Proceedings of the National Academy of Sciences of the United States of America 
108:9804-9808. 
13. Zaunbrecher MA, Sikes RD, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of 
the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin 
resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of 
Sciences of the United States of America 106:20004-20009. 
CHAPTER 2 
 
 134 
14. Bhat ZS, Rather MA, Maqbool M, Ahmad Z. 2018. Drug targets exploited in 
Mycobacterium tuberculosis: Pitfalls and promises on the horizon. Biomed 
Pharmacother 103:1733-1747. 
15. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into 
fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of 
gyrA and gyrB mutations. PLoS One 7:e39754. 
16. Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, 
Niemann S, Van Ingen J, Cambau E. 2017. Consensus numbering system for the 
rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin 
Microbiol Infect 23:167-172. 
17. Meier A, Sander P, Schaper KJ, Scholz M, Bottger EC. 1996. Correlation of molecular 
resistance mechanisms and phenotypic resistance levels in streptomycin-resistant 
Mycobacterium tuberculosis. Antimicrob Agents Chemother 40:2452-4. 
18. Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S. 2012. 
rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium 
tuberculosis strains. Antimicrob Agents Chemother 56:2743-5. 
19. Ye M, Xu L, Zou Y, Li B, Guo Q, Zhang Y, Zhan M, Xu B, Yu F, Zhang Z, Chu H. 2018. 
Molecular Analysis of Linezolid Resistant Clinical Isolates of Mycobacterium abscessus. 
Antimicrob Agents Chemother doi:10.1128/AAC.01842-18. 
20. Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S, Zhang T. 2016. Pyrazinamide 
resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci 61:63-71. 
21. Bhat ZS, Rather MA, Maqbool M, UL Lah H, Yousuf SK, Ahmad Z. 2017. Cell wall: A 
versatile fountain of drug targets in Mycobacterium tuberculosis. Biomedicine & 
Pharmacotherapy 95:1520-1534. 
22. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, 
Viveiros M. 2012. Contribution of Efflux to the Emergence of Isoniazid and Multidrug 
Resistance in Mycobacterium tuberculosis. Plos One 7. 
23. Pawar A, Jha P, Konwar C, Chaudhry U, Chopra M, Saluja D. 2018. Ethambutol targets 
the glutamate racemase of Mycobacterium tuberculosis-an enzyme involved in 
peptidoglycan biosynthesis. Appl Microbiol Biotechnol doi:10.1007/s00253-018-9518-z. 
24. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez 
DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, 
Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for 
multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151-60. 
25. Chen XH, Hashizume H, Tomishige T, Nakamura I, Matsuba M, Fujiwara M, Kitamoto R, 
Hanaki E, Ohba Y, Matsumoto M. 2017. Delamanid Kills Dormant Mycobacteria In Vitro 
and in a Guinea Pig Model of Tuberculosis. Antimicrobial Agents and Chemotherapy 61. 
26. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, 
Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 
2000. A small-molecule nitroimidazopyran drug candidate for the treatment of 
tuberculosis. Nature 405:962-6. 
27. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, 
Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
135 
with promising action against tuberculosis in vitro and in mice. Plos Medicine 3:2131-
2144. 
28. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, 
Bifani P. 2015. Mutations in genes for the F420 biosynthetic pathway and a 
nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-
selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents 
Chemother 59:5316-23. 
29. Chiarelli LR, Mori G, Orena BS, Esposito M, Lane T, de Jesus Lopes Ribeiro AL, Degiacomi 
G, Zemanova J, Szadocka S, Huszar S, Palcekova Z, Manfredi M, Gosetti F, Lelievre J, 
Ballell L, Kazakova E, Makarov V, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, 
Pasca MR. 2018. A multitarget approach to drug discovery inhibiting Mycobacterium 
tuberculosis PyrG and PanK. Sci Rep 8:3187. 
30. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, 
Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell 
DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, 
Oldfield E. 2014. Multitarget drug discovery for tuberculosis and other infectious 
diseases. J Med Chem 57:3126-39. 
31. Campanico A, Moreira R, Lopes F. 2018. Drug discovery in tuberculosis. New drug targets 
and antimycobacterial agents. Eur J Med Chem 150:525-545. 
32. Chen H, Nyantakyi SA, Li M, Gopal P, Aziz DB, Yang T, Moreira W, Gengenbacher M, Dick 
T, Go ML. 2018. The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular 
Drugs. Front Microbiol 9:1627. 
33. Cruz VL, Ramos J, Melo MN, Martinez-Salazar J. 2013. Bacteriocin AS-48 binding to 
model membranes and pore formation as revealed by coarse-grained simulations. 
Biochim Biophys Acta 1828:2524-31. 
34. Hendrickson DG, Soifer I, Wranik BJ, Botstein D, Scott McIsaac R. 2018. Simultaneous 
Profiling of DNA Accessibility and Gene Expression Dynamics with ATAC-Seq and RNA-
Seq. Methods Mol Biol 1819:317-333. 
35. Haas BJ, Chin M, Nusbaum C, Birren BW, Livny J. 2012. How deep is deep enough for 
RNA-Seq profiling of bacterial transcriptomes? Bmc Genomics 13. 
36. Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. 
Nat Rev Genet 10:57-63. 
37. Sekyere JO, Asante J. 2018. Emerging mechanisms of antimicrobial resistance in bacteria 
and fungi: advances in the era of genomics. Future Microbiology 13:241-262. 
38. Winglee K, Lun SC, Pieroni M, Kozikowski A, Bishai W. 2015. Mutation of Rv2887, a 
marR-Like Gene, Confers Mycobacterium tuberculosis Resistance to an Imidazopyridine-
Based Agent. Antimicrobial Agents and Chemotherapy 59:6873-6881. 
39. van Rensburg IC, Loxton AG. 2015. Transcriptomics: the key to biomarker discovery 
during tuberculosis? Biomark Med 9:483-95. 
40. Malone KM, Rue-Albrecht K, Magee DA, Conlon K, Schubert OT, Nalpas NC, Browne JA, 
Smyth A, Gormley E, Aebersold R, MacHugh DE, Gordon SV. 2018. Comparative 'omics 
analyses differentiate Mycobacterium tuberculosis and Mycobacterium bovis and reveal 
distinct macrophage responses to infection with the human and bovine tubercle bacilli. 
Microb Genom doi:10.1099/mgen.0.000163. 
CHAPTER 2 
 
 136 
41. Villarreal-Ramos B, Berg S, Whelan A, Holbert S, Carreras F, Salguero FJ, Khatri BL, 
Malone K, Rue-Albrecht K, Shaughnessy R, Smyth A, Ameni G, Aseffa A, Sarradin P, 
Winter N, Vordermeier M, Gordon SV. 2018. Experimental infection of cattle with 
Mycobacterium tuberculosis isolates shows the attenuation of the human tubercle 
bacillus for cattle. Scientific Reports 8. 
42. Aguilar-Ayala DA, Tilleman L, Van Nieuwerburgh F, Palomino DDJC, Vandamme P, 
Gonzalez-Y-Merchand JA, Martin A. 2017. The transcriptome of Mycobacterium 
tuberculosis in a lipid-rich dormancy model through RNAseq analysis. Scientific Reports 
7. 
43. Rodrigues L, Viveiros M, Ainsa JA. 2015. Measuring efflux and permeability in 
mycobacteria. Methods Mol Biol 1285:227-39. 
44. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. 2013. Differential 
analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 31:46-
53. 
45. Tarazona S, Furio-Tari P, Turra D, Pietro AD, Nueda MJ, Ferrer A, Conesa A. 2015. Data 
quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. 
Nucleic Acids Res 43:e140. 
46. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion 
for RNA-seq data with DESeq2. Genome Biol 15:550. 
47. Vansoolingen D, Dehaas PEW, Hermans PWM, Vanembden JDA. 1994. DNA-
Fingerprinting of Mycobacterium-Tuberculosis. Bacterial Pathogenesis, Pt A 235:196-
205. 
48. Gonzalez C, Langdon GM, Bruix M, Galvez A, Valdivia E, Maqueda M, Rico M. 2000. 
Bacteriocin AS-48, a microbial cyclic polypeptide structurally and functionally related to 
mammalian NK-lysin. Proc Natl Acad Sci U S A 97:11221-6. 
49. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, 
Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2009. The MIQE Guidelines: 
Minimum Information for Publication of Quantitative Real-Time PCR Experiments. 
Clinical Chemistry 55:611-622. 
50. Jindal HM, Zandi K, Ong KC, Velayuthan RD, Rasid SM, Samudi Raju C, Sekaran SD. 2017. 
Mechanisms of action and in vivo antibacterial efficacy assessment of five novel hybrid 
peptides derived from Indolicidin and Ranalexin against Streptococcus pneumoniae. 
PeerJ 5:e3887. 
51. da Cunha NB, Cobacho NB, Viana JF, Lima LA, Sampaio KB, Dohms SS, Ferreira AC, de la 
Fuente-Nunez C, Costa FF, Franco OL, Dias SC. 2017. The next generation of 
antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of 
diseases with social and economic impacts. Drug Discov Today 22:234-248. 
52. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. 2011. Targeting bacterial membrane function: an 
underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9:62-75. 
53. Wu X, Cherian PT, Lee RE, Hurdle JG. 2013. The membrane as a target for controlling 
hypervirulent Clostridium difficile infections. J Antimicrob Chemother 68:806-15. 
54. Ramon-Garcia S, Mikut R, Ng C, Ruden S, Volkmer R, Reischl M, Hilpert K, Thompson CJ. 
2013. Targeting Mycobacterium tuberculosis and other microbial pathogens using 
improved synthetic antibacterial peptides. Antimicrob Agents Chemother 57:2295-303. 
 STRATEGIES FOR ELUCIDATION OF AS-48 MODE OF ACTION 
 
 
 
137 
55. Smith J, Manoranjan J, Pan M, Bohsali A, Xu J, Liu J, McDonald KL, Szyk A, LaRonde-
LeBlanc N, Gao LY. 2008. Evidence for pore formation in host cell membranes by ESX-1-
secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect 
Immun 76:5478-87. 
56. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DE, Linderman JJ. 2011. Multiscale 
Computational Modeling Reveals a Critical Role for TNF-alpha Receptor 1 Dynamics in 
Tuberculosis Granuloma Formation. Journal of Immunology 186:3472-3483. 
57. Butcher EC, Berg EL, Kunkel EJ. 2004. Systems biology in drug discovery. Nature 
Biotechnology 22:1253-1259. 
58. Jensen PA, Zhu Z, van Opijnen T. 2017. Antibiotics Disrupt Coordination between 
Transcriptional and Phenotypic Stress Responses in Pathogenic Bacteria. Cell Reports 
20:1705-1716. 
59. Keren I, Minami S, Rubin E, Lewis K. 2011. Characterization and transcriptome analysis of 
Mycobacterium tuberculosis persisters. MBio 2:e00100-11. 
60. Sala A, Bordes P, Genevaux P. 2014. Multiple toxin-antitoxin systems in Mycobacterium 
tuberculosis. Toxins (Basel) 6:1002-20. 
61. Singh R, Barry CE, 3rd, Boshoff HI. 2010. The three RelE homologs of Mycobacterium 
tuberculosis have individual, drug-specific effects on bacterial antibiotic tolerance. J 
Bacteriol 192:1279-91. 
62. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I. 2002. ideR, An essential gene 
in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron 
metabolism, and oxidative stress response. Infect Immun 70:3371-81. 
63. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, Rubin EJ, Schnappinger D, 
Ehrt S, Fortune SM, Sassetti CM, Ioerger TR. 2017. Comprehensive Essentiality Analysis 
of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. 
MBio 8. 
64. Stewart GR, Wernisch L, Stabler R, Mangan JA, Hinds J, Laing KG, Young DB, Butcher PD. 
2002. Dissection of the heat-shock response in Mycobacterium tuberculosis using 
mutants and microarrays. Microbiology 148:3129-38. 
65. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient 
starvation model of Mycobacterium tuberculosis persistence by gene and protein 
expression profiling. Mol Microbiol 43:717-31. 
 
  
CHAPTER 2 
 
 138 
 
  
  
 
  
CHAPTER 3 
 
 140 
 
  
 IN VIVO APPROACH OF THE ANTIMICROBIAL ACTIVITY OF AS-48 AGAINST M. TUBERCULOSIS 
 
 
 
141 
INTRODUCTION 
 
THE USEFULNESS OF ANIMAL MODELS IN ANTIMICROBIAL DRUG RESEARCH 
In general, the in vivo approach to an infection is one of the key factors in 
researching new therapies and new antimicrobial treatments. Animal models 
exhibit a complexity that is almost impossible to achieve with an in vitro model 
and provide a unique environment to study the interaction of the bacterial 
infection, the host and the drug to be tested. Consequently, the information that 
could be obtained in these in vivo experiments is massive compared with other in 
vitro approaches of drug testing. Then, the use of animal models of infection is a 
first step for the design and development of preclinical assays, which in turn are 
the previous step of a clinical trial that has to be done in humans. Therefore, the 
use of suitable animal models provides an advantage in drug discovery and in 
new therapies to improve treatments. With animal models, it is possible to adjust 
several aspects such as dose schedule, drug concentration, assessments on toxicity, 
side effects and bacterial load.  
These factors must be duly justified in animal models according to the Basic 
Principles of the Declaration of Helsinki by the World Medical Association (1). In 
this document, it is say that “Clinical research conform to the moral and scientific 
principles that justify medical research and should be based on laboratory and 
animal experiments or other scientifically established facts”, so, always paying 
attention to ethical considerations, to improve human global health, it is 
mandatory to perform animal experiments. 
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DIVERSE ANIMAL MODELS IN TUBERCULOSIS RESEARCH 
Particularly, in tuberculosis research, we have to take into account that there 
is no animal reservoir of M. tuberculosis. Although apparently, this could seem a 
disadvantage (since no suitable animal model, close to human infection, could be 
easily implemented), the fact is that several animal models (2, 3) provide a highly 
representative panorama of the infection development in the human being, in 
terms of virulence, response to antitubercular drugs, etc. 
1. Guinea pig: Guinea pig was the first animal model used in 
tuberculosis research since the discovery of the etiologic agent of M. tuberculosis 
by Robert Koch. Nowadays, it is still considered as the reference model for vaccine 
testing, due to its similarity in the immunopathology with that of tuberculosis 
infected human beings (4). At early stage of the antibiotic research, guinea pig was 
also the reference animal model in drug susceptibility of the different first line 
drugs used in the treatment of tuberculosis (5-7). Recently, it has been 
demonstrated the activity of delamanid, one of the most recently discovered drugs 
against tuberculosis, against non-replicating and dormant bacilli of M. tuberculosis 
in the guinea pig model of infection (8). Chen X. and their colleges have also 
confirmed, in the guinea pig model, the previous studies performed in mice (9) to 
evaluate the activity of delamanid against dormant bacilli of tuberculosis; and 
showed the enhanced effect of delamanid in the common therapy for tuberculosis. 
 
2. Rabbits: Similarly to guinea pigs, rabbits have been also used as a 
preclinical approach to tuberculosis and for drug susceptibility studies. Both 
models, guinea pigs and rabbits share the advantage of being close to the 
pathology in humans due to the formation of granuloma and caseation in response 
to tuberculosis infection (2). 
 
3. Rats: In the case of rats, they are nearly considered as resistant to 
tuberculosis, the amount of bacterial inoculum required to infect them is higher 
than for guinea pig. Despite the fact that rats are the major model used for drug 
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testing and pharmacokinetic, this model cannot be considered for tuberculosis 
infection due to an adaptive response and a gradual clearance of the infection (10). 
 
 
4. Non-human primates (NHPs): These animal models commonly are 
used after a first approach in other animals models, such as mouse or guinea pig. 
But, recently, the interest in the scientific community for these models has been 
increased. Some of the NHP used for tuberculosis-drug testing or detention are the 
squirrel monkey (Saimiri sciureus)(11); the genera of the Aotus monkey (12), that 
was thought to be less sensitive to tuberculosis infection; the marmoset (Callithrix 
jacchus) (13), which present the advantage of their small size comparing with 
others NHPs and the baboons (Papio ursinus) (14). Finally,  the different kinds of 
macaques (15, 16), that shows a great similarity with the human anatomy and 
physiology: rhesus macaque (Macaca fascicularis) (17) or cynomolgus macaque 
(Macaca mulatta)(18) have been also widely used for tuberculosis research.    
 
5. Others: Other animal’s models like hamsters are also able to develop 
caseous granulomas, necrosis and fibrosis. Lately, minipig  (19), zebra fish (Danio 
rerio) (20) have been also assayed as tuberculosis models. 
 
THE MOUSE MODEL IN TUBERCULOSIS RESEARCH 
Nevertheless, the mouse (21)model is one of the best characterized models 
for preclinical assays related with activity of drugs in general and in tuberculosis 
infection in particular. It has been demonstrated that the efficiency of different 
combined antimicrobial therapies in mouse models are coherent with that of the 
subsequent results of clinical trials in humans. Moreover, the mouse model can 
help to elucidate the toxicity of the drug in different organs after long periods of 
exposure, such as those that are required for tuberculosis treatment (22).  The 
murin model is less expensive than rabbit and guinea pig models, in terms of price 
of the animals but also in space requirements in the animal facilities and in the 
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quantity of compound needed. Moreover the literature (Image 26) is more 
abundant than for guinea pig and rabbit, which are the most commonly used 
animal models (23). 
Image 26: Percentage of publications for each animal models in tuberculosis research. Based on 
the data published by Fonseca et al. (24). 
Recently, a model of infection that mimics the development of necrotic 
granulomas and the formation of caseation in the C3HeB/FeJ mice has been 
developed, the also called Kramnik mouse model. This mice strain reaches a 
plateau of infection, which allows to get a subchronic infection, later than other 
commonly used strains such as BALB/c. It has been proved that the necrotic core 
of the caseum granuloma of C3HeB/FeJ mice constitutes a hypoxic environment 
(25, 26). This model, in addition to present a caseous granuloma, is greatly 
heterogenic in terms of bacterial subpopulations and types of lesion, becoming an 
improved mouse model (27). 
For all these reasons, it is considered that the mouse model is the best option 
for animal studies in the infection of tuberculosis, hence, this is the in vivo model 
that we have used for our research on the activity of AS-48. 
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DESIGN OF IN VIVO MOUSE EXPERIMENTS 
There are several aspects that need to be determined prior to the design of 
an in vivo mouse infection experiment. These are the mouse genetic lineage, the 
bacterial strain, selected for the infection process, the route of infection and the 
drug administration via.  
1. It is necessary to choose carefully the genetic origin of the animals, 
and to decide whether using either inbred or outbred strains. Using inbred strains 
has some advantages (28): they are isogenic, which means that the animals are 
genetically identic individuals, and generally this results in a phenotypic 
uniformity, hence ensuring that the possible variability among different 
experiments (i.e. different response after a treatment) would not be due to genetic 
factors. Furthermore, the use of inbred strains allows a reduction in the number of 
mice needed for the experiments, which is an important ethical issue considering 
the three R’s (Reduction, Replacement and Refinement) recommended in animal 
experimentation. In contrast, an outbred strain model would use genetically 
heterogeneous animals; although this situation is closer to a normal human 
population, hence ensuring that results will be independent of particular genetic 
traits. It has as a drawback that the number of mice needed to have statistically 
significant results would be larger than with an inbred population. 
 
2. The bacterial strain. In many studies, the bacterial strain used for the 
infection was M. tuberculosis H37Rv, one of the international reference and mostly 
used strain in drug susceptibility either in vitro or in vivo. Other strains such as 
CDC1551, has been described as less virulent than H37Rv but the immune 
response seems to be faster and stronger than for H37Rv, in vivo (29, 30). To 
emulate a central nervous system of tuberculosis infection (which is the most 
aggressive form of extrapulmonary tuberculosis) M. tuberculosis clinical strain C3 
has been used (31). Even in some cases, only the cord factor (trehalose 6’6-
dimycolate) has been used to produce a granulomatous pathology (32). 
 
CHAPTER 3 
 
 146 
3. Infection route: Mouse model is not the natural host of M. 
tuberculosis, then the route of administration is not determined and several options 
are available. Given that tuberculosis infection commonly occurs through the 
respiratory tract, the best way to get a pulmonary infection in animals is 
performing the infection directly throw the respiratory system, which can be 
emulated by the use of aerosol (33) or performing the infection by the intranasal 
route or intratracheal route. However other routes have to be taken into account, 
like the intravenous route, commonly in the tail vein (31). 
 
 
4. Drug administration via. For drug administration any route could be 
used, but the most preferably one is the oral route (34), by oral gavage or by 
beverage or food intake. Specially, in the case of MDR-TB drug development is 
highly recommended to find an oral administration of drugs (35). But others routes 
could be implemented, such as the subcutaneous route (36), intraperitoneal or 
parenteral route (37).  In the case of vaccination, it has been demonstrated that the 
intratracheal route for vaccination is more active than the subcutaneous route (33). 
Currently, the treatment mainly include oral drug administration and parenteral 
drug delivery, but, the delivery of dry powder by inhalation is increasing the 
interest by the scientific and medical community (38-40).  
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OBJECTIVES 
The objectives of the animal experiments have been the following: 
1) To test the possible in vivo toxicity (acute and subchronic) of AS-48 
in the murine models, as well as the toxicity associated to particular 
administration routes. During the experiments, we observed the 
behavior or the response of the animals to the use of AS-48. For this, 
we have obtained tissues (brain, spleen, lungs, liver and kidneys) 
and blood from treated mice, and have analyzed them at different 
levels, either macroscopically, histologically or biochemically. 
2) To determine the maximal dosage that could be administered to treat 
the tuberculosis infection in mice without causing major toxic effects. 
3) To evaluate the antimycobacterial activity of the bacteriocin AS-48 
either in monotherapy or in its synergistic combination with 
ethambutol (EMB) in a model of tuberculosis infected mice. 
4)  Finally, we have considered the effect of this peptide in the normal 
faecal microbiota of the mice in order to expand our knowledge of 
how this peptide works in in vivo environment. 
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MATERIALS AND METHODS 
ANIMALS 
Females specific pathogen free C57BL/6 JRj mice and both, females and 
males specific pathogen free BALB/c JRj mice (Janvier Labs, Saint Berthevin 
Cedex, France) were used for the in vivo experiments. Mice were allowed to 
acclimatize for one week before experiments, and were eight-weeks-old when the 
experiments started. Food and water were provided ad libitum. Lighting was 
artificial in cycles of 12-hours light-dark. Mice for toxicity assays were kept in the 
animal facilities of the Centro de Investigaciones Biomédicas de Aragón (CIBA) (ES 50 
297 0012 011),  and for the efficacy assay (upon infection with M. tuberculosis) were 
allocated in BLS3 animal facilities of Centro de Encefalopatías y Enfermedades 
Transmisibles Emergentes (ES 50 279 0012 009), at the University of Zaragoza. Sterile 
food, water and bed were provided for infected mice, they were lodged in 
ventilated cages. All the experiments that we have performed have taken into 
account the three R’s principles. The aim was to minimize the number of animals 
required to assay the different conditions. For designing each protocol, the 
previous experiments were taken into account, and additionally, toxicological data 
of similar substances have been considered for the design of every experiment. All 
the procedures were accepted by the Comisión Ética Asesora para la Experimentación 
Animal of Aragón.  
For all the experiments, mice were randomly divided into the different 
groups. All mice were weighted at reception and ear-labelled. The body weight of 
the groups was calculated as an average of all the individuals. All dosages (drugs, 
anesthesia…) were adapted to the body weight of each group. Mice were weighted 
and examined thoroughly every day before and during drug administration, and 
every abnormality in the behavior was recorded. Mice were treated according to 
the experimental design of every assay (acute toxicity, administration route 
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toxicity, subchronic toxicity, M. tuberculosis infection, and efficacy experiments) as 
detailed in the following sections. 
Mice were euthanatized according to the standards and following a 
humanely procedure. Cervical dislocation was performed for the majority of the 
mice. Those mice for which the collection of blood was critical for biochemical and 
hematological test were euthanatized by using a carbon dioxide camera. 
After euthanatizing the mice, a necropsy was performed. The general look 
of the external surface of the body, skin, orifices, internal organs and digestive tract 
was examined carefully, and every single abnormality was recorded. 
 
ACUTE TOXICITY 
When for a particular compound no information about toxicity is available, 
the Organisation for Economic Co-operation and Development (OECD) guidelines 
recommend to start acute toxicity assays with a default value of 175 mg/kg orally, 
and when toxic effects are observed, to reduce gradually the dose and test toxicity 
again. It is considered that, testing acute toxicity in one sex (commonly females) is 
enough. The sample size must be small due to the severity of the process, 
accordingly to the OECD. 
Then, for our assays, since little previous information on the toxicity of AS-
48 was available, the dose of the antimicrobial peptide AS-48 for acute toxicity 
assays was selected based on such indications in order to calculate the LD50. The 
concentrations of AS-48 assayed were 127.27, 65, 26, 15, 10, 5 and 2.5 mg/Kg of 
body weight, administered intraperitoneally in 200 µl in seven adult C57BL/6 JRj 
female mice respectively (41). All the doses were administered and calculated for 
each mouse individually, according to its initial weight. 
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ADMINISTRATION ROUTE TOXICITY ASSAY 
Once the highest concentration of AS-48 that could be tested was 
determined in the acute toxicity assay, the different routes for treatment were 
assayed. The mice were divided in two groups of C57BL/6 JRj eight-weeks-old 
female mice, and received bacteriocin AS-48 by intraperitoneal or intranasal 
administration route, respectively. In these two groups, negative control mice 
were treated with sterile PBS through the respective administration route. For each 
administration route, two concentrations of AS-48 were assayed: two mice were 
treated with 2 mg/Kg body weight and two other mice with 1 mg/Kg body 
weight. All mice were weighted before starting the experiment and every time 
before the administration of each dosage. The dosing schedule were three times 
per week during two weeks. 
For the intranasal route, mice were anesthetized by inhalation of 
isofluorane mixed with 5-3% of oxygen and kept asleep between the two 
applications of 20 µl needed to get the final concentration of AS-48.  For the 
intraperitoneal route, the final volume injected was 100µl (41). After the sacrifice, 
necropsy was performed, and blood and organs were also analyzed. The organs 
extracted for further histological examination were: brain, spleen, lungs, liver and 
kidneys (42). 
 
SUBCHRONIC TOXICITY  
We stablished four groups of four BALB/c JRj eight-weeks-old mice: two 
groups of males and two of females. Within each group, mice were treated every 
day during 9 days with 4, 2 and 1 mg/Kg of body weight of AS-48, and PBS as a 
control, respectively. Every concentration was assayed then in duplicated for both 
sexes, as well as the negative PBS control (Table 15). All the AS-48 preparations 
were dissolved in sterile PBS and administered via intraperitoneal. Prior to 
administrations, mice were anesthetized with isofluorane mixed with 5-3% of 
oxygen. After the final point, on day 10 of the experiment, mice were euthanatized 
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and necropsy was done. Blood was obtained via cardiac puncture, collected in 
tubes with 0.8% of EDTA and hematological test was done. Organs (kidneys, 
lungs, brain, liver and spleen) were collected and kept in formalin for subsequent 
histopathology examinations. 
Table 15: Groups of mice to assay the subchronic toxicity of AS-48 in BALB/c JRj 
intraperitoneally. 
Group Treatment Sex 
1 PBS Male 
 4mg/Kg of AS-48 Male 
 2mg/Kg of AS-48 Male 
 1mg/Kg of AS-48 Male 
2 PBS Male 
 4mg/Kg of AS-48 Male 
 2mg/Kg of AS-48 Male 
 1mg/Kg of AS-48 Male 
3 PBS Female 
 4mg/Kg of AS-48 Female 
 2mg/Kg of AS-48 Female 
 1mg/Kg of AS-48 Female 
4 PBS Female 
 4mg/Kg of AS-48 Female 
 2mg/Kg of AS-48 Female 
 1mg/Kg of AS-48 Female 
 
M. TUBERCULOSIS INFECTION IN MICE 
In order to infect mice chronically with M. tuberculosis, eight-weeks-old 
BALB/c JRj mice were first anesthetized with isofluorane and then two 
instillations of 20 µl of a bacterial suspension (containing 200 cfu of M. tuberculosis 
H37Rv in total) were inoculated by the intranasal route to each mouse. The 
bacterial suspension was added drop-by-drop in the nasal orifices of each mouse 
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leaving time to assimilate the whole volume in the breathing, this protocol was 
adapted from Uranga S. et al (43). After two weeks, the infection of tuberculosis 
was evolved enough to represent a model of chronic infection, then specific 
treatments (as described in the following sections) were applied to the mice. It has 
been demonstrated that the volume of bacterial suspension used to infect mouse 
intranasally correlates with the efficiency of the infection: when the bacterial 
inoculum is contained in 40 µl, the percentage of colonization is higher than if the 
volume is 10 µl; in the latter  case, the efficiency of the bacterial infection could 
decrease up to 80% of what expected (43). 
 
EFFICACY EXPERIMENTS IN MICE 
Groups of 8-weeks old BALB/c JRj female mice, with six animals each, were 
done in order to assay the efficacy of different treatments containing bacteriocin 
AS-48, either alone or in combination with ethambutol. A total of seven different 
groups were formed, which received the following treatments: the untreated 
control group received PBS only, a group was treated with therapeutic dosage of 
isoniazid (10 mg/Kg), two groups were treated with bacteriocin AS-48 only at two 
different concentrations (2 mg/Kg and 1 mg/kg respectively), another two groups 
were treated with the same concentration of AS-48 and a subinhibitory 
concentration of ethambutol (10 mg/Kg), and the last group was treated with the 
subinhibitory concentration of ethambutol only (Table 16).  
The treatment was administered for five days per week during four weeks, 
and the dosages were administered by the intraperitoneal route. Mice were 
thoroughly observed after treatment and weight control was performed once a 
week. The mice whose weight loss was higher than the 20% of their initial weight, 
were euthanatized. After the final point of the experiment, animals were 
euthanatized by cervical dislocation, lungs were collected and kept frozen at least 
24 hours in order to avoid contaminations when plating. 
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In order to quantify the number of CFUs allocated in the lungs, they were 
lysed in 1 ml of sterile water with tissue homogenizer and plated. For this, tubes 
containing lysed lungs were centrifuged 5 min at 1000 rpm to collect all the 
homogenized tissue. Serial 1:20 dilutions were done in PBS supplemented with 
0.1% tyloxapol. A volume of 100µl of the corresponding dilution were plated in 
Middlebrook 7H10 media supplemented with albumin, dextrose, and catalase 
(ADC). Plates were incubated for 20 days at 37°C, and after this period the number 
of CFUS were counted. To prevent dissication, plates were sealed with Parafilm™ 
and covered with aluminum paper. 
Table 16: Groups of six BALB/c JRj female mice for the efficacy assay. 
Group Treatment 
1 PBS 
2 10 mg/Kg of INH 
3 2 mg/Kg of AS-48 
4 1 mg/Kg of AS-48 
5 2 mg/Kg of AS-48 + 10 mg/Kg of EMB 
6 1 mg/Kg of AS-48 + 10 mg/Kg of EMB 
7 10 mg/Kg of EMB 
 
HEMATOLOGICAL AND BIOCHEMICAL ANALYSIS 
For hematological analysis, whole blood samples were collected from the animals 
once the subchronic toxicity assay was finished. In order to avoid coagulation 1.5-2.2 mg 
of EDTA/ml of blood were added. The parameters measured were: white blood cells 
(WBC), lymphocytes (Lym), monocytes (Mon), granulocytes (Gran), red blood cells (RBC), 
hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), 
reed cell distribution width (RDW), platelet count (PLT), mean platelet volume (MPV), 
platelet distribution width (PDW) and procalcitonin (PCT). The blood samples were 
analyzed with the in the animal facilities at CIBA. 
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HISTOPATHOLOGICAL EXAMINATION 
Several organs were collected (liver, spleen, lungs, brain and kidneys) from mice 
after the subchronic toxicity assays. Whole organs were fixed in formalin (4% 
formaldehyde) during 24 hours and included in paraffin. Samples were cut in slices, 
dehydrated and stained with hematoxylin-eosin (HE), sections were prepared by the 
Service of Pathological Anatomy at CIBA. Organ preparations were scanned with Aperio 
AT2 (Leica) and examined and photographed with Aperio eSlide Manager (Leica). 
  
CHAPTER 3 
 
 156 
  
 IN VIVO APPROACH OF THE ANTIMICROBIAL ACTIVITY OF AS-48 AGAINST M. TUBERCULOSIS 
 
 
 
157 
RESULTS 
C57BL6 MICE EXHIBIT ACUTE TOXICITY WHEN THE CONCENTRATION OF AS-
48 IS ≥ 2.5 MG/KG BODY WEIGHT 
To assess the highest dose of AS-48 that could be used, in terms of toxicity, we 
firstly performed one experiment with a series of seven doses of AS-48 ranging from 
127.27 to 2.5 mg/Kg body weight. Seven adult C57BL/6 JRj female mice received 
intraperitoneally a single dose each of AS-48 at a different concentration. 
Mice who received doses of AS-48 at concentrations higher than or equal to 10 
mg/Kg body weight deceased in 15-20 minutes after administration. The other two mice, 
that had received 5 mg/kg and 2.5 mg/Kg body weight of AS-48, presented depressed 
appearance, dyspnea and slowed movements; they were monitorized during a couple of 
hours and left in the cage. After 12 hours post-administration, they were found to be dead. 
We could appreciate that in several cases the duodenum showed an irritated surface and 
distention. No other alterations in other organs were observed. In the two mice that 
received 15 mg/Kg and 10 mg/Kg body weight of AS-48, respectively, we could 
appreciate a slightly haemorrhagic tissue in the subcutaneous area of the armpit. 
In conclusion, the concentrations of AS-48 assayed seemed to be toxic for this mice 
lineage and through this administration route.  
 
INTRAPERITONEAL VS. INTRANASAL ROUTE: TOXICITY ASSAY  
In the previous experiment, we had determined that AS-48 resulted in acute 
toxicity when administered intraperitoneally at concentrations equal to or above 
2.5 mg/Kg of body weight. We wanted to test next whether toxicity could depend 
on the administration route in the same mouse strain. For this, different groups of 
C57BL/6 JRj female mice were divided according to the administration route and 
the treatment received (Table 17). Bacteriocin AS-48 was administered at 
concentrations lower than 2.5 mg/Kg of body weight. 
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Table 17: Groups of mice for testing the different administration routes in the toxicity of 
AS-48. 
  
 
 
 
 
 
IP: intraperitoneal; IN: intranasal; PBS: phosphate buffer saline. 
On one hand, for the intraperitoneal route, the two mice in group 2 received 
the highest dose (2 mg/Kg body weight) and deceased 40 minutes after the first 
administration. Before dying, they showed depressed behavior, eyelid partially 
closed and slow breathing. In the necropsy, we observed a dark region in the distal 
segment of the spleen and the jejunum with an orange coloring. We continued 
with the treatment of the control group (group 1) and the group treated with 1 
mg/Kg body weight (groups 3) after 36 hours. The two mice of the group 3, treated 
with 1 mg/Kg body weight, showed eyelid partially closed, back bend and 
reduced mobility after the first administration of bacteriocin AS-48; however, they 
died after the second dosage. The intraperitoneal control group (group 1, receiving 
PBS) was euthanatized; no significant abnormality was observed macroscopically 
in the organs. 
On the other hand, the intranasal treatment was prolonged for two weeks, 
administering a total of six doses, as scheduled. All mice in groups 5 and 6 showed 
a weight decrease and typical sign of suffering, such as hunched posture, 
piloerection, eyelids partially closed and low mobility, but after around 10 minutes 
they recovered the normality. Mice belonging to group 5 (2 mg/Kg of AS-48) were 
not administered the second dosage due to their weight loss observed after 
administration of the first dosage. These mice finally recovered their original 
Group Administration route Treatment 
1 IP PBS 
2 IP 2mg/Kg of AS-48 
3 IP 1mg/Kg of AS-48 
4 IN PBS 
5 IN 2mg/Kg of AS-48 
6 IN 1mg/Kg of AS-48 
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weight and could receive the third, fourth, fifth and sixth dosages. At the end of 
the experiment mice treated by the intranasal route, were euthanatized and blood 
and organs were collected (Image 27). Besides, the macroscopic observation of the 
different tissues and organs, lungs, kidneys, liver, spleen and brain were analysed 
by its histopathology. 
Image 27: Scheme of the experiments to evaluate the different routes of administration. 
 
Furthermore, haematological analysis was performed (the different 
haematological parameters are listed in Table 18). In general, we could not 
determine a common pattern of the different altered values associated to the 
treatment with AS-48. The platelets (PLT) also appeared to be lower than the 
standard values in the PBS control of both administration routes, and in the groups 
treated with 1 mg/Kg of AS-48. Low values of PLT indicate thrombocytopenia, 
although no abnormal bleeding were observed during the sacrifice.  
On the contrary we observed that the values of red blood cells (RBC), 
haemoglobin (HGB) and haematocrit (HCT) are higher than the standards in mice 
treated with PBS, treated with 2 mg/Kg of AS-48 in the intraperitoneal treatment 
and just in the group treated with 1 mg/Kg of AS-48, in the intranasal treatment. 
High values of RBC could cause their agglomeration in the vessel and capillary, 
which conclude in a lack of oxygen in the different tissues. The HCT measures the 
volume that take up the red blood cells in the blood; high HTC values indicate 
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dehydration or hypoxia, this could be related to the fact that we also have high 
values of RBC and the possibility of not good distribution of oxygen. .  
Table 18: Haematological parameters measured in mice of the administration route 
experiment. 
 
In the necropsy of each mouse, besides of the carefully examination of the 
tissues, several organs were collected, fixed, stained and histologically examined. 
We observe that brain and kidneys have a normal histological structure, we did 
not observe any signs of edema, hyperplasia or dysplasia, inflammation or atypical 
cells. In the case of the spleen, the white pulp is slightly hyperplasic in all the mice, 
we hypothesised that is due to the characteristic of the strain. We could not observe 
any difference between the control group and the treated ones in terms of the 
spleen histology. In some of the lungs we observe some areas with haemorrhages 
and swelling but with a conserved architecture and without fibrinoid tissues. We 
did not observe a relation between these changes in the lungs and the treatments.  
In the case of the liver they present some differences in the histology 
between each group of treatment. First, in the intraperitoneal treatment group, we 
noticed that mice of the control treated with PBS have a correct structure of the 
organ, with very few accumulated lymphocytes (arrow in Image 28, D)) and 
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hepatocytes with a slightly vegetal-like deformation (clear cytoplasm and 
polygonal edges). In contrast, the livers of the mice treated with 2mg/Kg of AS-48 
showed sinusoidal dilatation (arrows in Image 28, E)) , vegetal-like deformation 
of the parenchyma, and slightly patched in the panoramic view. We observe 
several binuclear cells or with prominent nuclei (cirlces in Image 28, G)), this could 
be due to a process of regeneration or repair.  Mice treated with 1mg/Kg of AS-48 
show a diffuse patched in the general histology of the liver and vegetal-like 
changes in the hepatocytes (Image 28, F)). 
 
Image 28: Pictures of histological slices of mice livers from the experiment of 
intraperitoneal treatment with AS-48. A), B) and C) Panoramical view of the liver of mice 
treated with PBS, 2 mg/Kg of AS-48 and 1 mg/Kg of AS-48, respectively. D) Higher augment 
of liver treated with PBS; arrow: lymphocyte accumulated. E) and G) Higher augment of 
liver treated with 2 mg/Kg of AS-48; arrows: dilated sinusoids; circles: binuclear cells. And 
F) Higher augment of liver treated with 1 mg/Kg of AS-48, detail of vegetal-like changes in 
the hepatocytes. 
CHAPTER 3 
 
 162 
Second, in the intranasal treatment group, livers of mice of the control 
treated with PBS have very few mixed infiltrate (lymphocytes and eosinophils) but 
a general healthy aspect (Image 29, A) and D)). Also the group treated with 
1mg/Kg of AS-48 show a healthy appearance with no vegetal-like changes (Image 
29, C) and F)). On the contrary, the liver of the mice treated with 2mg/Kg of AS-
48 show a ballon cell degeneration (at a high augment, Image X, E)), vegetal-like 
changes. We also noticed that there is a loss of nuclei in the centrilobular cells that 
could means the beginning of a necrosis process (green circle, Image 29, E)). 
 
Image 29: Histological slices of mice liver from the experiment of intranasal treatment 
with AS-48. A), B) and C) Panoramical view of the liver of mice treated with PBS, 2 mg/Kg 
of AS-48 and 1 mg/Kg of AS-48, respectively. D), E) and F) Higher augment of liver treated 
with PBS, 2 mg/Kg of AS-48 and 1 mg/Kg of AS-48 respectively. Circle in panel E) indicates 
the centrilobular necrosis. 
 
We could conclude that AS-48 at 1 or 2 mg/Kg of body weight is toxic for 
C57BL/6 JRj female mice when administered by the intraperitoneal route, but it 
seems to be better tolerated when administered by the intranasal route.  
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NO TOXICITY OBSERVED IN VIVO WHEN TREATING BALB/C MICE WITH AS-48 
DURING 10 DAYS 
Given the results of the acute toxicity assay, we considered whether the 
toxicity could be linked to the mouse strain. Then, we designed a pilot probe with 
a mouse of the lineage BALB/c, which received intraperitoneally two doses of AS-
48 at 218 mg/Kg (i.e. the same concentration as used in the acute toxicity assay 
with the C57BL6 mice). In these conditions, we observed an absence of toxicity. In 
consequence, we decided to proceed further experiments with BALB/c mice 
only.For the subchronic toxicity assay, the following concentrations of AS-48 were 
administered to BALB/c mice: 4, 2 and 1 mg/Kg body weight. The doses were 
administered via intraperitoneal in a volume of 200 µl daily during 10 days (Table 
15). 
All the mice treated with 4mg/Kg of AS-48 were euthanatized (Humane 
Endpoint), after two days of administration, due to the evidence of suffering and 
distress consisting in abnormal posture and movement, depressed look, loss of 
normal temperature, piloerection and eyelids partially closed. 
The rest of the mice (receiving either PBS or AS-48 at 2 or 1 mg/Kg) 
continued the procedure with normality. In general, female mice (groups 3 and 4; 
Table 2??) looked groomed than males (groups 1 and 2). During the ten days of the 
experiment, none of the animals showed any alteration in the movement and in 
the behaviour and their breathing and food uptake was completely normal (Image 
30).  
Image 30: Scheme of the in vivo subchronic toxicity of AS-48. 
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They were euthanatized by CO2 camera for a complete extraction of the 
blood for further analysis. In the necropsy, mice did not show any abnormality, 
and all organs and epithelia looked healthy macroscopically. 
In conclusion, AS-48 is toxic intraperitoneally after two administrations of 
4 mg/Kg in BALB/c mice. When 2 or 1 mg/Kg of AS-48 was administered, no 
toxicity was observed after 10 consequently days. Moreover, weight of the mice 
did not vary along the process, Image 31, indicating the wellness of the mice. In 
females body weight varied slightly more between groups of treatment than in 
males, although females looked smarter than males. They all also showed a great 
variation between individuals particularly in groups treated with 1 mg/Kg of AS-
48.  
Image 31: Body weight of male mice in subchronic toxicity assay. A) Body weight of males 
and B) body weight of females 
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In the haematological study of the blood samples obtained after the 
subchronic toxicity assay, we observed also heterogeneous values (Table 19; it was 
not possible to obtain the blood of one male treated with 2 mg/kg of AS-48). With 
the exception of one mice from the control group, the mean platelet volume (MPV) 
presented high values which. In some cases, imply certain types of diabetes, but 
in this case, we have to pay a special attention to the low values of PLT observed 
in mice treated with 2 mg/Kg of AS-48. When these two events happen, low values 
of PLT and high of MPV, could indicate that AS-48 is toxic for example it occurs 
when a chemotherapy is administered in cancer patients.  
We also could observe that RBC, HGB and HCT are generally higher than 
the standards. Also, the values of white blood cells (WBC), lymphocytes (Lym), 
Monocytes (Mon) and Granulocytes (Gran) seems to be higher than the standards, 
mainly in females. This may mean that the mice could be fighting off an infection, 
although we did not observe any sign of infection during the treatment neither in 
the necropsy. In this case females show values more altered than males, but during 
the experiment the general behaviour and appearance were better than the males, 
they did not show any distress sign and smarten up better than males. 
Table 19: Haematological parameters measured in the subchronic toxicity assay. 
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Furthermore, we have analysed the possible toxicity through histology 
examinations. Those mice that were treated with 4mg/Kg of AS-48 (death after 
two administrations) exhibits a great toxicity in the liver, we can observe a great 
patched appearance in panel A) of Image 32. In the case of the males, the damage 
were more severe than in females: liver present subcapsular necrosis (arrows and 
bracket, Image 32, B)) and, portal and periportal necrosis building bridges 
between portal spaces (Image 32, C)). We observed several haemorrhagic focus 
and some cells with nuclei lost (Image 32, D)). In females, do not exhibits that 
severe necrosis, but the parenchyma present a hydropic degeneration in the 
centrolobular area.  
 
Image 32: Pictures from the histological slices of mice livers treated with 4 mg/Kg of AS-
48 in the sucbhronic toxicity assay. A) Panoramical view of a live with patched necrosis; 
B) Arrows and bracket indicates the subcapsular necrosis area; C) Detail of the hepatic 
parenchyma with portal and periportal necrosis forming bridges; D) Higher augment of 
the necrotic area, hepatocytes with loss of nuclei. 
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In the livers of the mice treated with 2 mg/Kg of AS-48, 1 mg/Kg of AS-48 
and the control group with PBS, we did not observe any abnormality. Just one of 
the males treated with 2 mg/Kg of AS-48 have slightly modifications in the normal 
appearance of the hepatic parenchyma. 
We also have observed the histology of kidneys, spleen, brain and lungs. In 
the case of the lungs some of them presented some alterations such as some 
haemorrhagic areas, but without any fibrinoid appearance or red blood 
organization, so the haemorragic is not due to a thrombus and could be due to the 
process of euthanasia and/or due to the extraction. The rest of the organs present 
a normal architecture, and there were not any sign of toxicity or tissue damage. 
 
IN VIVO  EFFICACY OF AS-48 AND SYNERGISTIC COMBINATIONS OF AS-48 
AND ETHAMBUTOL 
The main objective was to test the efficacy of AS-48 against M. tuberculosis 
infected mice. The efficacy of treatments containing AS-48 were compared with 
that of the reference antituberculosis drug isoniazid. In addition, we explored in 
vivo the potential synergistic relationship between AS-48 (at two concentrations 
that presented synergism in in vitro conditions and were within the limits of the 
subchronic toxicity in vivo) and a sub-inhibitory dose of ethambutol (a first-line 
antituberculosis drug), and compared the efficacy of such combined treatment of 
AS-48 and ethambutol versus the bacteriocin as a mono-therapy (Table 16). For 
comparing data from the in vitro MIC determinations and the in vivo toxicity, we 
assumed that one kilogram of body weight is equivalent to one liter; this 
estimation allowed us to correlate also the MIC in vitro with the possible MIC in 
vivo. 
Mice belonging to the group treated with 2mg/Kg of AS-48 alone were 
deceased after the first 10 days of treatment. Along treatment, mice that were 
treated with AS-48 only, mainly group 3 and 4 (2 mg/Kg and 1 mg/Kg of AS-48), 
showed an altered behavior, in terms of depression, piloerection, isolation and 
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reduction of the movement, for the period starting right after administration up to 
one hour after treatment. Interestingly, mice from groups 3, 4, 5 and 6 (treated with 
2 mg/Kg of AS-48, 1 mg/kg of AS-48, 2 mg/kg of AS-48 + 10 mg/Kg of EMB and 
1 mg/Kg of AS-48 +10 mg/Kg of EMB, respectively), i.e. all mice receiving 
bacteriocin AS-48 looked depressed after inoculation but their aspect improved 
considerably during the last two weeks of treatment compared with the first 
administrations. We can speculate that after several inoculations of bacteriocin AS-
48, an immune adaptation happens and this could mitigate the adverse effects of 
the administration of AS-48.  
After the final point of this experiment all animals were sacrificed, spleen 
and lungs were collected, examined in order to determine the lesions provoked by 
the tuberculosis infection and frozen. From the macroscopic appearance of both 
organs we could determine the evolution of the infection and estimate the 
dilutions that would be needed to plate in order to determine the exact bacterial 
load in lungs. Every mouse showed formation of granulomas in their lungs, but in 
the case of the group treated with isoniazid those lesions were much smaller than 
the rest of the groups, as expected. 
In the untreated control, the bacterial load reached a value of 6.5 log cfu/ml. 
Animals in groups 3 and 4, which were treated with only AS-48, had higher 
bacterial loads than the ones in the untreated control group, 7.5 log cfu/ml and 6.6 
log cfu/ml respectively. In the case of group 3 (treated with 2 mg/Kg of AS-48), 
mice deceased before the experiment was completed, so the high bacterial load in 
these animals could be due to the fact that the treatment was given for a much 
shorter time than the other groups. The only groups in which we could observe a 
slight decrease were groups 5 and 6, i.e. those in which treatment was a 
combination of AS-48 and ethambutol (Image 33); for these groups, bacterial loads 
were 6.3 log cfu/ml and 5.98 log cfu/ml respectively.  
We can speculate that the concentration of ethambutol in combination with 
AS-48, even at subinhibitory concentrations, could provide certain improvement 
in mice health in the infected animals, in comparison with the groups receiving 
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only AS-48. Nevertheless, since in the control group (group 7) treated only with 
ethambutol, the number of cfu was slightly lower (5.91 log cfu/ml) than in the 
groups treated with both EMB and AS-48, it can be concluded that no synergy was 
observed when the combined treatment was applied in these conditions. 
Image 33: Representation of the efficacy assay of the different concentrations of AS-48 
alone or in combination with EMB against M. tuberculosis in Balb/c JRj mice. 
 
On the other hand, the isoniazid efficiently reduced the number of cfus in 
lungs, resulting in a decrease of three log compared with the untreated control. In 
the case of the group treated with ethambutol only, given that this drug was 
administered at a subinhibitory dose, it was not expected to reduce significantly 
the number of cfu in the lung of infected mice.  
The percent survival graph with the data obtained from the efficacy assay 
helps to understand the effect of AS-48 in infected mice (Image 34). All mice in 
group 2 (treated with 10 mg/Kg of isoniazid), group 7 (treated with subinhibitory 
concentration (10 mg/Kg) of ethambutol), and the untreated group survived all 
along the experiment. Survival of mice in group 5 (treated with 2 mg/Kg of AS-48 
and 10 mg/Kg of ethambutol) was higher (80%) than that in the other groups 
where AS-48 was administered. The group treated with 1 mg/Kg of AS-48 and 10 
mg/Kg of ethambutol (group 6) had a percentage of survival of 60%. Comparing 
group 5 and 3 (both receiving AS-48 at 2 mg/Kg, with or without ethambutol, 
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respectively), the group in which the treatment includes ethambutol (group 5) had 
a much higher survival rate than the group treated with monotherapy with AS-48. 
We can observe the same phenomenon when we compare groups 4 and 6, both 
with the same concentration of AS-48 (1 mg/Kg) but group 6 receiving also 10 
mg/Kg of ethambutol. In general, those groups that were treated with a combined 
therapy exhibited higher survival percentage than the ones receiving the same 
amount of AS-48 in monotherapy.  
Image 34: Survival of the different treatments groups of mice in the efficacy assay (groups 
1, 2 and 7 have the same tendency). 
 
At different points, body weights were recorded and plotted (Image 35). 
We can observe that at the beginning of the experiment there was little variability 
in body weigh between groups but at the end of the experiment, differences in 
body weigh between groups had increased and also within each group variability 
between animals had also increased. Body weight of animals in group treated with 
2 mg/Kg of AS-48 only confirm the distress suffered by the mice: the weight 
decreased (and also the survival) reaching a diminution of the 20% in the body 
weight which is one of the aspects considered as humane final point. 
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Image 35: Body weight recorded during the efficacy assay in all the mice groups. 
 
In the necropsy of mice, we could highlight that all of them presented 
granuloma and lesions in both lungs. We could also notice that, due to the infection 
process, the spleen increased considerably its size. Nevertheless, the lesions 
observed in mice of group 2, treated with isoniazid, were less severe than the other 
groups. According to the extent of the lesions observed in the necropsy of lungs, 
we estimated the dilutions needed for determining accurately the number of cfu.  
In conclusion, we could understand that, even the dose of ethambutol is in 
a subinhibitory concentration, this would help to mitigate the adverse effects 
caused by the accompanying drug AS-48. Those treatments in which both drugs, 
ethambutol and AS-48 were combined, showed slighty better results, in terms of 
percentage of survival and cfu reduction, than those in which AS-48 was 
administered alone. Despite that, we could not reach a significant decrease in the 
number of cfu in lungs obtained from the infected animals. 
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DISCUSSION 
The main objective of this work has been to determine the toxicity of 
bacteriocin AS-48 in mice, in order to define the concentrations that could be used 
safely for treating M. tuberculosis infection in this experimental model, as well as 
to do a preliminary assessment on the efficacy of AS-48 to reduce bacterial burden 
in the lungs of infected mice. In general, the results of our experiments have 
revealed that AS-48 has important toxicity issues, given the high concentrations 
that would be needed in order to be effective against M. tuberculosis, and under the 
conditions assayed, AS-48 contributed very little to reduce bacterial load in 
infected animals. At the same time, these experiments have revealed potential 
approaches to further explore the usefulness of bacteriocin AS-48, opening 
interesting perspectives that will be explored in the future. 
 
TOXICITY 
According to the ODCE, a product is considered as safe when there is an 
absence of toxicity up to a dose of 2 g/L(44). We looked in the literature for data 
on toxicity of other antimicrobial peptides, in order to have a reference for 
designing our experiments with AS-48. For example, the lipophilic peptide 
YV11455 (45) was tested against Staphylococcus aureus (MRSA) in murine models, 
and resulted between 54-270-fold more effective than its analogue, the 
glycopeptide antibiotic vancomycin. Peptide YV11455, which targets the bacterial 
membrane, does not cause any sign of acute toxicity at a maximum dose of 12 
mg/Kg body weight, since it resulted in a biochemical analysis similar to those of 
untreated animals, and no severe modifications in the histology of the organs was 
observed. 
Due to the low solubility of AS-48 in aqueous solvents (maximum 
concentration reached has been 2.5 mg/ml) we were not able to test 2 g/L as this 
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is the concentration recommended by the ODCE. Then, we used much lower 
concentrations of AS-48 for the toxicity assays, starting with 127 mg/Kg, a value 
close to that recommended by OEDC, and this quantity was reduced stepwise 
until no toxicity was found.  
Even with such low concentrations, according to the result of the acute 
toxicity assay, AS-48 resulted highly toxic presented clear signs of morbidity in 
our experiment in C57BL/6 mice. However, in BALB/c mice, they showed no 
toxicity at the same concentrations. We have to consider the genetic and 
physiological differences between both mice strains to elucidate why AS-48 is 
more toxic for one strain than for the other. Both strains are inbred mice and are 
commonly used for toxicity assays, and there are many factors such as levels of 
gene expression, allelic variants and/or the interaction with the environment, that 
result in different phenotypes between them. For example, Su S.H. et al. (46) 
demonstrated that the activity of the bronchoalveolar macrophages was 
differentially regulated in C57BL/6 and in BALB/c in terms of the immunological 
response in response to physical exercise. They showed that C57BL/6 presents a 
higher phagocytic activity than BALB/c, but also, C57BL/6 exhibits a high 
expression of the macrophage receptor with collagenous structure (MARCO) and 
this factor could imply the innate resistance of C57BL/6 to tuberculosis infection 
(46).  
Moreover, both strains do not respond in the same way at different 
environmental stress stimuli. It has been demonstrated that BALB/c strain 
increases the metabolic rate when is exposed to high altitude indicating a minor 
adaptation to the hypoxic stress compared with the C57BL/6 strain (47). On the 
contrary, under a social defeat, BALB/c mice reduce their metabolic efficiency and 
their body weight, but C57BL/6 increase their food intake and present invariably 
metabolic changes compared with BALB/c (48). In the histology, we have 
observed that livers of C57BL/6 mice presented more damages than the livers of 
BALB/c mice, with the same dose of AS-48.  
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However, the mice that received the highest dose of AS-48 (4 mg/Kg) 
shows and appearance of necrosis more severe than the others doses. With this, 
we can confirm the toxicity of that concentration of AS-48 in this conditions. We 
also hypothesize that the damages observed in the lungs could be due to the 
euthanasia method, CO2, which could cause a collapse and haemorrhage in the 
lungs. In some cases the damages observed in lungs could also be due to the 
extraction from the thoracic cavity, generating some bleeding in the areas to be 
studied.  
From our experiments, we can conclude that C57BL/6 mice are more labile 
to AS-48 than BALB/c, although the determination of the mode of action of AS-48 
in the organism or how the toxicity appears is beyond the scope of this work. For 
further understanding, it would be necessary to perform pharmacokinetic and 
pharmacodynamic studies. 
While testing the toxicity associated to different administration routes, the 
toxicity observed in the group treated intraperitoneally was severe, and toxicity 
observed after the intranasal route was milder. Among the reasons that could 
explain this lower toxicity, we cannot exclude the fact that a fraction of the 
bacteriocin given intranasally would have been “redirected” to the gastric route, 
and could be degraded by digestive enzymes. If so, the final concentration 
absorbed would be less than the one theoretically assayed. According to the work 
of del Castillo-Santaella T. et al. (49) the gastric enzyme, pepsin, only degrades AS-
48 partially, but a further degradation occurs in the duodenum with the action of 
trypsin and chymotrypsin, this phenomenon occurs in a time-depend manner.  
Nevertheless, it was observed that a fraction of AS-48 keep intact under 
these conditions and are able to avoid digestive degradation, possibly due to the 
different conformation that AS-48 can have or the domains that expose in certain 
media (49). Given that in the discovery of new antituberculosis drugs, one of the 
preferences is to develop a drug that can be administered orally, this would be the 
Achilles’s heel of bacteriocin AS-48. 
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On the other hand, the intranasal route for administering an 
antituberculosis agent has the advantage of the direct delivery of the antimicrobial 
to the lung (50). However, for the intranasal administration, we anesthetized mice 
and the effect of the anesthesia during a prolonged treatment could imply an 
increase of the toxicity and a decrease in the effectiveness of the treatment. As a 
first approximation, in the subchronic toxicity test and consequently in the efficacy 
test, we used the intraperitoneal route as this can be done with shorter anesthesia 
time. It is evident that comparing other administration routes would give us more 
information about which administration route would be the optimal one for 
administering bacteriocin AS-48 while minimizing its toxicity. 
 
EFFICACY 
For the efficacy assays, the administration of the antituberculosis agents 
with the aim of decreasing the bacterial load in the infected lungs could be given 
either through intranasal administration or by aerosol. Again, we have to consider 
the high exposure to anaesthesia with isoflurane, given that the treatment of 
tuberculosis would last for one month under our experimental conditions. The 
aerosol delivery has the limitation that a great concentration of compound is 
needed to allow the drug to reach the lungs in an effective concentration. 
Moreover, in comparison with other administration routes, the amount of drug 
dispensed to each mouse could vary and the exact drug load could not be 
calculated accurately. 
Usually, both, isoniazid and ethambutol are administered orally, and the 
concentrations used in our efficacy experiment were calculated considering the 
indications for the oral administration (51) as well as other studies. For example, 
according to Plinke et al.(52)  in female 8-week-old C57BL/6 there is a positive 
effect in the reduction of the CFUs in majority of the organs when the mice were 
treated with 25-50 mg/Kg body weight of ethambutol. To boost the effect of 
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ethambutol with AS-48 we decided to use subinhibitory concentrations of 
ethambutol in vivo as shown in the in vitro assays. 
Jindal et al. (42) assayed the efficacy of antimicrobial synthetic peptides 
derived from indolicin and ranalexin in a murine model of Streptococcus 
pneumoniae infection. These studies demonstrated the antimicrobial action of these 
peptides against a systemic infection (pneumococcal pneumonia) and also the 
synergy effect between different peptides and between peptides and antibiotics 
such as ceftriaxone and erythromycin, resulting in an efficient combined therapy 
(42). The lipophilic peptide YV11455 (45) was tested against Staphylococcus aureus 
(MRSA) in murine models, and resulted between 54-270-fold more effective than 
its analogue, vancomycin.  
Other peptides, such as the microcin J25 that targets the bacterial RNA 
polymerase, have been tested against Salmonella infections, showing a great 
reduction in the number of CFUs in spleen and liver, and more interestingly 
demonstrated an antimicrobial effect in the whole organism (53). 
Although all the infected mice in the efficacy assay formed granuloma, the 
heterogeneity of the vascularity in granuloma could decrease blood irrigation and 
consequently the accessibility of the drug to the site of infection and to the 
compartments where non-proliferative bacteria reside. If we would have achieved 
a good decrease in bacterial load in the infected mice it would be highly relevant 
to perform new assays with the Kramnik model as well as a murine model of acute 
infection, as described by Rullas J. et al. (54). As the vascular architecture is 
destroyed in the caseous centre of necrotic lesions and cavities, this leads also to 
failed immune response due to poor access of circulating T lymphocytes, a 
reduction of oxygen and nutrient supply and the consequent metabolic quiescence 
of bacterial cells.  
Then, to reach the caseum, where quiescence bacilli are, drugs must diffuse 
from the cellular border of the necrotic area to the centre of the caseous region 
without the assistance of active or facilitated transport mechanisms (55). In the 
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Kramnik (C3HeB/FeJ strain) model, with caseous formation, it is also shown that 
the survival rate decreases when it is compared with a common model such as 
BALB/c (26). Therefore in this study we decided to perform a traditional chronic 
infection for the efficacy assay and check if AS-48 could have an antitubercular 
effect as it has been demonstrated in vitro.  
We have to take in consideration that this is the first time that in vivo 
experiments have being done in mammals. Recently, Baños et al. (56) described 
experiments carried out in rainbow trout (Oncorhynchus mykiss) with a protective 
result of the treatment against Lactococcus garvieae, reducing the mortality caused 
by this pathogen. They also have taken into consideration the use of the producer 
strain of AS-48, UGRA10, in the diet as a preventive action against this pathogen. 
For this animal model, they reached a reduction in the bacterial load and an 
increase of the survival (100µg intraperitoneally and 12.5µg/ml in baths). As we 
have said before, the tuberculosis infection is extremely difficult to emulate in an 
in vivo model, due to the lack of natural reservoir (besides the human) so, the 
absence of a succesful effect of AS-48 in this experiments could be linked to the 
conditions.  
Further experiments with other animal models will be needed to explore 
the possible applications that AS-48 could have against infectious diseases.To 
enhance the access of the drug to the target in an in vivo model we also have to 
consider the drug vehicle, in this case we have used PBS as a common harmless 
vehicle. This system could also be improved with the use of nanoformulation, for 
example in the case of rifampicin/poly (lactic-co-glycolic acid), Ohashi K.et al. (57) 
described that nanoparticles containing mannitol microspheres increased the 
rifampicin uptake by inhalation in the pulmonary macrophages. 
As we have seen, the intranasal route is less harmful for mice, so the 
treatment using an aerosol application could enhance its effect and reduce the 
possible in vivo toxicity. 
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We also propose, other drugs combination such as including AS-48 to the 
complete treatment against M.tuberculosis, the use of isoniazid, rifampicin, 
ethambutol and pyrazinamide together with AS-48 could boost the effectiveness 
of the common treatment and result in a reduction of the time and second side-
effects. 
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CONCLUSIONS 
 
 Bacteriocin AS-48 shows bactericidal activity against M. tuberculosis 
complex, either laboratory and reference strains or clinical isolates. 
 AS-48 has a variable activity against non-tuberculous mycobacteria. 
 Synergy relationship between AS-48 and lysozyme. 
 The modified bacteriocins from the wild type AS-48 have a lesser or equal 
bactericide activity against M. tuberculosis than the wild type. 
 Porins mutants of M. smegmatis do not exhibit synergy between AS-48 and 
lysozyme, only the double porin mutant, ML10, has a synergy FICI of 0.5. 
 Ethambutol and AS-48 exhibit a great synergy against M. tuberculosis. 
 Antimicrobial concentrations of AS-48 are not cytotoxic in human and 
murine macrophage cell lines. 
 Ethambutol and AS-48 also have a synergy activity in the infected 
macrophages against M. tuberculosis. 
 M. tuberculosis exhibits more morphological damage with a synergistic 
combination than when AS-48 is acting alone. 
 The activity of AS-48 is not mediated by efflux pumps. 
 AS-48 is capable to depolarize the membrane potential, both, time and 
concentration dependent. 
 AS-48 is targeting the mycobacterial membrane. 
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 The ratio of expression of Toxin-Antitoxin genes is 2-5 times higher than 
non-treated cultures. 
 The activity of AS-48 also affect the mobility of DNA, thus the gene 
expression could be altered. 
 AS-48 is a multitarget drug so, generate a resistant mutant is less probable 
than a unique-target drug. We have not been able to generate a resistant 
M. tuberculosis mutant against AS-48. 
 The toxicity of AS in in vivo mice models is higher than the toxicity reached 
in vitro. 
 BALB/c mice are less sensitive to AS-48 than C57BL/6, resulting 
hepatotoxic for this mice strain. 
 The combined treatment of AS-48 and ethambutol is less toxic in vivo than 
the same concentration of AS-48 alone. 
 The different treatments with AS-48 alone or in combination with 
subinhibitory concentrations of ethambutol do not reduce significantly 
bacteria burden in infected mice, treated by the intraperitoneal route. 
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ANNEX I: AS-48 PURIFICATION 
 
The circular bacteriocin, AS-48, was purified according to Cebrian et al. (1). 
Briefly, 5L of reconstituted Esprion 300 (4% E-300, DMV Int., Veghel, Netherland) 
medium plus 1% glucose (E-300-G) were inoculated at 8% with a BHI (DIFCO) 
Enterococcus faecalis UGRA10 pre-inoculum. The culture was grown at 30˚C with 
shaking and controlled pH of 6.55 during 18-20h.  
Once the culture was growth, it was directly mixed with reconstituted 
Sephadex CM-25 in 1:10 (v/v) proportion for ionic interchange purification. 
Matrix and culture were mixed for 1h and them the CM-25 was disposed of in a 
chromatography column. The matrix was washed with 1L of distillate water, and 
then, the peptide was eluted with 1L of NaCl 2M. 50ml fractions were collected 
and their antimicrobial activity tested against Enterococcus faecalis JH2-2. 
Active fractions were concentrated and desalted using reverse-phase C-18 
open columns. For this, 4 g of C-18 were reconstituted in an organic solvent 
(solvent B, Isopropanol: Acetonitrile, 2:1, 0.1% TFA) and equilibrated in the 
aqueous solvent (solvent A, distilled water +0.1% TFA). In this condition, the 
active fractions were applied to the column. The NaCl was removed from the 
column washing it with 5 column volumes, and the peptide was eluted in a solvent 
B gradient (20%, 40%, 60%, and 80%). The active fraction (60%) was lyophilized, 
resuspended in solvent A and purified to homogeneity by reverse phase-HPLC 
chromatography. The equipment includes a chromatographic (Agilent 1100 Series) 
with a degassing (G123779A), a manual injector (61328B), a quaternary bomb of 
high pressure (G1311A) and a wavelength detector. Semipreparative scale 
purification was performed using a C18 Vydac 218TP510 (10x250mm, 300Å; The 
Separation Group, Hesperia) column. The sample was load, and the peptide was 
eluted with a lineal gradient of solvent B in solvent A from 40% to 805 in 25 min at 
3mL/min. The desired AS-48 peak was manually collected, lyophilized and stored 
until use. 
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ANNEX II: SYNERGY BETWEEN CIRCULAR BACTERIOCIN AS-48 AND ETHAMBUTOL AGAINST 
MYCOBACTERIUM TUBERCULOSIS 
As part of this work we have published one paper referred to the first part 
of this thesis. 
The title of the publication is: Synergy between Circular Bacteriocin AS-48 and 
Ethambutol against Mycobacterium tuberculosis. It was accepted the 26th of June of 
2018 and published in the number of September 2018 in the journal of 
Antimicrobial Agents of Chemotherapy. 
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ANNEX III: THE EU APPROVED ANTIMALARIAL PYRONARIDINE SHOWS ANTITUBERCULAR ACTIVITY 
AND SYNERGY WITH RIFAMPICIN, TARGETING RNA POLYMERASE 
During the period of developing this work I have collaborated performing 
some experiments detailed in the following paper: The EU approved antimalarial 
pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA 
polymerase. 
I performed some experiments of synergy between rifampicin and 
pyronaridine in vitro against M. tuberculosis and analysed the FICI results. This 
work was accepted the 5th of August of 2018 and published in the journal 
Tuberculosis in September of 2018.
Synergy between Circular Bacteriocin AS-48 and Ethambutol
against Mycobacterium tuberculosis
Clara Aguilar-Pérez,a,b,c Begoña Gracia,a,b,c,d Liliana Rodrigues,a,b,c,d,e* Asunción Vitoria,a,b,c,d,h Rubén Cebrián,f*
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ABSTRACT The increasing incidence of multidrug-resistant Mycobacterium tubercu-
losis strains and the very few drugs available for treatment are promoting the dis-
covery and development of new molecules that could help in the control of this dis-
ease. Bacteriocin AS-48 is an antibacterial peptide produced by Enterococcus faecalis
and is active against several Gram-positive bacteria. We have found that AS-48 was
active against Mycobacterium tuberculosis, including H37Rv and other reference and
clinical strains, and also against some nontuberculous clinical mycobacterial species.
The combination of AS-48 with either lysozyme or ethambutol (commonly used in
the treatment of drug-susceptible tuberculosis) increased the antituberculosis action
of AS-48, showing a synergic interaction. Under these conditions, AS-48 exhibits a
MIC close to some MICs of the first-line antituberculosis agents. The inhibitory activ-
ity of AS-48 and its synergistic combination with ethambutol were also observed on
M. tuberculosis-infected macrophages. Finally, AS-48 did not show any cytotoxicity
against THP-1, MHS, and J774.2 macrophage cell lines at concentrations close to its
MIC. In summary, bacteriocin AS-48 has interesting antimycobacterial activity in vitro
and low cytotoxicity, so further studies in vivo will contribute to its development as
a potential additional drug for antituberculosis therapy.
KEYWORDS AS-48, antimicrobial peptides, antituberculosis activity, synergism,
antimycobacterial agents, bacteriocins, Mycobacterium tuberculosis, intracellular
infection
Mycobacterium tuberculosis is the causal agent of tuberculosis, a disease that mainlyaffects the lungs and was responsible for 1.6 million deaths in 2016; it is the
infectious disease with the highest mortality rate (1). M. tuberculosis is an intracellular
pathogen residing in pulmonary macrophages within granulomas, where it is mostly
kept in latent forms, the host defense mechanism against this pathogen. Infection
progresses into active disease when the host immune system is suppressed and the
granulomas cannot contain the bacilli. In this way, coinfection with HIV in tuberculosis
patients is one of the key factors behind the increase in the incidence of tuberculosis,
predominantly in countries where both diseases are endemic.
Tuberculosis is a curable disease, where the active forms are generally susceptible to
diverse antimicrobials, such as the first-line drugs (isoniazid, pyrazinamide, ethambutol
[EMB], rifampin, and streptomycin), which are prescribed as standard treatment for
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tuberculosis. However, the huge incidence of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) M. tuberculosis strains (which are not responsive to standard
treatment and need to be treated with second-line drugs such as aminoglycosides and
fluoroquinolones, among others) has exacerbated the need for developing alternatives
for an effective treatment. During 2016, about 490,000 cases of tuberculosis were
caused by MDR strains, and 6.2% of them were caused by XDR strains (1).
In the context of drug resistance, not only in respect to tuberculosis but also in
connection with many other bacterial pathogens, antimicrobial peptides (AMPs) may
have great potential for use in treatment, either by themselves or in combination with
other antimicrobials. AMPs are produced by prokaryotic or eukaryotic organisms. They
are peptides and proteins, mostly cationic and with an amphiphilic nature, that are
ribosomally synthesized. Most of the bacterial lineages can produce AMPs, called
bacteriocins, that exhibit antimicrobial activity primarily against those species that are
phylogenetically closely related with the producer species. Recently, a classification
system of bacteriocins (2) was accepted whereby class I (less than 10 kDa) encompasses
all the peptides that undergo enzymatic modification during biosynthesis, providing
molecules with uncommon amino acids and structures that have an impact on their
properties. Thus, there are lanthipeptides (class Ia), head-to-tail cyclized peptides (class
Ib), sactibiotics that are sulfur–-carbon-containing peptides (class Ic), and linear
azol(in)e-containing peptides (class Id). Class II (less than 10 kDa) includes unmodified
bacteriocins that do not require enzymes for their maturation; finally, class III consists
of heat-labile bacteriocins without modifications that are larger than 10 kDa and with
bacteriolytic or nonlytic mechanisms of action.
The prototype of the ribosomally synthesized and posttranslationally modified
peptides (RiPPs) is the bacteriocin AS-48, which undergoes head-to-tail cyclization to
render a circular molecule (class Ib). All of these cyclized peptides are synthesized as a linear
precursor containing a leader sequence with a high molecular weight, and then they are
posttranslationally modified. AS-48 is a 70-amino-acid, alpha-helical membrane-interacting
peptide produced by Enterococcus faecalis that displays a broad antimicrobial spectrum
against Gram-positive and Gram-negative bacteria. The mechanism of AS-48 antibacterial
activity involves the accumulation of positively charged molecules at the membrane
surface, leading to a disruption of the membrane potential (3, 4). The antimicrobial
activity of AS-48 has already been proven in food products (5) and has been observed
against numerous Gram-positive bacteria, including Listeria monocytogenes and entero-
toxic Staphylococcus aureus (6).
Most of the studies on bacteriocins focus on their potential applications as food
preservatives, and only a few of studies are focused on their potential biomedical
applications and, specifically, antimicrobial or antituberculosis activity. Activity of nisin
and lacticin 3147 has been shown againstMycobacterium strains such asMycobacterium
kansasii, Mycobacterium avium subsp. paratuberculosis, and M. tuberculosis H37Ra; in
particular, lacticin 3147 exhibits greater antimycobacterial activity than nisin (7). The
antimycobacterial activities of several bacteriocins were found to be similar to the
activity of rifampin against M. tuberculosis (8).
In this work, we have investigated the antituberculosis activity of bacteriocin AS-48
alone and in combination with lysozyme and first-line drugs used in the treatment of
tuberculosis, both in in vitro cultures and also in M. tuberculosis-infected macrophages.
We report that AS-48 is active against M. tuberculosis and other mycobacterial species
and synergizes with EMB. Bacteriocin AS-48 was not found to be cytotoxic at the doses
required for inhibiting mycobacterial growth. Moreover, AS-48 caused depolarization of
mycobacterial membranes and altered morphology of the bacilli. In conclusion, we
demonstrate that bacteriocin AS-48 has positive features supporting its potential role
in tuberculosis treatment.
RESULTS
Bacteriocin AS-48 showed bactericidal activity againstM. tuberculosis complex.
The activity of AS-48 was determined against several mycobacteria, including M.
Aguilar-Pérez et al. Antimicrobial Agents and Chemotherapy
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tuberculosis complex reference strains, clinical isolates, and other clinically relevant
nontuberculous mycobacteria (NTM).
First, we tested AS-48 activity against M. tuberculosis complex clinical and reference
strains. The MICs of AS-48 were quite uniform, between 16 and 64 g/ml (Table 1; see
also Table S1 in the supplemental material), and there was no difference in the MICs of
AS-48 between active replicating cells and the nonreplicative strain SS18b of M.
tuberculosis. We observed a similar MIC of AS-48 for Mycobacterium smegmatis and
other NTM (see below).
The kill kinetics indicated that bacteriocin AS-48 is bactericidal since concentrations
equal to the MIC and 2 MIC were capable of reducing the number of live bacteria in
a culture of M. tuberculosis H37Rv. First, after 1 or 2 days of treatment, the number of
CFU was reduced by almost 2 logs in comparison with levels in untreated cultures. After
6 days of treatment with 128 or 64 g/ml of AS-48, no live bacteria could be detected
(Fig. 1), and this was found to be statistically significant by a linear regression test (P
values of 0.0005 and 0.0001, respectively).
Synergy between lysozyme and nisin was previously observed in Gram-positive
bacteria (9, 10). Similarly, we have observed that the presence of lysozyme resulted in
an increase in M. tuberculosis susceptibility to AS-48. First, we tested lysozyme activity
against mycobacterial strains and found that different mycobacterial strains or species
have more variability in the MICs of lysozyme (Tables 1 and S1) than the MIC obtained
for AS-48. Notably, the nonreplicating strain SS18b of M. tuberculosis was found to be
greatly resistant to lysozyme. Second, we tested the susceptibility of mycobacterial
strains to AS-48 in the presence of lysozyme (Table 2). We found that, for most strains,
susceptibility to AS-48 greatly increased (between 64- and 16-fold) in the presence of
subinhibitory concentrations of lysozyme. In order to quantify the effect of lysozyme on
growth inhibition by AS-48, we calculated the fractional inhibitory concentration index
(FICI). The results of all strains assayed are indicated in Table 2. For reference strains,
TABLE 1Mycobacterial strains used and MICs of AS-48 and lysozyme
Strain
MIC (g/ml)
Source or referenceAS-48 Lysozyme
H37Rv 32–64 200–400 37
H37Ra 32 400 38
BCG Pasteur 1173 32 200–400 Laboratory collection
Mt103 64 400 39
CDC1551 64 400 40
GC 1237 16–32 400 41
H37Rv phoP 64 400 42
SS18b 32–64 1,200 43
M. smegmatis mc2155a 64 400 44
aFast-growing mycobacteria.
FIG 1 Kill kinetics of bacteriocin AS-48 at 64 and 128 g/ml against cultures of M. tuberculosis H37Rv.
Untreated cultures were used as controls.
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maximum synergism was observed for H37Rv and, to a lesser extent, for Mycobacterium
bovis BCG, H37Ra, H37Rv phoP, GC 1237 (Beijing genotype), CDC1551, and Mt103.
Although technically synergism is defined as an FICI of 0.5, we consider the strains
Mt103 and HMS 1548, which resulted in FICIs slightly over 0.5, to have weak synergistic
interactions. The synergy effect occurred in all of the M. tuberculosis complex strains
analyzed.
Bacteriocin AS-48 has variable activity against NTM. In most NTM, the MIC of
AS-48 is the same as that for M. tuberculosis (i.e., 64 g/ml), with the exception of
slow-growing mycobacterial species such as Mycobacterium xenopi, Mycobacterium
lentiflavum, and Mycobacterium gordonae. For M. xenopi and M. gordonae, the value of
the MIC of AS-48 was 2 g/ml, and the MIC of lysozyme was 9.375 g/ml. In
contrast, the MIC of AS-48 against M. lentiflavum was higher than 256 g/ml, and the
MIC of lysozyme was also higher than 1,200 g/ml, indicating that this mycobacterial
species is less susceptible to AS-48 and to lysozyme (Table S1).
Synergy test between AS-48 and first-line antituberculosis drugs. AS-48 has
been tested also in combination with the main first-line antituberculosis drugs, EMB,
isoniazid, streptomycin, and rifampin. The combination of AS-48 and EMB was the only
one to present a synergistic relation, with an FICI of 0.09375, which was the lowest FICI
obtained in all the assays (Fig. 2).
Is AS-48 targeting the mycobacterial membrane? In order to explore whether
bacteriocin AS-48 could be targeting the mycobacterial membrane, we carried out
experiments for ethidium bromide accumulation, and we determined the ability of
AS-48 for depolarizing the mycobacterial membrane.
It is assumed that AS-48 forms pores in the membrane (11), thus making the cell
more permeable to compounds such as ethidium bromide. Therefore, in an ethidium
bromide accumulation assay, we would expect that the fluorescence detected would
be higher in the presence of AS-48, reflecting the increased accumulation of ethidium
bromide as a result of the effect of AS-48 on the bacterial membrane. We compared the
effect of AS-48 with that of verapamil, a well-known efflux inhibitor (12), which produces an
increase in the accumulation of ethidium bromide. In the presence of AS-48, fluorescence
due to accumulated ethidium bromide increased in a concentration-dependent manner
although the kinetics of accumulation was rather distinct from that observed with vera-
pamil (Fig. 3).
The determination of membrane potential was carried out using a BacLight kit
according to the manufacturer’s instructions using M. smegmatis mc2155 and M. bovis
TABLE 2MIC of AS-48 in the presence of different concentrations of lysozyme and the
fractional inhibitory concentration index
Strain
MIC of AS-48 (g/ml) at the indicated lysozyme concn
(g/ml)
FICIa400 200 100 50 25 12.5
H37Rv 0.03125 0.0625 1 4 32 0.25
H37Ra 0.03125 2 4 16 32 0.375
BCG Pasteur 0.125 2 16 32 0.3125
Mt103 0.125 4 32 32 64 64 0.5625
CDC1551 0.125 16 32 64 64 0.5
GC 1237 0.03125 4 8 32 0.375
H37Rv phoP 0.125 8 32 64 64 0.375
M. smegmatis mc2155 0.125 32 64 64 1
HMS 1500 0.03125 8 32 0.375
HMS 1531 0.03125 0.5 4 8 0.375
HMS 1536 0.03125 8 32 0.5
HMS 1546 0.03125 2 8 32 0.5
HMS 1548 0.03125 2 16 32 0.5312
HMS 1292 0.03125 4 16 32 0.3125
HMS 1278 0.03125 2 8 32 0.5
aThe fractional inhibitory index (FICI) is calculated as follows: FICI (MICAS-48 in the presence of lysozyme/MICAS-48 alone)
(MIC
lysozyme in the presence of AS-48
/MIClysozyme alone). An FICI of0.5 indicates synergism, a value of 0.5 to 4 indicates no
interaction, and a value of 4.0, indicates antagonism.
Aguilar-Pérez et al. Antimicrobial Agents and Chemotherapy
September 2018 Volume 62 Issue 9 e00359-18 aac.asm.org 4
 o
n
 August 28, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
BCG cells. In a representative control experiment, in the untreated cells, 3.4% of cells
were depolarized, whereas in the cells treated with the protonophore carbonyl cyanide
m-chlorophenylhydrazone (CCCP), the percentage of depolarized cells was 94.93%. We
assessed the effect of AS-48 at several concentrations and for different times of
incubation (1 or 24 h). We observed that AS-48 depolarized cells in a concentration-
dependent manner, and this effect was much higher in the cells incubated with AS-48
for 24 h than in those tested after 1 h of incubation. Data in Fig. 4 show that the
percentage of depolarized cells after 24 h is 67.04% in the presence of 128 g/ml of
AS-48, 26.34% with 64 g/ml, and 18.68% with 32 g/ml. Again, this demonstrates that
the depolarization of the cells is concentration dependent and increases with time.
Antimicrobial concentrations of AS-48 are not cytotoxic for macrophage cell
lines. The cytotoxicity of AS-48 on human and mouse lung macrophage cell lines was
carried out by MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide]
and neutral red assays.
In both protocols, 70% cell viability was observed at concentrations of AS-48
below 128 g/ml, which is considered noncytotoxic according to standard international
protocols (13). Even when slight differences in cell viability were observed below 32
g/ml of AS-48, they were not significant (Fig. 5). We did not observe a concentration-
dependent cytotoxic effect in any of the cell lines assayed. At 128 g/ml, 40% cell
viability was observed (Fig. 5) (P value of 0.0001).
Lysozyme cytotoxicity was also analyzed, and, as expected, no cytotoxicity was
observed in these cell lines. Finally, we assayed cytotoxicity of some of the synergistic
combinations of AS-48 and lysozyme that showed great antimicrobial effect in M.
FIG 2 Synergism between AS-48 and EMB in M. tuberculosis H37Rv. For the reference strains CDC1551,
Mt103, H37Ra, and H37Rv phoP, the plot had the same shape, indicating that synergy between AS-48 and
EMB was very similar to that in H37Rv.
FIG 3 Assay of ethidium bromide (EtBr) accumulation in M. smegmatis cells in the presence of different
concentrations of AS-48. VP, verapamil, used as control for the maximum accumulation of ethidium
bromide; Bact, negative control with only a bacterial suspension.
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tuberculosis, and we found that these combinations did not cause any cytotoxic effect
(Fig. 5).
Treatment with AS-48 results in morphological changes in M. tuberculosis. We
treated M. tuberculosis cells with AS-48, along with untreated cells as a control, and
samples were taken at several time points for microscopic observation. We found that
at short time exposures, cells were affected by AS-48 (Fig. 6): the morphology of cells
treated with a concentration of AS-48 equal to the MIC after 48 h and 72 h was rougher
than that of the control.
Moreover, we assayed the combination of 8 g/ml of AS-48 with 25 g/ml of
lysozyme and analyzed cells at 24, 48, and 96 h after treatment. When bacterial cells
were treated with a synergistic combination of AS-48 and lysozyme, they exhibited
greater morphological damage (Fig. 7) than cells treated with AS-48 alone (Fig. 6).
Synergy between EMB and AS-48 in the infected macrophages. In the model of
Raw 264.7 cells infected with M. tuberculosis H37Rv-green fluorescent protein (GFP), we
FIG 4 Flow cytometry assay for determination of membrane depolarization. The positive control con-
tained just a bacterial suspension. CCCP, ionophore showing maximum membrane depolarization. The
concentration of AS-48 and the time of exposure to AS-48 are shown below each bar.
FIG 5 Representative results of the cell viability assays, as determined by neutral red uptake technique
in cell cultures of J774.2 murine macrophages. Cell suspensions with no compounds added were used
as a positive control. ns, not significant.
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observed low FICI values (Table 3) ranging from 0.5 and 0.18, which is indicative of
synergism. These FICI values were similar to those obtained in the in vitro antimyco-
bacterial assays. The combination of 2 g/ml AS-48 and 2 g/ml EMB resulted in the
lowest FICI value. Other combinations also resulted in synergistic FICI values but to a
lesser extent (Table 3). The determination of viable bacteria after treatment with EMB
and AS-48 resulted in a reduction of CFU counts between 90 and 99.9% in comparison
with totals in untreated controls. The efficacy of AS-48 for killing intracellular pathogens
was previously proven by Abengózar et al. (14) when they showed the anti-leishmanial
activity of AS-48 in Raw 264.7 infected macrophages. Despite the fact that the infection
mechanism is different between Leishmania and mycobacteria, these experiments
show that AS-48 is active against pathogens residing intracellularly in macrophages.
DISCUSSION
During recent years, we have witnessed a decline in the number of deaths and
incidence of tuberculosis globally; however, recent reports estimate that 600,000
FIG 6 Scanning electron microscopy images of M. tuberculosis H37Rv under different conditions. (A and B) Positive
control after 48 and 72 h of growth, respectively. (C and D) Cells treated with 64 g/ml of AS-48 for 48 and 72 h,
respectively.
FIG 7 Scanning electron microscopy images of M. tuberculosis H37Rv treated with a synergistic combination of 8 g/ml of AS-48 and 25 g/ml of lysozyme
after treatment for 24 h (A) 48 h (B), and 96 h (C).
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people had MDR or rifampin-resistant (RR) tuberculosis in 2016, which represents a
notable increase over the previous year (1). Drug-based treatment for MDR or RR
tuberculosis is available only for 20% of these patients, and it is much longer, more
expensive, and more toxic than treatment of drug-susceptible tuberculosis. More
worryingly, the success rate of MDR tuberculosis treatment is around 50%. Altogether,
these facts clearly mean that there is an imperative need for researching new drugs
against tuberculosis and, more specifically, against MDR and RR tuberculosis.
The pipeline of new antituberculosis drugs in clinical development includes just
seven new compounds (petromanid, delpazolid, SQ-109, GSK-3036656, Q-203, PBTZ-
169, and OPC-167832), which, although promising, seems to be insufficient for the
treatment of tuberculosis since it requires at least three drugs to be administered
simultaneously (15).
Natural or synthetic peptides are emerging as a promising source of novel antimi-
crobials (16). Currently, there are two AMPs in phase 2 of clinical development (murepa-
vadin and brilacidin) for treating, respectively, Pseudomonas aeruginosa and S. aureus
infections. As with most AMPs, both target the bacterial membrane, an interesting new
target for treating persistent infections such as tuberculosis (17). Other membrane-
targeting compounds have been shown to be effective in vitro against Clostridium
difficile (18). The interest in the possible application of AMPs in tuberculosis treatment
has arisen since it was demonstrated that a high proportion of AMPs active against P.
aeruginosa also showed activity against M. tuberculosis (19). Recently, the activity of
antimicrobial peptides against several species of mycobacteria has been reviewed (20).
Bacteriocins are AMPs produced by certain genera of bacteria, such as lactic acid
bacteria. Previously, antimicrobial activity of bacteriocin AS-48 has been reported (4). In
this study, we report the activity of bacteriocin AS-48 against M. tuberculosis.
Susceptibility of M. tuberculosis strains to bacteriocin AS-48 ranged from 16 to 64
g/ml, including reference strains and several clinical isolates ofM. tuberculosis selected
by their different spoligotype and restriction fragment length polymorphism (RFLP)
profiles. We found that AS-48 is bactericidal against M. tuberculosis. Several other
bacteriocins have been reported as effective against M. tuberculosis in in vitro assays (7,
21–23): colistin has a MIC of 16 g/ml (24), and nisin showed a MIC of 60 g/ml
against M. tuberculosis H37Ra (7). The authors described variants of nisin with an
enhanced antimicrobial activity (22) against M. tuberculosis as well as other naturally
occurring bacteriocins such as lacticin 3147 (MIC90 of 7.5 g/ml) (7). Bacteriocins
capable of strongly inhibiting growth of M. tuberculosis at a concentration similar to
that of rifampin have also been described (8).
The success in the improvement of antituberculosis activity of nisin derivatives (22)
prompted us to explore whether variants of AS-48 (altered in residues important for
maturation, conformation stability, etc.) could have reduced MICs in comparison with
the MIC of wild-type AS-48. However, none of these variants resulted in a significant
change of their MICs against M. tuberculosis (data not shown), similar to what has been
described for other bacterial species (4).
We have also explored susceptibility of other mycobacterial species to AS-48 and
TABLE 3 Intracellular MICs and FICs of AS-48 and EMB alone or in combination and FICIsa
MIC (g/ml) FIC
FICIbAS-48 EMB AS-48 EMB
32
16 0.125 0.5 0.007 0.50
8 0.5 0.25 0.03 0.28
2 2 0.06 0.12 0.18
16
aValues were determined in Raw 264.7 cells infected with M. tuberculosis H37Rv-GFP. EMB, ethambutol.
bThe fractional inhibitory index (FICI) is calculated as follows: FICI (MICAS-48 in the presence of ethambutol/MICAS-48 alone)
(MIC
ethambutol in the presence of AS-48
/MICethambutol alone). An FICI of0.5 indicates synergism, a value of 0.5 to 4 indicates no
interaction, and a value of 4.0 indicates antagonism.
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found that for some species (M. smegmatis, Mycobacterium fortuitum, and Mycobacte-
rium mucogenicum, three fast-growing mycobacteria) the MIC of AS-48 did not change
significantly from that of M. tuberculosis. Carroll et al. (22) also described a rather
uniform susceptibility of nisin derivatives between M. tuberculosis, M. kansasii, and M.
avium. For other mycobacterial species (slow-growing and chromogenic species),
however, we obtained either very low MICs (2 g/ml forM. xenopi andMycobacterium
gordonae), or we could not detect any inhibition of growth up to 256 g/ml (M.
lentiflavum).
Lysozyme is an enzyme present in respiratory tract secretions as part of the body’s
defense mechanisms against microbes. It has been reported that the combination of
lysozyme and bacteriocins such as nisin results in a synergistic effect against many
bacterial pathogens such as C. difficile (25). This synergistic effect of lysozyme has also
been described for AS-48 (10). Lysozyme acting on the cell wall could facilitate the
access of AS-48 into the bacteria and increase its bactericidal effect. Through synergy
tests, we have found that AS-48 strongly synergizes with lysozyme, as has been
reported for other bacterial species (10).
From the early dates of antituberculosis treatment, it became evident that mono-
therapy results in the selection of drug-resistant strains, so a combination therapy was
established as a gold standard for antituberculosis treatment, with decreased proba-
bilities to develop resistance. Thus, for any new antituberculosis agent, it is interesting
to investigate not only its own antimicrobial activity but also its interactions with other
drugs in use against tuberculosis. We have investigated the interactions between AS-48
and first-line antituberculosis drugs by using a checkerboard assay, considered an
accurate drug combination analysis method (26) that has been used for demonstrating
synergism of drugs and drug candidates in M. tuberculosis (27, 28). We found that there
is synergism between AS-48 and EMB. In fact, the synergism between AS-48 and EMB
was stronger than that of AS-48 and lysozyme. We can hypothesize that EMB, by
inhibiting biosynthesis of arabinogalactan in the cell wall, could facilitate the access of
AS-48 to its potential target, the mycobacterial membrane. The work by Kalita et al. (29)
reported synergism between the antimicrobial human neutrophil peptide 1 (HNP-1)
and the antituberculosis drugs isoniazid and rifampin and, hence, proposed the use of
this AMP as an adjuvant in antituberculosis chemotherapy.
We conducted two experiments aimed at investigating the potential effect of AS-48
on the cell membrane. On the one hand, by determining the proportion of depolarized
cells after AS-48 treatment, we found that this effect was both concentration and time
dependent. On the other hand, in ethidium bromide accumulation assays, we moni-
tored a time course increase in fluorescence and also an AS-48 concentration-
dependent effect. Thus, we have demonstrated by using two independent methods
that AS-48 acts on mycobacterial membranes.
In the intracellular M. tuberculosis growth assays in macrophages, the combina-
tion of AS-48 and EMB readily showed strong synergism, and the FICI values
obtained were similar to the ones found in in vitro cultures. However, when we
tested the interaction between AS-48 and lysozyme in the intracellular model of
infection, no synergistic effect was observed under any of the conditions tested, in
contrast with what we have observed in in vitro cultures. We can speculate either
that lysozyme could not get inside the macrophages and thus could not reach the
intracellular bacteria residing in the phagosome or that it could have been de-
graded by the macrophage.
In summary, we have reported here the antituberculosis activity in vitro of circular
bacteriocin AS-48 on both extracellular and intracellular bacteria. Interestingly, we have
found that in both systems, AS-48 strongly synergizes with EMB, hence opening the
way to further explore the interaction of other AMPs with antituberculosis drugs and
their future potential use as adjuvants of current antituberculosis treatments or as part
of a new, alternative therapeutic regimen.
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MATERIALS AND METHODS
Bacterial strains and culture conditions.Mycobacterial strains used in this work for in vitro tests are
listed in Table 1 (see also Table S1 in the supplemental material). All strains were cultured in Middlebrook
7H9 medium (Difco) supplemented with 10% albumin-dextrose-catalase (ADC) (BD) and 0.05% Tween 80.
For drug susceptibility testing, Tween 80 was replaced by 0.5% glycerol. Cultures were incubated at 37°C
in 25-cm2 flasks. Cultures on solid medium were performed in Middlebrook 7H10 agar (Difco) supple-
mented with 10% ADC and 0.05% Tween 80.
For infection assays, a recombinant strain of M. tuberculosis H37Rv (ATCC 27294) constitutively
expressing a green fluorescent protein (H37Rv-GFP) was used as a reporter for the intracellular myco-
bacterial replication assay (30). This strain was grown in Middlebrook 7H9 medium supplemented with
10% oleic acid-albumin-dextrose-catalase (OADC; Difco), 0.05% Tween 80 (Sigma-Aldrich), 0.5% glycerol
(Euromedex), and 50 g/ml hygromycin B (Invitrogen). Cultures were maintained at 37°C under static
conditions for up to 14 days to reach the exponential phase of bacterial growth before being used for
the intracellular mycobacterial replication assay.
Cell cultures. The following cell lines were used: murine macrophages MHS (Health Protection
Agency [HPA] Culture Collections 95090612), J774.2 (European Collection of Authenticated Cell Cultures
[ECACC] 85011428), Raw 264.7 (TIB-71), and human monocytes THP-1 (ECACC 88081201). MHS cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM), and the rest were cultivated in RPMI 1640
medium with GlutaMAX (Gibco) and containing 10% heat-inactivated fetal bovine serum (FBS; Gibco).
When cells were to be used for cytotoxicity assays, antibiotics (penicillin, streptomycin, and ciprofloxacin)
were added to cell precultures. Cells were cultured in a controlled 5% CO2 atmosphere at 37°C.
MIC. Serial broth microdilutions were made to determine the MIC of AS-48, which was purified to
homogeneity from the E. faecalis UGRA10 strain (31) according to Ananou et al. (32), lysozyme (L3790;
Sigma-Aldrich), and other antimicrobials (isoniazid, moxifloxacin, streptomycin, and EMB [Sigma-
Aldrich]).
Dilutions of compounds were made in 100 l of culture medium for mycobacterial strains in sterile
96-well polypropylene flat-bottom plates. Wells were inoculated with 1  105 CFU in 100 l and
incubated at 37°C for 7 days for slow-growing mycobacteria or for 4 days for fast-growing species. Then,
30 l of 0.1 mg/ml filter-sterilized resazurin (Sigma-Aldrich) was added. The results were revealed after
48 h in the case of slow-growing mycobacteria or after 24 h for fast-growing species. Positive and
negative controls were added in all the experiments, and moxifloxacin (Sigma) at 0.5 mg/ml was used
in all the assays as a control (33).
Kill kinetics. We determined the kill kinetics in order to find out whether the antituberculosis effect
of bacteriocin AS-48 could be bactericidal or bacteriostatic. For this, Mycobacterium tuberculosis H37Rv
was grown in culture medium until exponential phase, then diluted to 106 CFU/ml, and separated in
three flasks. Bacteriocin AS-48 was added to cultures to give final concentrations of 64 and 128 g/ml,
and the third culture was left untreated as a control. All cultures were incubated at 37°C. After 1, 2, 6, and
9 days of incubation, samples of 100 l were taken, and serial 1:10 dilutions in phosphate-buffered saline
(PBS) supplemented with tyloxapol (a nonionic surfactant) at 0.1% was added to avoid bacterial
clumping. Dilutions were plated on Middlebrook 7H10 agar supplemented with ADC, in triplicate, and
plates were incubated for 3 weeks at 37°C. The numbers of CFU for each time point and culture were
determined and plotted as log CFU versus time, and results were analyzed for significance by a linear
regression test.
Synergy test. The synergy assay blends gradients of two compounds to evaluate their activities and
the interactions between them. In fresh medium for culturing mycobacteria, solutions at 4-fold the
highest concentration to be tested were prepared for each compound. Then, both compounds were
serially 2-fold diluted in sterile 96-well flat bottom plates; one of the compounds was diluted along the
columns, and the other was diluted in the rows. The first column would then have just one of the
compounds, and the last row would have the other; the rest of the plate would be a matrix of both
gradients. Finally, wells were inoculated as described above and incubated and treated with resazurin as
in a conventional MIC assay.
FIC index analysis. The fractional inhibitory concentration (FIC) index allows objective identification
of any interaction between two compounds against a particular bacterial strain, indicating whether there
is synergy, no interaction, or antagonism.
In the 96-well plate, the first column shows the MIC of one of the compounds (X), and the last row
shows the MIC of the second compound (Y). For each well in which there is no growth next to a well with
growth, the FIC must be calculated using the following formulas: FICX  MICX in the presence of Y/MICX alone
and FICY  MICY in the presence X/MICY alone.
Both values, together with other points of inhibition, can be represented graphically, and a concave
line will be indicative of synergy. Alternatively, the addition of FICX and FICY indicates the FICI value. An
FICI value up to 0.5 indicates synergy, a value between 0.5 and 4 indicates that there is no interaction
between the compounds, and a value over 4 indicates antagonism (34, 35).
Ethidium bromide accumulation assay. The ethidium bromide assay assessed the capacity to
accumulate ethidium bromide at increasing concentrations of bacteriocin AS-48. M. smegmatis was
cultivated until the culture reached an optical density at 600 nm (OD600) of 0.6 to 0.8 under the
conditions mentioned above. The culture was centrifuged, and the pellet was washed in PBS supple-
mented with 0.05% Tween 80; then, the OD600 was adjusted to 0.8 in the same buffer further
supplemented with 0.4 % glucose. Ethidium bromide was used at 1 g/ml combined with inhibitory and
subinhibitory concentrations of AS-48. Verapamil at 75 g/ml was used as a positive control showing the
highest accumulation of ethidium bromide. A control experiment was done with PBS-Tween 80 buffer
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and no bacterial inoculum to set the values of fluorescence of the compounds by themselves. Other
controls were done without ethidium bromide. Accumulation of ethidium bromide was measured by
recording fluorescence at 530-nm excitation and 590-nm detection for 1 h (12).
Cytotoxicity assays. An MTT assay and neutral red assay (36) were used to determine AS-48
cytotoxicity in MHS and J774.2 murine macrophages and THP-1 human macrophages. Cells were
cultured in 96-well flat-bottom plates with the appropriate medium. THP-1 monocytes were differenti-
ated to macrophages by using 10 ng/ml of phorbol 12-myristate 13-acetate (PMA) (P1585-1MG; Sigma-
Aldrich) for 72 h. The concentrations used for cytotoxicity assays were 15,000 cells/well (MHS) and 20,000
cells/well (J774.2) for mouse lung macrophages and 50,000 cells/well (THP-1) for human lung macro-
phages. They were cultured for 24 h, and then the compounds were added dissolved in fresh culture
medium. Absorbance was measured in an MTT assay at 570 and 650 nm and by fluorescence in the case
of neutral red at 530- and 645-nm excitation and emission wavelengths, respectively. Percent cell viability
in comparison with that of untreated controls was determined, and treatments were considered to be
cytotoxic or not according to the International Organization for Standardization (13). To check the lack
of differences between samples treated with lower concentrations of AS-48, we performed one-way
analysis of variance (ANOVA) tests.
Analysis of the bacterial membrane potential. M. smegmatis and M. bovis BCG membrane
potentials were measured by a BacLight bacterial membrane potential kit (B34950; Thermo Fisher);
integrity of the membrane potential results in fluorescence due to the accumulation of DiOC2 (3) inside
bacterial cells. Bacterial cells were treated with several concentrations of AS-48 for 24 h to assess its effect
on membrane potential. The samples were analyzed by flow cytometry.
Samples for SEM. The effect of AS-48 on the morphology of M. tuberculosis H37Rv was analyzed by
scanning electron microscopy (SEM). SEM images were acquired using an SEM Inspect F50 (FEI Company,
Eindhoven, The Netherlands). Bacterial cultures treated with AS-48 at 64 g/ml or with 8 g/ml of AS-48
plus 25 g/ml of lysozyme were diluted to 105 CFU/ml, and samples were first fixed with glutaraldehyde.
Then, samples were washed three times with 10 PBS, filtered through a 0.1-m-pore-size filter (0.1-m
VCTP Isopore membrane filter; Millipore), and then dehydrated with a graded ethanol series and kept in
100% ethanol. Finally, ethanol was evaporated at room temperature, and samples were covered with a
thin layer of metal (Pt; 15 nm) and examined at 15,000 eV and different magnifications.
M. tuberculosis macrophage infection assay. Cultures of H37Rv-GFP were maintained with stirring
for 3 days before infection to ensure that bacterial cells were in exponential growth. Then, bacterial cells
were washed twice with PBS without Mg2 and Ca2, followed by a third wash with RPMI 1640 medium
supplemented with 10% FBS (RPMI-FBS), and centrifuged at 70  g for 2 min to pellet bacterial clumps;
the supernatant corresponded to a homogenous suspension of bacteria. Bacterial titer was determined by
measuring the optical density at 600 nm and by measuring enhanced GFP (EGFP) fluorescence on a Victor
Multilabel Counter (PerkinElmer); the sample was further diluted in RPMI-FBS medium prior to infection. Raw
264.7 macrophages were used for the intracellular mycobacterial replication assay and harvested by using
Versene (Life Technologies). Macrophages were prepared at a concentration of 5  105 cells/ml, infected at
a multiplicity of infection (MOI) of 1:2 with H37Rv-GFP, and incubated in RPMI-FBS cell culture medium at 37°C
with stirring at 120 rpm. After 2 h, cells were centrifuged at 160  g for 5 min, resuspended in the same
volume of fresh medium containing 50 g/ml of amikacin to kill extracellular bacteria, and incubated for 1 h
at 37°C with shaking at 120 rpm. Cells were washed and resuspended in the same volume of fresh medium.
Infected cells were seeded in 384-well plates (Greiner Bio-One) at 2  104 cells/well containing compound
(AS-48, EMB, and lysozyme diluted in water). Plates were incubated for 5 days at 37°C in 5% CO2. Infected cells
were stained for 30 min with Syto60 dye (Invitrogen) at a final concentration of 5 M. Finally, images were
acquired (as described below), and then cells were lysed with Dulbecco’s PBS (DPBS)–0.1% Triton X-100 buffer
for 1 min to release intracellular bacteria. The number of viable bacterial cells was determined by serially
plating dilutions on Middlebrook 7H11 (Difco) agar plates, supplemented with 0.5% glycerol, 10% OADC, and
50 g/ml hygromycin B. After 3 weeks of incubation at 37°C in 5% CO2, the numbers of viable bacteria (CFU)
were calculated.
Image acquisition and analysis. Images were acquired on an automated fluorescent confocal
microscope (Opera; PerkinElmer), using a 20 water immersion lens. Syto60-labeled cells were detected
using a 640-nm excitation laser coupled with a 690/70-nm detection filter, and GFP-labeled bacteria were
detected using a 488-nm laser coupled with a 540/75-nm detection filter. A series of six images was taken
per well, and each one was analyzed using the Columbus system (version 2.5.1; PerkinElmer) image
analysis software. Briefly, the images were processed to determine the output image of GFP mask and
remove background in that channel. Then, the output images corresponding to the Syto60 values were
processed similarly to assess morphological parameters of cells. Properties of intensity and morphology
were filtered to select the correct nuclear population. Spots corresponding to the bacteria infecting the
cells were detected, and bacterial number and the area in pixels were determined for each cell. The
intracellular bacterial growth was quantified by the total intracellular bacterial area (pixels) per well. In
order to consider a cell infected, the number of bacteria within the cell area was set as 1. Efficiency of
infection and effectivity of treatment with compounds were determined in terms of the percentage of
infected cells and mean M. tuberculosis area per infected cell.
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A B S T R A C T
The search for compounds with biological activity for many diseases is turning increasingly to drug repurposing.
In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to
have in vitro activity against Mycobacterium tuberculosis (MIC 5 μg/mL). In macromolecular synthesis assays,
pyronaridine resulted in a severe decrease in incorporation of 14C-uracil and 14C-leucine similar to the effect of
rifampicin, a known inhibitor of M. tuberculosis RNA polymerase. Surprisingly, the co-administration of pyr-
onaridine (2.5 μg/ml) and rifampicin resulted in in vitro synergy with an MIC 0.0019–0.0009 μg/mL. This was
mirrored in a THP-1 macrophage infection model, with a 16-fold MIC reduction for rifampicin when the two
compounds were co-administered versus rifampicin alone. Docking pyronaridine in M. tuberculosis RNA poly-
merase suggested the potential for it to bind outside of the RNA polymerase rifampicin binding pocket.
Pyronaridine was also found to have activity against a M. tuberculosis clinical isolate resistant to rifampicin, and
when combined with rifampicin (10% MIC) was able to inhibit M. tuberculosis RNA polymerase in vitro. All these
findings, and in particular the synergistic behavior with the antitubercular rifampicin, inhibition of RNA
polymerase in combination in vitro and its current use as a treatment for malaria, may suggest that pyronaridine
https://doi.org/10.1016/j.tube.2018.08.004
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could also be used as an adjunct for treatment against M. tuberculosis infection. Future studies will test potential
for in vivo synergy, clinical utility and attempt to develop pyronaridine analogs with improved potency against
M. tuberculosis RNA polymerase when combined with rifampicin.
1. Introduction
The search for new drugs that could be used as effective treatments
for neglected diseases continues due to both the lack of effective
treatments and drug resistance. In particular,Mycobacterium tuberculosis
(Mtb), the causative agent of tuberculosis (TB), results in approximately
1.6 million fatalities out of 10.4 million new cases in 2016 [1]. For
decades, there has been extensive research focused on developing
molecules that could overcome drug resistance, shorten the duration of
TB therapy and attempt to avoid drug-drug interactions with ther-
apeutics used to treat patients co-infected with HIV infection [2–5]. For
well over 70 years, compounds have been evaluated in the in vivo
mouse model [6] and some of these could be suitable for reevaluation
[7]. With a shortage of funding for future research [8] there is a need
for enhancing the efficiency of TB drug discovery efforts. Increasingly,
there has been some interest in using drug repurposing, namely taking
drugs approved for another purpose and leveraging them for additional
diseases [9]. This can be facilitated using high-throughput screening of
libraries of approved drugs from the FDA or other regulatory agencies,
computational or virtual screening using docking or pharmacophores,
machine learning or combinations of methods, knowledge-based
methods, gene-expression data or serendipity [9–14]. These approaches
are particularly important for addressing neglected and rare diseases
where the urgency is great and an already approved drug would shorten
the path to the clinic and perhaps mitigate the treatment regimen
length.
In this context we focus on tuberculosis, with an example being
from a previously published medium-throughput screen of approved
drugs which identified several compounds with previously unknown
activity against Mtb, including the antimalarial compound primaquine
(MIC=5 μM) [15]. Moreover, numerous compounds with antimalarial
activity in vitro have been found to have activity against Mtb in vitro
[16], such as the 4-aminoquinoline antimalarials (e.g. mefloquine and
its enantiomers [17,18]) (Fig. S1). Similarly, another recent re-
purposing example for Mtb identified from a high throughput screen is
the proton pump inhibitor lansoprazole which has to be activated to the
sulphide [19] to possess activity in vitro but this needs to be provided
directly as the metabolite to obtain efficacious in vivo concentrations
greater than the MIC [20].
Pyronaridine is a potent antimalarial (EC50= 13.5 nM versus
Plasmodium falciparum) with chemical similarity to the aminoquinolines
that has been widely used in China [21]. It is currently used in com-
bination with artesunate in the European Medicines Agency-approved
Pyramax against P. falciparum and Plasmodium vivax infections [22]
(Fig. S1). As an antimalarial compound, pyronaridine is active against
the intraerythrocytic stage of the disease, with less toxicity than the
antimalarial chloroquine, as well as activity against drug-resistant
forms of the disease [22]. Pyronaridine-treated animals did not show
behavioral disturbances or neurotoxicity. In rat and human liver mi-
crosomes, the major metabolite is the quinoneimine. Metabolite char-
acterization based on the blood, urine, and feces samples obtained in a
mass balance study, allowed for identification of nine primary and four
secondary metabolites of pyronaridine [23].
In a previous study, following initial docking of pyronaridine to a
homology model ofMtb topoisomerase I (Topo I) [24–26], pyronaridine
was selected to evaluate its antitubercular activity in vitro because of its
promising in vivo PK and antimalarial activity (and good selectivity
index). In this work, our goals were to assess whether pyronaridine
could then be considered an antitubercular and a starting point for
further optimization or progression to future in vivomodels of infection.
2. Methods
All the experiments were performed in a BSL-3 safety laboratory
with trained researchers to avoid any risk of contamination.
2.1. Drugs and reagents
Pyronaridine tetraphosphate and additional antimalarial com-
pounds (chloroquine, primaquine, quinine, mefloquine, halofantrine,
amodiaquine, lumefantrine and quinoline) were obtained from Sigma
Aldrich (Dorset, England and St. Louis, MO). Efflux inhibitors including
carbonyl cyanide m-chlorophenylhydrazone (CCCP), thioridazine, ver-
apamil, reserpine and phenylalanine-arginine beta-naphthylamide
(PAβN) were purchased from Sigma-Aldrich (Madrid, Spain).
2.2. MIC determination in mycobacterial species
Mtb strains were grown at 37 °C in Middlebrook 7H9 broth (BD
biosciences), supplemented with albumin-dextrose-catalase (10%), and
a surfactant agent (Tween 80 or Tyloxapol) at 0.05%. MIC values for
the compounds were determined by broth microdilution method using
resazurin as an indicator of bacterial growth [27]. MIC values were also
determined on solid Middlebrook 7H11 medium (BD biosciences)
supplemented with oleic acid-albumin-dextrose-catalase (OADC), by
incubating plates at 37 °C for about 21 days and the growth was visually
evaluated. In both cases, culture media contained serial dilutions of
drugs (1–40 μg/mL), and the MIC was taken as the lowest drug con-
centration that prevented visible growth on plates or resazurin color
change. MICs are given as the average of at least three independent
determinations.
The Mtb extensively drug resistant clinical strain was grown as
above to OD595 0.2–0.3 and diluted 1000-fold in Middlebrook 7H9
broth, supplemented with albumin-dextrose-catalase (10%). The test
compound was dispensed in 384-well plates using Echo® 555 liquid
handler (Labcyte, San Jose, CA) at selected concentration, 50 μl of di-
lutedMtb culture was added to each well and incubated for 7 days 37 °C
followed by addition of AlamarBlue® (ThermoFisher Scientific). The
plate was read using Cytation 3 multi-mode plate reader after 24–48 h
incubation at 37 °C to determine MIC.
Mycobacterium smegmatis cells were grown in Middlebrook 7H9
broth supplemented with 0.2% glycerol and 0.05% Tween-80. Cultures
were grown to OD600= 0.6, diluted to a final OD600 of 0.05 with fresh
media and aliquoted into a 100-well growth plate. Serial dilutions of
the compounds were added to the culture. The untreated culture was
taken as a control. The growth was monitored at 595 nm with con-
tinuous shaking at 200 rpm. The readings were analyzed by GraphPad
Prism software (version 5.0) to determine growth kinetics and MIC of
the compounds.
2.3. Growth inhibitory activity versus ESKAPE bacteria
Pyronaridine was assayed for its growth inhibitory ability of bac-
teria in the ESKAPE class, which were listed amongst the top global
health priorities by the WHO in 2017 [28]. The MIC determination of
pyronaridine versus relevant strains of Enterobacter cloacae (ATCC
13047), Staphylococcus aureus (ATCC 43300), Klebsiella pneumoniae
(BAA 2146), Acinetobacter baumannii (ATCC 19606), Pseudomonas aer-
uginosa (HER 1018), and Enterococcus faecium (NCTC 7171) followed
the liquid dilution method [29].
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2.4. Combination studies with pyronaridine and other antitubercular drugs
The MICs of isoniazid, rifampicin, and ciprofloxacin for Mtb were
assessed at a range of concentrations in the presence of pyronaridine at
a sub-inhibitory concentration (2.5 μg/mL). As a control, the MICs of
isoniazid, rifampicin, and ciprofloxacin were also determined in the
absence of pyronaridine. All MIC determinations were done following
the protocol described above.
For estimating more precisely the interaction between rifampicin
and pyronaridine, we used the checkerboard assay, in which a range of
concentrations of rifampicin was combined with a range of concentra-
tions of pyronaridine, and calculated FIC and FICI (Fractional
Inhibitory Concentration Index) [30,31]. For a drug, FIC is the ratio
between its MIC in the combination and the MIC of the drug alone. For
a pair of drugs, FICI is the addition of the two individual FIC values. A
FICI value up to 0.5 indicates synergy, when it is between 0.5 and 4
indicates there is no interaction between the compounds, and a FICI
value over 4 indicates antagonism.
2.5. Intracellular mycobacterial replication assay
72 h Phorbol-12-Myristate-13-Acetate (PMA, 50 ng/mL, Sigma-
Aldrich) differentiated human THP-1 macrophages (ATCC#TIB-202)
and murine RAW264.7 (ATCC#TIB-71) suspensions were infected with
GFP-expressing Mtb H37Rv (MOI= 2) in RPMI-1640 Glutamax
medium (Gibco) containing 10% heat-inactivated Fetal Bovine Serum
(FBS, Gibco; RPMI-FBS) during 2 h under mild shaking (120 rpm) as
previously described [32,33]. Cells were washed with RPMI-FBS and
treated with amikacin (50 μg/mL, Sigma-Aldrich) for 1 h to kill bacteria
still present in the culture medium. The infected cells were washed
twice and 50 μL of cell suspension was added per well in 384-well assay
plates containing Pyronaridine, as well as positives (isoniazid MIC x
100, and dose response curves (DRC) for rifampicin) and negative
(DMSO 1%) controls. The MICs of rifampicin were assessed at a range of
concentrations in combination with pyronaridine at 4 sub-inhibitory
concentrations (ranged from 0.39 to 3.125 μg/mL) only on THP-1 cells.
As a control, the MICs of rifampicin was also determined in the absence
of pyronaridine. Microplates were incubated for 5 days at 37 °C with 5%
CO2.
The cells were stained with Syto60, 5 μM (Invitrogen) for 30min at
37 °C with 5% CO2 before imaging. Image acquisitions were performed
on an automated confocal microscope (Opera, PerkinElmer) using a
20× water objective. Syto60-labeled cells were detected using excita-
tion (Ex) at 640 nm and emission (Em) at 690 nm and GFP-bacteria
were detected using Ex at 488 nm and Em at 540 nm. A series of 6
images was taken by well and each one was analyzed using the image-
analysis software Columbus system (version 2.5.1, PerkinElmer)
(Fig. 1A). Briefly, the two images were first segmented to remove
background and normalize pixel intensities between images. Then, cell
nuclei and cytoplasm were detected using an intensity detection algo-
rithm applied on the Syto60 channel. Properties of intensity and mor-
phology were filtered to correctly select the cell population. A spot
detection algorithm based on the GFP channel was applied for the de-
tection of Mtb-GFP in cells and in whole image, when cell lysis was
observed for infected THP-1 cells. The bacterial intensity and area in
pixels were measured. The image-based parameters that correlate to
bacterial growth are the percentage of infected cells and the bacterial
area (pixel) per cell and per well. The number of cells informed as to the
cytotoxicity of the compound for effective concentrations. Typically,
drugs demonstrated a dose-dependent decrease on both bacterial area
and percentage of infected macrophages. In this study, the parameter
used as a read-out was the area of bacteria present per cell and per well
(expressed in px) for infected RAW264.7 and THP-1 macrophages, re-
spectively. Normalizations were performed based on the average values
obtained for the negative (DMSO 1%) and positive (isoniazid 10 μg/mL)
controls. Inhibition of bacterial replication was determined for
rifampicin alone and in combination with pyronaridine at different
concentrations. Percentage of inhibition is plotted against the log10 of
the compound concentration, determined in the absence or the pre-
sence of pyronaridine at different concentrations. Fitting was performed
by Prism software using the sigmoidal dose-response (variable slope)
model, constraining top and bottom values of the curve to 100% and
0% respectively. The MIC corresponded to the first concentration on the
bottom of the curve.
2.6. Efflux studies with pyronaridine
The in vitro activity of pyronaridine was determined in Mtb mutants
with deletions in genes encoding efflux pumps by using the protocol
above. The MIC of pyronaridine in the presence of efflux inhibitors was
determined to evaluate the contribution of efflux activity to Mtb sus-
ceptibility to this drug. For this, we initially determined the MIC of the
efflux inhibitors CCCP, thioridazine, verapamil, reserpine and PAβN,
according to the Middlebrook 7H9 broth microdilution protocol de-
scribed above, and the results were recorded with resazurin dye [27].
Next, the impact of the efflux inhibitors (at one fourth of their MIC) on
the MIC of pyronaridine was determined by the same method, in a
range of two-fold pyronaridine concentrations from 80 to 0.6 μg/mL.
The inoculated 96-well plates were incubated for 6 d at 37 °C and for an
additional 2 d after the addition of the redox indicator (30 μl of a re-
sazurin solution at 0.1mg/ml). A change from blue to pink indicates
reduction of resazurin and therefore bacterial growth. Thus, the MIC
was defined as the lowest concentration of compound that prevented
this color change.
Finally, the detection of ethidium bromide efflux on a real-time
basis by the Mtb strains was performed using a fluorometric method
previously described [34]. Briefly, Mtb strains were grown in 7H9-ADC
medium at 37 °C until an OD600 of 0.6–0.8. Cultures were centrifuged at
2880×g for 10min, the supernatant was discarded, the pellet was
washed in phosphate buffered saline (PBS; pH 7.4), and the OD600 was
adjusted to 0.8 with PBS with 0.05% Tween 80. Aliquots of 100 μL of
bacterial suspension were transferred into wells of a 96-well plate
containing ethidium bromide at a concentration of 1 μg/mL. To de-
termine the effect of pyronaridine and verapamil on the accumulation
of ethidium bromide, 10 μL of each compound was added to the cor-
responding well of the 96-well plate. Each inhibitor was used at a
maximum concentration of one-half of their MIC to not compromise the
cellular viability. Relative fluorescence was acquired every 51 s for
60min at 37 °C in a Synergy HT detection microplate reader (Biotek
Instruments), using 530/25 nm and 590/20 nm as excitation and de-
tection wavelengths, respectively.
2.7. In silico docking of pyronaridine
The development of the homology model created for Mtb topoi-
somerase I has been described previously [24,25]. Docking was per-
formed on this model in Discovery Studio version 4.1 (Biovia, San
Diego, CA) using libdock as described previously [26]. For this study we
also docked pyronaridine into RNA polymerase (5UHG) at the D-AAP1
site [35], sphere size 8.36Å, using the same protocol.
2.8. Gyrase enzymatic assays
Mtb and Escherichia coli DNA gyrase supercoiling assays were carried
out as described previously [36,37]. For IC50 determinations, com-
pounds, dissolved in DMSO, were included in supercoiling assays at a
range of concentrations; the final DMSO concentration was kept< 5%.
2.9. Topoisomerase I assay
The relaxation of supercoiled pUC18 DNA was carried out as de-
scribed previously [38]. Briefly, 500 ng DNA was incubated with 1 unit
G. Mori et al. Tuberculosis 112 (2018) 98–109
100
of Mtb topoisomerase I (MttopoI) for 30min at 37 °C in buffer con-
taining 40mM Tris·HCl (pH 8.0), 20mM NaCl, 5 mM MgCl2 and 1mM
EDTA. Enzyme inhibition assays were carried out with a preincubation
of the enzyme and various concentrations of the compounds at 37 °C for
15min, followed by the addition of the substrate DNA. After incubating
at 37 °C for 30min, the samples were electrophoresed in a 1.2% agarose
gel for 12 h at 2.5 V/cm, stained with ethidium bromide (0.5 μg/mL),
and the DNA bands were visualized using a gel documentation system
(Bio-Rad, Hercules, CA, USA).
Fig. 1. High content phenotypic infection assay for the determination of pyronaridine effect on Mycobacterium tuberculosis replication in THP-1 human
macrophages. (A) Steps of the multiparametric image analysis. Cells (nuclei and cytoplasm) were detected by an intensity detection algorithm applied on the Syto60
channel. A spot detection algorithm based on the GFP channel was applied for the detection of Mtb-GFP in whole image and in cells and the bacterial intensity and
area in pixels were measured. The bacterial replication was quantified by the total bacterial area (pixel) per well. Experiments have been carried out in duplicate.
Fitting was performed by Prism software using the sigmoidal dose−response (variable slope) model. 1: Typical 2-color image; 2 and 3: Circled objects correspond
respectively to detected nuclei and detected cells, 4: Filled white objects correspond to total bacteria area. (B) Effects of rifampicin and pyronaridine combinations on
inhibition of bacterial replication in PMA-differentiated THP-1 macrophages. The parameter used as a read-out was the area of bacteria present per well.
Normalizations were performed based on the average values obtained for the negative (DMSO 1%) and positive (isoniazid 10 μg/mL) controls. Percentage of
inhibition is plotted against the log10 of the rifampicin (RIF) concentration, determined in the absence or in the presence of pyronaridine (Pyro) at different
concentrations. (C) Effects of rifampicin and pyronaridine combinations on THP-1 macrophage viability. Cell viability was measured by comparison to the average
value obtained for the positive control (isoniazid 10 μg/mL). Experiments were carried out in duplicate.
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2.10. RNA polymerase assay
The specific activity of Mtb RNA polymerase was determined by
promoter non-specific transcription assay using calf thymus DNA as
template. RNA polymerase and different concentration of compounds
(rifampicin or/and pyronaridine) were preincubated at 37 °C for 10min
followed by addition of reaction buffer (40mM Tris/HCl, pH 8.0,
10 mM MgCl 2, 1 mM Na2 -EDTA, 14mM β-mercaptoethanol, 200 μM
NTPs, 20 μCi (740 kBq) [ 3H] UTP ml −1 and 15 μg calf thymus DNA ml
−1). The reactions were carried out at 37 °C for 30min and stopped by
spotting on Na2 EDTA-soaked DE81 filter papers. Filters were washed
twice with 5% Na2HPO4 for 15min each and then rinsed with ethanol.
The filter paper was dried and the [3H] UMP incorporation was mea-
sured by liquid scintillation counting. Specific activities of the RNA
polymerases were expressed as nmoles [3H] UMP incorporated per mg
protein in 30min [39].
2.11. InhA enzymatic assay
The expression and purification of recombinant Mtb InhA were
performed as previously described [40]. The substrate 2-trans-octenoyl-
CoA was synthesized from 2-trans-octenoic acid and coenzyme A via
anhydride formation following acylation, as previously described [41].
Compounds were dissolved in 100% DMSO. The enzyme reaction
contained 30mM PIPES pH 7.5, 50mM NaCl and 0.1 mM EDTA. InhA
(100 nM) was preincubated for 10min at room temperature with
0.250mM NADH and compounds at a final concentration of 1% (v/v)
DMSO in 150 μL reaction volume. The reaction was started by the ad-
dition of 2-trans-octenoyl-CoA at a final concentration of 1.5mM. De-
pletion of NADH was followed by measuring the absorbance of NADH
(340 nm) in the reaction for 20min using a spectrophotometer plate
reader (CLARIOstar - BMG LABTECH). Inhibition percentage and IC50
values were calculated based on the initial rates of reaction.
2.12. iniBAC promoter induction assay
A Mycobacterium bovis BCG strain harboring iniBAC promoter fused
to mWasabi was grown to OD595= 0.2. Pyronaridine was plated in 96-
well black well plates in quadruplet at 0, 10, 50 and 100 μM using an
Echo® 555 liquid handler (Labcyte, San Jose, CA) maintaining equal
amounts of DMSO (0.5 μl) in each sample, followed by addition of
200 μl of BCG strain. The wasabi fluorescence was read at 0, 24 and
48 h post treatment. Fold induction was calculated as ratio with DMSO
only control.
2.13. Metabolic labeling
Metabolic labeling was performed withMtb H37Ra strain, for which
the MIC for pyronaridine was established by REMA to be 37.5 μM. The
macromolecular synthesis (MMS) assay was performed in a microplate
format. Pre-culture of Mtb H37Ra was grown in complete Middlebrook
7H9 broth (BD biosciences), supplemented with albumin-dextrose-cat-
alase (10%) and 0.05% Tween 80 to OD600 0.4. After harvesting of the
cells by 10min centrifugation at 4000× g and room temperature and
their washing with Sauton medium under the same conditions, the
bacteria were suspended to a final OD600= 0.5 in Sauton medium.
100 μL of the culture was added to the wells of 96-well plate containing
the drugs aliquoted in 2 μL DMSO (streptomycin was dissolved in
water). The control drugs were used in 10×MIC values forMtb H37Ra;
i.e., 0.05 μg/mL for rifampicin (RIF) and 5 μg/mL for streptomycin
(STR), while pyronaridine was used at 8×MIC and 4×MIC. This was
followed by the addition of the radioactive substrates 14C-uracil (ARC,
specific activity 53mCi/mmol), 14C-L-leucine (Moravek Biochemicals,
specific activity 328mCi/mmol) or 14C-acetate (ARC, specific activity
106mCi/mmol), in the final concentrations 1.5 μCi/ml, 0.5 μCi/ml and
1.0 μCi/ml, respectively. After 3 h of incubation at 37 °C the cultures
were transferred from the wells into equal volume of ice-cold 10% TCA
and the mixtures were precipitated on ice for 1 h. The precipitates were
collected by 20min centrifugation at 14,000× g and 4 °C and washed 2
times with 5% TCA. The final pellets were suspended in 100 μL of water
and incorporated radioactivity was quantified by scintillation counting.
Large-scale 14C-acetate metabolic labeling of Mtb H37Ra was per-
formed in Middlebrook 7H9 broth (BD biosciences), supplemented with
albumin-dextrose-catalase (10%) and 0.05% Tyloxapol at 37 °C. The
culture was grown until OD600 reached∼0.2. Pyronaridine in the final
concentration 8×MIC was then added from DMSO stock (final con-
centration of DMSO in the culture was 1%). Radiolabelling with 14C-
acetate (ARC, specific activity 106mCi/mmol) in the final concentra-
tion 0.5 μCi/ml was performed for 3 or 24 h, after 1 or 24 h of drug pre-
treatment. Three aliquots corresponding to 2mL of culture of OD600 0.5
were harvested from each control and drug-treated cultures and these
were used for extraction of DNA, proteins and lipids.
DNA was extracted by Bacterial DNA extraction Kit (BioTeke
Corporation, Beijing, China) according to the manual with a few
modifications: (i) the cells were inactivated by heating 10min at 95 °C
prior to each extraction; (ii) incubation with Lysozyme was performed
at 37 °C for 2 h and deproteinisation with Proteinase K at 70 °C for 1 h;
(iii) DNA was eluted with 50 μL of elution buffer. Extracted DNA was
dried in a vacuum concentrator and resuspended in 20 μL ddH2O. 2 μL
were used for scintillation counting and the rest was loaded onto a 0.7%
agarose gel. After separation, DNA was transferred on a nylon mem-
brane (HybondTM-N+ (Amersham)) by an alkaline transfer using 0.4M
NaOH. Dried membranes were exposed to autoradiography film Biomax
MR-1 (Kodak) at −80 °C for 1 month.
Proteins were precipitated with 10% TCA as described above. Final
pellets were suspended in 500 μL of ddH2O and 10 μL were analyzed by
SDS-PAGE followed by Western blotting. The membrane was exposed to
autoradiography film Biomax MR-1 (Kodak) at −80 °C for 8 d. The
proteins were visualized by staining with Ponceau S.
Lipids were extracted as described previously [42] and dissolved in
100 μL of Solvent I (see below). 5 μL aliquots of the lipid extracts were
analyzed by TLC on silica gel plates (Merck) in Solvent I: CHCl3/
CH3OH/NH4OH/H2O (65:25:0.5:4); Solvent II CHCl3/CH3OH/H2O
(20:4:0.5); and Solvent III: petroleum ether/ethyl acetate (98:2; 3
times). After chromatography, the plates were exposed to auto-
radiography film (BioMax MR) at −80 °C for 8 d.
2.14. Protein expression reporter assay
Mycobacterium bovis BCG expressing mWasabi under constitutive
hsp60 promoter was grown (OD595= 0.3–0.4). The compounds were
plated in 96-well black clear bottom plates using Echo® 555 liquid
handler in quadruplicates. To each well 200 μl of BCG culture was
added and mWasabi fluorescence was read at 0 h and subsequent time
points using Synergy Neo 2 multi-mode plate reader (BioTek,Winooski,
VT, USA).
3. Results
3.1. In vitro activity of pyronaridine against mycobacteria and ESKAPE
bacteria
Several antimalarial compounds (mefloquine, pyronaridine, chlor-
oquine and amodiaquine) were tested for their in vitro activity against
Mtb alongside isoniazid as a positive control. Pyronaridine had weaker
activity against Mtb than isoniazid, with an MIC of 5 μg/mL, whilst the
other compounds were not active with an MIC ≥20 μg/mL (Fig. S1;
Table 1). The MIC of pyronaridine against M. smegmatis was
15.54–31.08 μg/mL (Table 1, Fig. S2) [26]. Additionally, we found that
pyronaridine exhibited an MIC>25 μg/mL versus relevant strains of E.
cloacae, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E.
faecium.
G. Mori et al. Tuberculosis 112 (2018) 98–109
102
3.2. Ex vivo activity of pyronaridine
The efficacy of pyronaridine was next investigated with an in-
tracellular model of Mtb infection. To this end, we resorted to a fluor-
escence image-based assay for the monitoring of pyronaridine activity
against a 5-day growth of Mtb H37Rv-GFP within human PMA-differ-
entiated THP-1 and murine RAW264.7 macrophages. As expected [32],
the MIC of rifampicin was 0.1 μg/mL (Fig. 1B and Fig. S4A). Pyronar-
idine displayed an MIC of.12.5 μg/mL in human THP-1 macrophages
(Fig. 1B) and was devoid of cytotoxicity in human macrophages
(Fig. 1C). On the other side, it did not have any effect on intracellular
growth up to 3.1 μM in murine macrophages (Fig. S4A) and showed
cytotoxicity for higher concentrations (Fig. S4B).
Interestingly, the presence of sub-inhibitory concentrations of pyr-
onaridine (1.56 and 3.12 μg/ml) increased the Mtb susceptibility to ri-
fampicin in human macrophages, resulting in a 16-fold decrease in the
MIC. The FICI was calculated to quantify the effect of pyronaridine on
growth inhibition by rifampicin. And FICI values ranging from
0.19–0.31 were obtained indicating a synergistic relationship (synergy
when FICI< 0.5). We also performed BRAID analysis with these data
[43] (Fig. S5), which also suggests this combination is synergistic
(κ=3.91).
3.3. Efflux studies
First, we determined the MIC of pyronaridine against three Mtb
knockout mutants, each carrying a deletion in a specific gene encoding
an efflux pump protein previously reported to be involved in drug
susceptibility, virulence and other bacterial processes: Tap [44–48],
P55 [49,50], and Mmr [51]. All these efflux mutants presented the
same level of susceptibility to pyronaridine as the parental WT strain
Mtb H37Rv, hence excluding any likely role of Tap, P55 or Mmr efflux
pumps in the transport of this drug.
Since Mtb has many other putative drug efflux pumps [52] we next
explored the possibility of general inhibition of efflux pumps to check
whether this could lead to an increase of the activity of pyronaridine
[53]. We found that all five efflux pump inhibitors that were tested
were incapable of decreasing the whole-cell activity of pyronaridine.
This suggested that efflux does not play a major role in susceptibility to
this drug.
Pyronaridine has been described as a modulator of the activity of P-
glycoprotein [54]. Other compounds having inhibitory activity of P-
glycoprotein, such as reserpine and verapamil, are frequently used as
global efflux inhibitors in laboratory conditions [53]. Hence, we tested
whether pyronaridine could modulate efflux. Pyronaridine at con-
centrations equal to one-half and one-fourth of its MIC decreased the
accumulation of ethidium bromide, whereas verapamil at the same
concentrations readily increased the accumulation of ethidium bromide
(Fig. S3). This suggests that pyronaridine is not likely to be an efflux
inhibitor.
3.4. Searching for the pyronaridine target(s)
To find the pyronaridine target, spontaneous Mtb colonies resistant
to pyronaridine (ranging from 5 to 10-fold MIC) were isolated, but
unfortunately the resistance profile was not confirmed (data not
shown).
With the same purpose, a panel of Mtb mutants (Table 2) harboring
different known mutations in genes encoding for drug targets (NTB1,
DR1, 88.7) [55–57], activators (53.3 and 81.10) [57,58], and in-
activator (Ty1) [58] was used to study the mechanism of action of
pyronaridine. All Mtb mutants were sensitive to pyronaridine sug-
gesting that the mechanism of action was different than that in-
vestigated.
Finally, pyronaridine was tested against two MDR M. tuberculosis
clinical isolates, resistant to isoniazid, rifampicin, ethambutol and
streptomycin [59]. Interestingly, these clinical isolates were fully re-
sistant to pyronaridine. An additional clinical MDR strain resistant to all
four first line drugs harboring the rpoB-S450L mutation in the ri-
fampicin resistance determining region (RRDR) was fully susceptible to
pyronaridine on its own and showed comparable growth inhibition
curve (Fig. S6). Further enzymatic and metabolic assays were per-
formed to try to elucidate the mechanisms of action and resistance to
pyronaridine in Mtb.
3.5. Enzymatic assay with InhA
As the initial MDR clinical isolates (Table 2) were resistant to both
pyronaridine and INH we considered enoyl-ACP reductase (InhA) as a
possible target for pyronaridine. Inhibition of purified InhA by pyr-
onaridine was studied in triplicate at a final concentration of 100 μM
using triclosan as a positive control [60]. InhA was ruled out as a target
for pyronaridine, as the compound did not show any inhibitory effect at
this concentration.
3.6. iniBAC promoter induction assay
The iniBAC promoter has been shown to be induced by cell wall
inhibitors in Mtb. We tested pyronaridine for induction of iniBAC using
a promoter-reporter strain. We did not observe any significant induc-
tion of the iniBAC promoter with this compound suggesting a me-
chanism of action that may not be involving effects on cell wall bio-
synthesis.
3.7. Enzymatic assay with topo I
Pyronaridine was previously docked in the homology model of topo
I (LibDock score 126.85) and when tested in vitro exhibited a weak
inhibition of the relaxation activity of MttopoI at IC50 25.9 μg/mL
(Fig. 2). This value is higher than the MIC for pyronaridine.
Table 1
In vitro activity against Mtb H37Rv and M. smegmatis of selected antimalarial
compounds.
Compounds MIC in M. tuberculosis H37Rv (μg/ml)
Mefloquine 20
Pyronaridine 5
Chloroquine > 20
Amodiaquine > 20
Isoniazid (Control) 0.05
Table 2
Pyronaridine activity against wild type and drug resistant mutants of Mtb.
Mtb strains MIC (μg/mL) References
Pyronaridine INH
H37Rv 5–10 0.025 –
NTB1 (dprE1, G387S) 5–10 0.025 [55]
DR1 (mmpL3, V681I) 5–10 0.025 [56]
88.7 (pyrG, V186G) 5–10 0.025 [57]
53.3 (Rv2466c, W28S) 5–10 0.025 [58]
Ty1 (Rv3405c, c190t) 5–10 0.025 [87]
81.10 (ethA, D1109-37) 5–10 0.025 [57]
IC1 (resistant to STR,
INH, RIF, EMB)
40 >0.2 [59]
IC2 (resistant to STR, INH, RIF, EMB, PZA,
ETH, CAP)
40 > 0.2 [59]
Table note: STR: streptomycin, INH: isoniazid, RIF: rifampicin, EMB: etham-
butol, PZA: pyrazinamide, ETH: ethionamide, CAP: capreomycin, FQ: fluor-
oquinolones.
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3.8. Enzymatic assays with DNA gyrase
DNA gyrase was explored as a possible pyronaridine target using a
series of antimalarial aminoquinoline compounds and testing their
ability to inhibit the supercoiling reaction of DNA gyrases from Mtb and
E. coli (Fig. 3, Table 3 and Supplemental Table 1). We found that pyr-
onaridine is modestly active (IC50 25 μM; 23 μg/mL) againstMtb gyrase.
The compound was similarly active versus E. coli gyrase. An approx-
imate five-fold increase in IC50 from the MIC for pyronaridine suggests
that DNA gyrase is not the pyronaridine primary target. Mefloquine
showed the same activity versus E. coli gyrase as pyronaridine
(IC50= 25 μM; 10 μg/mL), but was relatively inactive against Mtb
gyrase (IC50 > 100 μM;>40 μg/mL). Chloroquine, primaquine, qui-
nine, halofantrine, amodiaquine, lumefantrine and quinoline and sev-
eral other analogs were inactive against gyrase like isoniazid, which
was used as a negative control (IC50 > 100 μM).
Under appropriate conditions, quinolone drugs, such as cipro-
floxacin, can stabilize a cleaved complex between gyrase and DNA
[61,62]. We have assessed whether pyronaridine can stabilize a clea-
vage complex between gyrase and DNA and have found no evidence
that it does (data not shown). This suggests that pyronaridine does not
bind the enzyme at the quinolone pocket, i.e. its weak activity likely
results from binding elsewhere on the enzyme, potentially suggesting a
novel binding site outside of the well-known quinolone pocket.
3.9. Metabolic labeling with 14C precursors
For evaluation of potential interference of pyronaridine with the
metabolism of nucleic acids, which could be caused by inhibition of
DNA gyrase, we performed macromolecular synthesis assays with 14C
precursors in Mtb H37Ra. In the initial experiment, we monitored the
incorporation of 14C-uracil, 14C-leucine and 14C-acetate into TCA-pre-
cipitated material after 3 h of radiolabeling. A severe decrease in in-
corporation of 14C-uracil into the TCA-precipitated material, similar to
the effect of rifampicin, a known inhibitor of RNA polymerase, indeed
pointed to inhibition of metabolism of nucleic acids (Fig. 4A). Strep-
tomycin was used as a control inhibitor affecting protein synthesis.
While it did not show any effects on 14C-uracil incorporation, the an-
tibiotic decreased radiolabeling of proteins with 14C-leucine by about
50% (Fig. 4B). Although pyronaridine caused even higher inhibition of
14C-leucine-radiolabeling of the cells, rifampicin triggered a similar
response. Therefore, we attributed these changes to secondary effects of
these drugs. 14C-acetate radiolabeling can be considered as a tool for
monitoring overall metabolic activity in the treated bacteria. As shown
in Fig. 4C, under the conditions used for radiolabeling, there was only a
minor inhibition of incorporation of this precursor to the mycobacterial
cells treated with the drugs, and thus we consider the changes observed
for pyronaridine and the control drugs in the 14C-uracil and 14C-leucine
radiolabeling experiment related to their cellular targets.
To investigate the effects of pyronaridine on Mtb H37Ra in more
detail we performed 14C-acetate labeling under three different condi-
tions: (i) 1 h drug treatment followed by 3 h radiolabeling; (ii) 1 h drug
treatment followed by 24 h radiolabeling; and (iii) 24 h drug treatment
followed by 24 h radiolabeling. While 3 h of 14C-acetate treatment did
not appear to label DNA, 24 h incubation of mycobacteria in the pre-
sence of 14C-acetate resulted in its incorporation to DNA and revealed
its inhibition in the presence of pyronaridine (Fig. S7A). At the same
time, we confirmed severe inhibition of labeling of the proteins in all
three conditions (Fig. S7B). Lipids extracted from the radiolabeled
cultures were analyzed by TLC. The gradual decrease in incorporation
of 14C-acetate into lipids with the duration of exposure to the drug very
likely reflects down-stream effects caused by prolonged treatment of the
cells with the drug, which affects primarily synthesis of nucleic acids
and consequently also proteins (Fig. S7C). These macromolecular
synthesis assays directed us to explore RNA polymerase as a potential
target for pyronaridine.
3.10. Protein reporter assays
M. bovis strain constitutively expressing mWasabi reporter was ex-
posed to pyronaridine and time-dependent effects of fluorescence were
studied. The time course experiment showed that pyronaridine treat-
ment abrogated synthesis of new mWasabi molecules similar to in-
hibition by rifampicin, a known inhibitor of RNA Polymerase (Fig. S8)
suggesting that this compound may putatively inhibit a step in protein
biosynthesis and was consistent with inhibition of 14C-Leucine in-
corporation (Fig. 4B).
3.11. Is RNA polymerase the cellular target of pyronaridine?
The crystal structure of Mtb RNA polymerase shows the potential for
two ligands, with rifampicin and the non-rifampicin-related compound
Nα-aroyl-N-aryl-phenylalaninamide (AAP) D-AAP1 bound to two in-
dependent sites (Fig. 5) [35]. Docking of pyronaridine in the same site as
D-AAP1 showed multiple potential interactions, including a cation-π and
two parallel displaced π-stacking interactions with residues R834 and
F350/H854, respectively, along with other hydrophobic interactions.
Following this docking study, we tested pyronaridine as a potential
inhibitor of Mtb RNA polymerase in vitro. Pyronaridine on its own
showed no inhibition of this enzyme (Fig. S9). However, when pyr-
onaridine is combined with rifampicin at 10% MIC approximately
∼50% inhibition of Mtb RNA-polymerase activity is observed (Fig. 6).
This suggests that both compounds can bind RNA polymerase si-
multaneously, likely in different binding pockets.
Fig. 2. Inhibitory activity of pyronaridine. 1 unit of MttopoI was incubated
with increasing concentrations of the molecule at 37 °C for 15min following
which, 500 ng of supercoiled pUC18 was added. The incubation was further
continued at 37 °C for 30min and the reaction was terminated by addition of
0.6% SDS-agarose dye. The reaction products were resolved on a 1.2% agarose
gel followed by staining with EtBr. Lane 1, supercoiled pUC18; lane 2, relaxa-
tion control; lanes 3–6, increasing concentration of pyronaridine.
Fig. 3. Inhibition of DNA supercoiling byMtb gyrase by pyronaridine. DNA
supercoiling assays were carried out as described previously [36]; the amount
of enzyme used was adjusted to give incomplete supercoiling to increase the
sensitivity of the assay. All lanes contain gyrase except the first, which contains
substrate only (relaxed pBR322 DNA). The last lane contains a control inhibitor
(sparfloxacin (200 μM); concentrations of pyronaridine are indicated above the
lanes.
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3.12. Drug combination studies
Combination studies were performed using pyronaridine at 2.5 μg/
mL to check any impact of this drug on the MICs of isoniazid, rifampicin
or ciprofloxacin (Table 4). In the case of isoniazid and ciprofloxacin, no
changes in the MICs were observed versus the MIC of either drug alone
suggesting a lack of interaction between pyronaridine and InhA and
gyrase inhibitors. Interestingly, pyronaridine at 2.5 μg/mL reduced the
MIC of rifampicin between 2- and 4-fold. This interaction between ri-
fampicin and pyronaridine was further investigated by using the
checkerboard assay; calculated FICI index ranged between 0.355 and
0.748, indicating a rather moderate synergism between these two drugs
in vitro. These FICI values are on the same range as those obtained in
Mtb infected macrophages, hence corroborating that both drugs sy-
nergize to a moderate level.
4. Discussion
Pyronaridine is a potent [21,63,64] antimalarial that is approved in
the EU as part of a combination therapy [22]. There have been several
efforts to ascertain the target of pyronaridine in malaria (including:
interference with the digestive system in P. falciparum and Plasmodium
berghei [65], inhibition of β-haematin to enhance haematin-induced
human blood cell lysis [66,67], inhibition of glutathione-dependent
haem degradation [66,68]) and hemozoin synthesis which have all
been reviewed [22]. These mechanisms are shared by aminoquinolines
such as chloroquine [69]. Interestingly, while several groups work on
both malaria and tuberculosis [70], the literature is silent on the ac-
tivity of pyronaridine against Mtb and potential targets for it. Recent
studies have demonstrated that pyronaridine possesses in vivo activity
against Trypanosoma cruzi, the causative agent of Chagas disease [22]
and that in human peripheral blood monocytes from controls and
Chagas disease patients it results in increased TNFα +CD8+, IL-
10 + and CD8+ [71]. Pyronaridine is also active against Babesia spp.
parasite [72] and against the Ebola virus [73]. As this molecule has
already been approved in the EU this may have a more direct path to
clinical testing for these and potentially other diseases.
In this study, it was demonstrated that pyronaridine has modest to
weak activity against Mtb in vitro (Table 1, Table 2, Fig. 1), but no
activity against ESKAPE pathogens. The possible Mtb inhibition me-
chanism of action was studied. Two Mtb clinical isolates resistant to
isoniazid, rifampicin, ethambutol and streptomycin were found to be
resistant to pyronaridine, while a clinical MDR strain resistant to all
four first line drugs harboring rpoB-S450L mutation in the rifampicin
resistance determining region (RRDR) retained its sensitivity to pyr-
onaridine. Interestingly, in macromolecular synthesis assays, treatment
with pyronaridine resulted in a severe decrease in incorporation of 14C-
uracil and 14C-leucine similar to the effect seen with rifampicin (Fig. 4).
This finding could point to the interference with the metabolism of
nucleic acids in mycobacteria (Table 2).
Most bacteria contain two type II topoisomerases: DNA gyrase and
DNA topoisomerase IV; Mtb being an exception: it only has a gyrase,
which exhibits topoisomerase IV-like properties (e.g. higher decatena-
tion activity compared with other gyrases) [74,75]. As E. coli possesses
both gyrase and topoisomerase IV we also tested pyronaridine (and
other selected aminoquinoline compounds) against E. coli topoisome-
rase IV and found higher activity against this enzyme (IC50=∼0.1 μM
for pyronaridine) than was found for gyrase. The interaction of ami-
noquinolines with Gram-negative topoisomerase IVs will be the subject
of future work. Interestingly, pyronaridine has been previously sug-
gested to possess decatenation activity (11 μM) against Plasmodium
falciparum DNA topoisomerase II activity in vitro [76]. Recent work has
also suggested that DNA gyrase in Mtb functions as a decatenase and
that RNA polymerase and topoisomerases have a functional association
[77]. Our work perhaps provides some evidence for the importance of
targeting (even at a very low level) DNA gyrase and DNA topoisomerase
I [78], as their IC50 values were broadly similar. Additionally, pyr-
onaridine and rifampicin similarly decrease the incorporation of 14C-
uracil and 14C-leucine eluding to a similar mechanism (Fig. 4). This
initially suggested to us the potential that pyronaridine may target RNA
polymerase as this is also the known target of rifampicin. The targeting
of RNA polymerase is important because mutations in the rifampicin
binding site can lead to resistance to this widely used drug. A recent
study has described RNA polymerase transcription initiation complexes
with rifampicin and a non-rifampicin RNA polymerase inhibitor [35].
The non-rifampicin molecule binds on the N-terminus of the RNA
polymerase bridge helix and aromatic residues interacted with three
subsites. When the residues in these sites were substituted rifampicin
resistance was observed. Pyronaridine when docked into this pocket
was found to overlap this non-rifampicin compound (Fig. 5B) with a
Libdock score of 144.1 which surpasses the best dock in the rifampicin
site (126.6). The potential for directly targeting Mtb RNA polymerase
was experimentally verified with the combination of pyronaridine and
Table 3
Screening of select antimalarial compounds against DNA gyrase.
Compound Gyrase IC50 μM (μg/ml)a
Mtb E. coli
Pyronaridine 25 (23) 25 (23)
Chloroquine > 100 (> 50) > 100 (> 50)
Mefloquine > 100 (> 40) 25 (10)
Amodiaquine > 100 (> 45) > 100 (> 45)
Isoniazid (Control) > 100 (> 15) > 100 (> 15)
a IC50 values for inhibition of gyrase-catalyzed supercoiling for compounds
are given in μM and μg/mL (in parentheses); isoniazid is included as a control.
Fig. 4. Macromolecular synthesis assays with Mtb H37Ra. The experiment was performed in 96-well plates. 14C-uracil and 14C-L-leucine labeling was carried out
in triplicates and 14C-acetate in duplicates, the values represent averages with standard errors. Pyronaridine (Pyr) was used in the final concentrations 300 μM
(8×MIC) and 150 μM (4×MIC), streptomycin (STR) at 5 μg/ml (10×MIC) and rifampicin (RIF) at 0.05 μg/ml (10×MIC).
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rifampicin (Fig. 6) versus the lack of activity of pyronaridine on its own
(Fig. S9) at concentrations up to 100 μg/ml. Different binding pockets
in RNA polymerase are also supported by our MDR mutant resistant to
all four first line drugs harboring the rpoB-S450L mutation (Fig. S6)
which retained pyronaridine activity. While rifampicin alone was not
effective against this isolate at the concentrations tested (Fig. S6),
pyronaridine has a slightly reduced EC50 in the clinical strain as com-
pared to the wild-type H37Rv strain. Taken as a whole, these data
suggest that when rifampicin and pyronaridine are administered si-
multaneously they both act by inhibiting RNA polymerase via binding
to unique binding pockets. This is similar to data found with rifampicin
and DAAP-1, which were additive and bound to unique sites within
RNAP [35]. Pyronaridine therefore represents a compound that is al-
ready clinically accessible, compared with DAAP-1, and thus could be
used to test the viability of a therapy to suppress rifampicin resistance
emergence as well as potentially return rifampicin sensitivity to re-
sistant strains.
Following these observations, the most interesting finding of this
current work was the in vitro and ex vivo synergy between rifampicin
and pyronaridine. It remains to be seen whether this will also be re-
flected in vivo, but if so it could lower the effective dose of rifampicin
(e.g. as shown in Fig. 6), mitigating side effects, and the length of
treatment. This represents an example of drug repurposing to lead to a
potential clinical candidate in the form of pyronaridine when used in
conjunction with rifampicin. There are other examples of compounds
showing synergy with rifampicin although their targeting of RNA
polymerase is unknown (biapenem [79], faropenem [80], 2-(quinolin-
4-yloxy)acetamides [81], 2(5H)-furanone-based compounds [82], In-
dole-2-carboxamide-based MmpL3 Inhibitors [83], timcodar [84],
thioridazine [85] and 7-amino-4-methyl-2H-chromen-2-one [86]) and
these show FICI values that are in line with what we observed with
pyronaridine (Supplemental Table 2).
This work therefore represents a starting point in the study of pyr-
onaridine as new, more active derivatives could be potentially syn-
thesized in order to use them alone or in combination with rifampicin.
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Fig. 5. Docking of pyronaridine in RNA-
polymerase. The crystal structure of Mtb RNA-
polymerase (5UHG, green) shows the potential
for two ligands, rifampicin (red) and the non-
Rif-related compounds-Nα-aroyl-N-aryl-pheny-
lalaninamide (AAP) D-AAP1 (light green), to
bind to two independent sites (A). Rifampicin
and pyronaridine (cyan) are synergistic, in a si-
milar manner as rifampicin and D-AAP1, so if
Mtb RNA-polymerase is the target of pyronar-
idine it is likely to bind to the D-AAP1 site (B).
The rigid docking of pyronaridine into RNA-
polymerase using the program libdock gener-
ated a score of 144.10, suggesting numerous
interactions between the ligand and the enzyme.
The dock of pyronaridine proposes several po-
tential interactions with RNA-polymerase, in-
cluding a cation-π and two parallel displaced π-
stacking interactions with residues R834 and
F350/H854, respectively, along with other hy-
drophobic interactions (C).
Fig. 6. Inhibition of M. tuberculosis RNAP activity by Pyronaridine in the
presence of Rifampicin (10% MIC). Transcription assays carried out in the
presence of rifampicin (10% MIC) along with increasing concentration of pyr-
onaridine (0–25 μg/ml). The transcription in the presence of 10% MIC of ri-
fampicin without pyronaridine is considered as 100%. The experiment was
carried out three times and error bars indicate sd. Unpaired t-test was used for
statistical analysis. P-value<0.05 was considered as significant. * ≤ 0.05, **
≤ 0.01.
G. Mori et al. Tuberculosis 112 (2018) 98–109
106
Acknowledgments
The work was supported by a grant from the European Community's
Seventh Framework Program (Grant 260872). V.N. is a J.C. Bose fellow
of Department of Science and Technology, Government of India. Work
in A.M.’s lab is also funded by the Biotechnology and Biosciences
Research Council (UK) Institute Strategic Programme Grants BB/
J004561/1 and BB/P012523/1. K.M. acknowledges support by
Ministry of Education, Science, Research and Sport of the Slovak
Republic (grant 0395/2016 for Slovak/Russian cooperation in science
2015-15075/33841:1-15E0) and by the Research and Development
Operational Programme funded by European Regional Development
Fund (Contract ITMS 26240120027). Work in PB.’s lab is also sup-
ported from the European Community (ERC-STG INTRACELLTB Grant
n° 260901), the Agence Nationale de la Recherche (ANR-10-EQPX-04-
01), the Feder (12001407 (D-AL) Equipex Imaginex BioMed) and the
Région Nord Pas de Calais (convention n°12000080). J.A. acknowl-
edges support by Ministry of Economy and Competitiveness of Spain
(grant SAF-2013-48971-C2-2-R). None of these sponsors had any role in
study design; in the collection, analysis and interpretation of data; in
the writing of the report; and in the decision to submit the article for
publication. S.E. Kindly acknowledges several collaborators for their
continued work on pyronaridine including Dr. Mary Lingerfelt, Dr.
Peter Madrid, Dr. Robert Davey, Dr. Jair Lage de Siqueira-Neto as well
as Dr. Iain Old, Dr. Stewart Cole and our MM4TB colleagues for support
and encouragement.
Appendix A. Supplementary data
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.tube.2018.08.004.
References
[1] Anon. Global tuberculosis report 2016. 2016http://www.who.int/tb/publications/
global_report/en/.
[2] Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F,
Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E,
Nunn P, Floyd K, Raviglione MC. Twenty years of global surveillance of anti-
tuberculosis-drug resistance. N Engl J Med 2016;375:1081–9.
[3] Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol
Toxicol 2005;45:529–64.
[4] Ballel L, Field RA, Duncan K, Young RJ. New small-molecule synthetic anti-
mycobacterials. Antimicrob Agents Chemother 2005;49:2153–63.
[5] Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD,
Schito M, Maeurer M, Nunn AJ. New antituberculosis drugs, regimens, and adjunct
therapies: needs, advances, and future prospects. Lancet Infect Dis 2014;14:327–40.
[6] Ekins S, Perryman AL, Clark AM, Reynolds RC, Freundlich JS. Machine learning
model analysis and data visualization with small molecules tested in a mouse model
of Mycobacterium tuberculosis infection (2014-2015). J Chem Inf Model
2016;56:1332–43.
[7] Mikusova K, Ekins S. Learning from the past for TB drug discovery in the future.
Drug Discov Today 2017;22:534–45.
[8] Riccardi G, Old IG, Ekins S. Raising awareness of the importance of funding for
tuberculosis small-molecule research. Drug Discov Today 2016;22:487–91.
[9] Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of ap-
proved drugs for rare and neglected diseases. Drug Discov Today 2011;16:298–310.
[10] Ekins S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res
2011;28:1786–91.
[11] Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning
applications for predicting pharmacological properties of drugs and drug re-
purposing using transcriptomic data. Mol Pharm 2016;13:2524–30.
[12] Djaout K, Singh V, Boum Y, Katawera V, Becker HF, Bush NG, Hearnshaw SJ,
Pritchard JE, Bourbon P, Madrid PB, Maxwell A, Mizrahi V, Myllyjallio H, Ekins S.
Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tu-
berculosis. Sci Rep 2016;6:27792.
[13] Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP,
Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty
SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using
gene-expression signatures to connect small molecules, genes, and disease. Science
2006;313:1929–35.
[14] Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer
2007;7:54–60.
[15] Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis
agents amongst known drugs. Tuberculosis (Edinb) 2009;89:364–70.
[16] Ekins S, Reynolds R, Kim H, Koo M-S, Ekonomidis M, Talaue M, Paget SD,
Woolhiser LK, Lenaerts AJ, Bunin BA, Connell N, Freundlich JS. Bayesian models
leveraging bioactivity and cytotoxicity information for drug discovery. Chem Biol
2013;20:370–8.
[17] Bermudez LE, Meek L. Mefloquine and its enantiomers are active against
Mycobacterium tuberculosis in vitro and in macrophages. Tuberc Res Treat
2014;2014:530815.
[18] Danelishvili L, Wu M, Young LS, Bermudez LE. Genomic approach to identifying the
putative target of and mechanisms of resistance to mefloquine in mycobacteria.
Antimicrob Agents Chemother 2005;49:3707–14.
[19] Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. Lansoprazole is an
antituberculous prodrug targeting cytochrome bc1. Nat Commun 2015;6:7659.
[20] Mdanda S, Baijnath S, Shobo A, Singh SD, Maguire GEM, Kruger HG, Arvidsson PI,
Naicker T, Govender T. Lansoprazole-sulfide, pharmacokinetics of this promising
anti-tuberculous agent. Biomed Chromatogr 2017:31.
[21] Chang C, Lin-Hua T, Jantanavivat C. Studies on a new antimalarial compound:
pyronaridine. Trans R Soc Trop Med Hyg 1992;86:7–10.
[22] Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-
Fuhrer I, Rim HJ. Review of pyronaridine anti-malarial properties and product
characteristics. Malar J 2012;11:270.
[23] Morris CA, Dueker SR, Lohstroh PN, Wang LQ, Fang XP, Jung D, Lopez-Lazaro L,
Baker M, Duparc S, Borghini-Fuhrer I, Pokorny R, Shin JS, Fleckenstein L. Mass
balance and metabolism of the antimalarial pyronaridine in healthy volunteers. Eur
J Drug Metab Pharmacokinet 2015;40:75–86.
[24] Godbole AA, Ahmed W, Bhat RS, Bradley EK, Ekins S, Nagaraja V. Inhibition of
Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II to-
poisomerase poison. Biochem Biophys Res Commun 2014;446:916–20.
[25] Godbole AA, Ahmed W, Bhat RS, Bradley EK, Ekins S, Nagaraja V. Targeting
Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.
Antimicrob Agents Chemother 2015;59:1549–57.
[26] Ekins S, Godbole AA, Keri G, Orfi L, Pato J, Bhat RS, Verma R, Bradley EK, Nagaraja
V. Machine learning and docking models for Mycobacterium tuberculosis topoi-
somerase I. Tuberculosis (Edinb) 2017;103:52–60.
[27] Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin
microtiter assay plate: simple and inexpensive method for detection of drug re-
sistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother
2002;46:2720–2.
[28] WHO. Global priority list of antibiotic-resistant bacteria to guide research, dis-
covery, and development of new antibiotics. 2017http://www.who.int/medicines/
publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
[29] Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial
activity: a review. J Pharmaceut Anal 2016;6:71–9.
[30] Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J
Antimicrob Chemother 2003;52:1.
[31] (ESCMID) ESoCMaID. EUCAST Definitive Document E.Def 1.2, May 2000: termi-
nology relating to methods for the determination of susceptibility of bacteria to
antimicrobial agents. Clin Microbiol Infect 2000;6:503–8.
[32] Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J,
Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ,
Skovierova H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou
ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P. High content
screening identifies decaprenyl-phosphoribose 2' epimerase as a target for in-
tracellular antimycobacterial inhibitors. PLoS Pathog 2009;5:e1000645.
[33] Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, Lafont F,
Baulard A, Iantomasi R, Brodin P. Phenotypic assays for Mycobacterium tubercu-
losis infection. Cytometry A 2017;91:983–94.
[34] Rodrigues L, Viveiros M, Ainsa JA. Measuring efflux and permeability in myco-
bacteria. Methods Mol Biol 2015;1285:227–39.
[35] Lin W, Mandal S, Degen D, Liu Y, Ebright YW, Li S, Feng Y, Zhang Y, Mandal S,
Jiang Y, Liu S, Gigliotti M, Talaue M, Connell N, Das K, Arnold E, Ebright RH.
Structural basis of Mycobacterium tuberculosis transcription and transcription in-
hibition. Mol Cell 2017;66:169–179 e8.
[36] Karkare S, Yousafzai F, Mitchenall LA, Maxwell A. The role of Ca(2)(+) in the
activity of Mycobacterium tuberculosis DNA gyrase. Nucleic Acids Res
2012;40:9774–87.
[37] Reece RJ, Maxwell A. Tryptic fragments of the Escherichia coli DNA gyrase A
protein. J Biol Chem 1989;264:19648–53.
[38] Bhaduri T, Bagui TK, Sikder D, Nagaraja V. DNA topoisomerase I from
Table 4
Combination study of pyronaridine and isoniazid, rifampicin or ci-
profloxacin.
COMPOUND MIC (μg/ml)
INH 0.025
INH + PYR (2.5 μg/ml) 0.05
CIPRO 0.125
CIPRO + PYR (2.5 μg/ml) 0.125
RIF 0.0039
RIF + PYR (2.5 μg/ml) 0-0019 - 0.0009
Abbreviations: INH: isoniazid, CIPRO: ciprofloxacin, RIF: rifampicin,
PYR: pyronaridine.
G. Mori et al. Tuberculosis 112 (2018) 98–109
107
Mycobacterium smegmatis. An enzyme with distinct features. J Biol Chem
1998;273:13925–32.
[39] Malshetty V, Kurthkoti K, China A, Mallick B, Yamunadevi S, Sang PB, Srinivasan N,
Nagaraja V, Varshney U. Novel insertion and deletion mutants of RpoB that render
Mycobacterium smegmatis RNA polymerase resistant to rifampicin-mediated in-
hibition of transcription. Microbiology 2010;156:1565–73.
[40] Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs Jr. WR,
Blanchard JS. Enzymatic characterization of the target for isoniazid in
Mycobacterium tuberculosis. Biochemistry 1995;34:8235–41.
[41] He X, Alian A, Stroud R, Ortiz de Montellano PR. Pyrrolidine carboxamides as a
novel class of inhibitors of enoyl acyl Carrier protein reductase from
Mycobacterium tuberculosis. J Med Chem 2006;49:6308–23.
[42] Esposito M, Szadocka S, Degiacomi G, Orena BS, Mori G, Piano V, Boldrin F,
Zemanova J, Huszar S, Barros D, Ekins S, Lelievre J, Manganelli R, Mattevi A, Pasca
MR, Riccardi G, Ballell L, Mikusova K, Chiarelli LR. A phenotypic based target
screening approach delivers new antitubercular CTP synthetase inhibitors. ACS
Infect Dis 2017;3:428–37.
[43] Twarog NR, Stewart E, Hammill CV, Shelat AA. BRAID: a unifying paradigm for the
analysis of combined drug action. Sci Rep 2016;6:25523.
[44] Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi
J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB,
Rakesh, Waidyarachchi SL, Sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-
Juarrero M, Meibohm B, Bottger EC, Lenaerts AJ. Spectinamides: a new class of
semisynthetic antituberculosis agents that overcome native drug efflux. Nat Med
2014;20:152–8.
[45] Villellas C, Aristimuno L, Vitoria MA, Prat C, Blanco S, Garcia de Viedma D,
Dominguez J, Samper S, Ainsa JA. Analysis of mutations in streptomycin-resistant
strains reveals a simple and reliable genetic marker for identification of the
Mycobacterium tuberculosis Beijing genotype. J Clin Microbiol 2013;51:2124–30.
[46] Ramon-Garcia S, Mick V, Dainese E, Martin C, Thompson CJ, De Rossi E,
Manganelli R, Ainsa JA. Functional and genetic characterization of the tap efflux
pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother
2012;56:2074–83.
[47] Ainsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA, Martin C. Molecular cloning
and characterization of Tap, a putative multidrug efflux pump present in
Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol
1998;180:5836–43.
[48] Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein
PH, Cosma CL, Ramakrishnan L. Drug tolerance in replicating mycobacteria
mediated by a macrophage-induced efflux mechanism. Cell 2011;145:39–53.
[49] Ramon-Garcia S, Martin C, Thompson CJ, Ainsa JA. Role of the Mycobacterium
tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses,
and growth. Antimicrob Agents Chemother 2009;53:3675–82.
[50] Martinot AJ, Farrow M, Bai L, Layre E, Cheng TY, Tsai JH, Iqbal J, Annand JW,
Sullivan ZA, Hussain MM, Sacchettini J, Moody DB, Seeliger JC, Rubin EJ.
Mycobacterial metabolic syndrome: LprG and Rv1410 regulate triacylglyceride le-
vels, growth rate and virulence in Mycobacterium tuberculosis. PLoS Pathog
2016;12:e1005351.
[51] Rodrigues L, Villellas C, Bailo R, Viveiros M, Ainsa JA. Role of the Mmr efflux pump
in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother
2013;57:751–7.
[52] De Rossi E, Ainsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug
resistance: an unresolved question. FEMS Microbiol Rev 2006;30:36–52.
[53] Rodrigues L, Parish T, Balganesh M, Ainsa JA. Antituberculosis drugs: reducing
efflux=increasing activity. Drug Discov Today 2017;22:592–9.
[54] Qi J, Wang S, Liu G, Peng H, Wang J, Zhu Z, Yang C. Pyronaridine, a novel mod-
ulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in
vivo. Biochem Biophys Res Commun 2004;319:1124–31.
[55] Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar
N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A,
Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin
P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi
V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S,
Grosset J, Riccardi G, Cole ST. Benzothiazinones kill Mycobacterium tuberculosis
by blocking arabinan synthesis. Science 2009;324:801–4.
[56] Poce G, Bates RH, Alfonso S, Cocozza M, Porretta GC, Ballell L, Rullas J, Ortega F,
De Logu A, Agus E, La Rosa V, Pasca MR, De Rossi E, Wae B, Franzblau SG, Manetti
F, Botta M, Biava M. Improved BM212 MmpL3 inhibitor analogue shows efficacy in
acute murine model of tuberculosis infection. PLoS One 2013;8:e56980.
[57] Mori G, Chiarelli LR, Esposito M, Makarov V, Bellinzoni M, Hartkoorn RC,
Degiacomi G, Boldrin F, Ekins S, de Jesus Lopes Ribeiro AL, Marino LB, Centarova I,
Svetlikova Z, Blasko J, Kazakova E, Lepioshkin A, Barilone N, Zanoni G, Porta A,
Fondi M, Fani R, Baulard AR, Mikusova K, Alzari PM, Manganelli R, de Carvalho LP,
Riccardi G, Cole ST, Pasca MR. Thiophenecarboxamide derivatives activated by
EthA kill Mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG. Chem
Biol 2015;22:917–27.
[58] Albesa-Jove D, Chiarelli LR, Makarov V, Pasca MR, Urresti S, Mori G, Salina E,
Vocat A, Comino N, Mohorko E, Ryabova S, Pfieiffer B, Lopes Ribeiro AL, Rodrigo-
Unzueta A, Tersa M, Zanoni G, Buroni S, Altmann KH, Hartkoorn RC, Glockshuber
R, Cole ST, Riccardi G, Guerin ME. Rv2466c mediates the activation of TP053 to kill
replicating and non-replicating Mycobacterium tuberculosis. ACS Chem Biol
2014;9:1567–75.
[59] Menendez C, Rodriguez F, Ribeiro AL, Zara F, Frongia C, Lobjois V, Saffon N, Pasca
MR, Lherbet C, Baltas M. Synthesis and evaluation of alpha-ketotriazoles and al-
pha,beta-diketotriazoles as inhibitors of Mycobacterium tuberculosis. Eur J Med
Chem 2013;69:167–73.
[60] Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from
Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry
2000;39:7645–50.
[61] Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JI. Nalidixic acid resistance: a
second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A
1977;74:4772–6.
[62] Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of nalidixic
acid: purification of Escherichia coli nalA gene product and its relationship to DNA
gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A
1977;74:4767–71.
[63] Okombo J, Kiara SM, Mwai L, Pole L, Ohuma E, Ochola LI, Nzila A. Baseline in vitro
activities of the antimalarials pyronaridine and methylene blue against Plasmodium
falciparum isolates from Kenya. Antimicrob Agents Chemother 2012;56:1105–7.
[64] Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, Croft SL. Anti-
malarial efficacy of pyronaridine and artesunate in combination in vitro and in
vivo. Acta Trop 2008;105:222–8.
[65] Wu LJ, Rabbege JR, Nagasawa H, Jacobs G, Aikawa M. Morphological effects of
pyronaridine on malarial parasites. Am J Trop Med Hyg 1988;38:30–6.
[66] Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P.
Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents
Chemother 2006;50:2197–200.
[67] Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An as-
sessment of drug-haematin binding as a mechanism for inhibition of haematin
polymerisation by quinoline antimalarials. Biochem Pharmacol 1998;55:727–36.
[68] Famin O, Krugliak M, Ginsburg H. Kinetics of inhibition of glutathione-mediated
degradation of ferriprotoporphyrin IX by antimalarial drugs. Biochem Pharmacol
1999;58:59–68.
[69] Sullivan Jr. DJ, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism
of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 1996;93:11865–70.
[70] Okombo J, Chibale K. Insights into integrated lead generation and target identifi-
cation in malaria and tuberculosis drug discovery. Acc Chem Res 2017;50:1606–16.
[71] Otta DA, de Araujo FF, de Rezende VB, Souza-Fagundes EM, Eloi-Santos SM, Costa-
Silva MF, Santos RA, Costa HA, Siqueira Neto JL, Martins-Filho OA, Teixeira-
Carvalho A. Identification of anti-trypanosoma cruzi lead compounds with putative
immunomodulatory activity. Antimicrob Agents Chemother 2018 Mar 27;62(4).
[72] Rizk MA, El-Sayed SA, Terkawi MA, Youssef MA, El Said el Sel S, Elsayed G, El-
Khodery S, El-Ashker M, Elsify A, Omar M, Salama A, Yokoyama N, Igarashi I.
Optimization of a fluorescence-based assay for large-scale drug screening against
Babesia and theileria parasites. PLoS One 2015;10:e0125276.
[73] Ekins S, Freundlich J, Clark A, Anantpadma M, Davey R, Madrid P. Machine
learning models identify molecules active against Ebola virus in vitro. F1000Res
2015;4:1091.
[74] Aubry A, Fisher LM, Jarlier V, Cambau E. First functional characterization of a
singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium
tuberculosis. Biochem Biophys Res Commun 2006;348:158–65.
[75] Manjunatha UH, Dalal M, Chatterji M, Radha DR, Visweswariah SS, Nagaraja V.
Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase.
Nucleic Acids Res 2002;30:2144–53.
[76] Chavalitshewinkoon P, Wilairat P, Gamage S, Denny W, Figgitt D, Ralph R.
Structure-activity relationships and modes of action of 9-anilinoacridines against
chloroquine-resistant Plasmodium falciparum in vitro. Antimicrob Agents
Chemother 1993;37:403–6.
[77] Ahmed W, Sala C, Hegde SR, Jha RK, Cole ST, Nagaraja V. Transcription facilitated
genome-wide recruitment of topoisomerase I and DNA gyrase. PLoS Genet
2017;13:e1006754.
[78] Nagaraja V, Godbole AA, Henderson SR, Maxwell A. DNA topoisomerase I and DNA
gyrase as targets for TB therapy. Drug Discov Today 2017;22:510–8.
[79] Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE,
Nuermberger EL, Lamichhane G. In vitro and in vivo activity of biapenem against
drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J
Antimicrob Chemother 2017;72:2320–5.
[80] Gurumurthy M, Verma R, Naftalin CM, Hee KH, Lu Q, Tan KH, Issac S, Lin W, Tan A,
Seng KY, Lee LS, Paton NI. Activity of faropenem with and without rifampicin
against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal ac-
tivity trial. J Antimicrob Chemother 2017;72:2012–9.
[81] Giacobbo BC, Pissinate K, Rodrigues-Junior V, Villela AD, Grams ES, Abbadi BL,
Subtil FT, Sperotto N, Trindade RV, Back DF, Campos MM, Basso LA, Machado P,
Santos DS. New insights into the SAR and drug combination synergy of 2-(quinolin-
4-yloxy)acetamides against Mycobacterium tuberculosis. Eur J Med Chem
2017;126:491–501.
[82] Ngwane AH, Panayides JL, Chouteau F, Macingwana L, Viljoen A, Baker B,
Madikane E, de Kock C, Wiesner L, Chibale K, Parkinson CJ, Mmutlane EM, van
Helden P, Wiid I. Design, synthesis, and in vitro antituberculosis activity of 2(5H)-
Furanone derivatives. IUBMB Life 2016;68:612–20.
[83] Stec J, Onajole OK, Lun S, Guo H, Merenbloom B, Vistoli G, Bishai WR, Kozikowski
AP. Indole-2-carboxamide-based MmpL3 inhibitors show exceptional anti-
tubercular activity in an animal model of tuberculosis infection. J Med Chem
2016;59:6232–47.
[84] Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP. The efflux
pump inhibitor timcodar improves the potency of antimycobacterial agents.
Antimicrob Agents Chemother 2015;59:1534–41.
[85] de Knegt GJ, Ten Kate MT, van Soolingen D, Aarnoutse R, Boeree MJ, Bakker-
Woudenberg IA, de Steenwinkel JE. Enhancement of in vitro activity of tuberculosis
drugs by addition of thioridazine is not reflected by improved in vivo therapeutic
efficacy. Tuberculosis (Edinb) 2014 Dec;94(6):701–7.
[86] Tandon R, Ponnan P, Aggarwal N, Pathak R, Baghel AS, Gupta G, Arya A, Nath M,
G. Mori et al. Tuberculosis 112 (2018) 98–109
108
Parmar VS, Raj HG, Prasad AK, Bose M. Characterization of 7-amino-4-methyl-
coumarin as an effective antitubercular agent: structure-activity relationships. J
Antimicrob Chemother 2011;66:2543–55.
[87] Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G, Venturelli A,
Savina S, Makarov V, Kolly GS, Molteni E, Binda C, Dhar N, Ferrari S, Brodin P,
Delorme V, Landry V, de Jesus Lopes Ribeiro AL, Farina D, Saxena P, Pojer F, Carta
A, Luciani R, Porta A, Zanoni G, De Rossi E, Costi MP, Riccardi G, Cole ST. 2-
Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibi-
tion of DprE1. ACS Chem Biol 2015;10:705–14.
G. Mori et al. Tuberculosis 112 (2018) 98–109
109
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Esta tesis se terminó de imprimir el 24 de marzo de 2019, 
día que conmemora la primera descripción 
de la bacteria Mycobaterium 
tuberculosis 
en 1882 por 
Robert 
Koch 
 
